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SUMMARY 
 
 
Keywords: Streptococcus pyogenes, pharyngitis, macrolide resistance, intrahost variation, 
scarlet fever 
 
 There are large geographical and temporal variations in the frequency of macrolide-
resistant Streptococcus pyogenes, as well in the associated resistance phenotypes. Although 
decreases in macrolide resistance were often associated with low macrolide consumption, 
natural fluctuations of macrolide resistant clones were also suggested to play an important 
role in the prevalence of resistant isolates and of resistance phenotypes.  
 The recent report of heterogeneity found among group A streptococcus (GAS) 
isolates recovered from the same patient raised the question of whether the strategy used in 
the microbiology laboratory, the study of microorganisms from a single colony, was 
leading to the underestimation of macrolide resistance rate. For that purpose, 321 GAS 
isolates, recovered from 35 pharyngitis patients from one hospital were screened for 
potential differences in antimicrobial resistance profiles and emm types of up to 10 isolates 
recovered from the same sample. In our collection, all the isolates recovered from the same 
patient presented an identical antimicrobial resistance profile and emm type, indicating that 
the single colony approach was suitable for a correct identification of macrolide resistance 
rates and other epidemiological studies. 
 In this thesis, the epidemiology of macrolide resistant GAS in Portugal is divided in 
3 periods - 1998 to 2003, 2004 to 2006 and 2007 to 2011. In all periods, macrolide 
resistance rates and macrolide resistance phenotypes and genotypes were determined; 
molecular characterization of the resistant population was accomplished by T typing, emm 
typing, pulsed field gel electrophoresis (PFGE) profiling and multilocus sequence typing 
(MLST). In the first period, macrolide resistance was high (27%) and stable. However, this 
stability was accompanied by a variation in the prevalence of the resistance phenotypes. In 
just 6 years, there was a complete inversion in the prevalence of macrolide resistance 
phenotypes. The molecular characterization of 325 resistant isolates revealed a diverse 
population, and the genetic lineages identified in Portugal were also identified in other 
European countries; the most common were T12-emm22-ST46, T28-emm28-ST52, T4-
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emm4-ST39, T12-emm12-ST36 and T1-emm1-ST28. This unusual situation motivated 
continuing the surveillance studies. Results from the analysis of the isolates recovered in 
2004-2006 allowed the identification of a decreasing trend in macrolide resistance that had 
started in 1999. The diversity in the clonal composition was still evident among the 156 
isolates studied and, with minor exceptions, the same genetic lineages were identified, 
although differences in their prevalence were noted. Among the most prevalent lineages 
were T28-emm28-ST52, T4-emm4-ST39, T11-emm11-ST403, and T12-emm22-ST46. In 
order to determine if this decline in macrolide resistance was sustained, the susceptibility 
of isolates recovered in 2007-2011 was determined and the clonal composition of the 
resistant population (n=139) was analyzed. The results showed that macrolide resistance 
continued to decline, reaching in 2011 the lowest value ever recorded in Portugal (2%). 
Again, macrolide resistant genetic lineages had been previously described in Portugal and 
other countries, with some changes in their prevalence. The lineage defined by T11-
emm11-ST403 was now the most prevalent, followed by T12-emm22-ST46, T12-emm12-
ST36 and T28-emm28-ST52.  
 One of the most intriguing observations was that this situation was paralleled by 
high macrolide consumption, emphasizing the critical role of the fluctuations in the 
resistant clones for the prevalence of resistance. 
 Although a small group of resistant lineages has been shown to be widely 
disseminated, little is known about the reasons for their success and their origin - ongoing 
acquisition of macrolide resistance genes followed by local spread or simple geographic 
dissemination. In order to see if the macrolide resistant GAS population was mirroring the 
general pharyngeal population or if their dynamics were independent, a collection of 803 
isolates, representing 50% of all isolates recovered from tonsillo-pharyngitis patients in 
Portugal from 2000 to 2005 was analyzed by all the typing methods mentioned above. This 
comparison allowed the identification of specific emm types and PFGE clones associated 
with each of the macrolide resistant phenotypes. Among the emm types found in this 
collection, emm4, emm22 and emm28 were associated with macrolide resistance and 
emm3, emm6, emm87 and emm89 with macrolide susceptibility. Furthermore, the 
usefulness of PFGE in typing S. pyogenes was reinforced with this work since it was the 
only method capable of differentiating macrolide resistant and susceptible isolates of the 
same emm types. Examples of this could be found in emm4 and emm1. Additionally, both 
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populations presented different diversities indicating that macrolide resistant GAS has its 
own dynamics, independent of the changing patterns of the general population.  
 The production of the exotoxins SpeA and SpeC was for a long time believed to be 
responsible for scarlet fever, one of the infections caused by S. pyogenes. However, the 
literature is contradictory and some studies failed to detect such associations. In order to 
find out any potential markers of this disease, we characterized a collection of 101 scarlet 
fever isolates and compared it with pharyngitis isolates (n=202) (these not associated with 
scarlet fever). To achieve this, the superantigen gene profile was determined for all 
isolates, in addition to the typing methods already mentioned. The results showed that ssa, 
speA and speC were associated with scarlet fever and that scarlet fever isolates are less 
diverse than the pharyngitis isolates, indicating that a restricted number of lineages have a 
higher propensity to cause this presentation. 
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RESUMO 
 
Palavras-chave: Streptococcus pyogenes, faringite, resistência aos macrólidos, variação no 
hospedeiro, escarlatina 
  
 Existem grandes variações geográficas e temporais na frequência de estirpes de 
Streptococcus pyogenes resistentes aos macrólidos, assim como na prevalência dos 
respectivos fenótipos de resistência. Apesar de uma diminuição na resistência aos 
macrólidos ter sido frequentemente associada a um baixo consumo deste antibiótico, foi já 
sugerido um papel importante para as flutuações naturais dos clones resistentes aos 
macrólidos na prevalência de estirpes resistentes e dos seus fenótipos.  
 Um estudo recente demonstrou a existência de heterogeneidade entre estirpes de 
estreptococos do grupo A (GAS) isoladas no mesmo doente, levantando a questão da 
validade de isolar e estudar uma só colónia a partir das placas primárias para a correcta 
determinação da resistência aos macrólidos. Para testar esta premissa, 321 estirpes de 
GAS, isoladas de 35 doentes do mesmo hospital, com um diagnóstico de faringo-
amigdalite, foram estudadas de modo a detectar possíveis diferenças na susceptibilidade 
antimicrobiana e no tipo e subtipo emm. Nesta colecção, todas as estirpes isoladas do 
mesmo doente apresentaram o mesmo perfil de resistência aos antimicrobianos e o mesmo 
tipo e subtipo emm, indicando que a estratégia utilizada é adequada para uma correcta 
identificação da taxa de resistência aos macrólidos e para outros estudos epidemiológicos. 
 Ao longo desta dissertação, o estudo epidemiológico das estirpes de GAS 
resistentes aos macrólidos está dividida em 3 períodos - 1998 a 2003, 2004 a 2006 e 2007 a 
2011. Em todos os períodos, a taxa de resistência aos macrólidos e a prevalência de cada 
um dos fenótipos e genótipos de resistência foram determinadas; a caracterização 
molecular da população resistente envolveu técnicas como a tipagem T, a tipagem emm, 
“pulsed field gel electrophoresis” (PFGE) e “multilocus sequence typing” (MLST).  
 No primeiro período, a resistência aos macrólidos foi elevada (27%), mas estável. 
No entanto, esta estabilidade não foi acompanhada por uma prevalência constante dos 
fenótipos de resistência. Em apenas 6 anos, assistiu-se a uma completa inversão na 
prevalência dos fenótipos de resistência. A caracterização molecular das 325 estirpes 
revelou uma população diversa e as linhagens genéticas identificadas em Portugal foram 
viii 
 
também identificadas noutros países Europeus; as mais comuns eram definidas por T12-
emm22-ST46, T28-emm28-ST52, T4-emm4-ST39, T12-emm12-ST36 e T1-emm1-ST28. 
Esta situação, muito pouco usual, motivou a continuação dos estudos de vigilância 
epidemiológica e os resultados da análise das estirpes isoladas entre 2004 e 2006 
permitiram a detecção de uma tendência decrescente na resistência aos macrólidos, que 
começara em 1999. Era ainda evidente uma diversidade na composição clonal da 
população que incluía 156 estirpes, e, com pequenas excepções, foram identificadas as 
mesmas linhagens genéticas, com algumas diferenças na sua prevalência. Entre as 
linhagens mais frequentes estavam as definidas por T28-emm28-ST52, T4-emm4-ST39, 
T11-emm11-ST403 e T12-emm22-ST46. Para saber se esta tendência decrescente ainda se 
mantinha, a resistência aos macrólidos entre 2007 e 2011 foi determinada e a composição 
clonal da população foi estudada (n=139). Os resultados mostraram que a tendência 
decrescente da resistência aos macrólidos ainda se mantinha, atingindo-se em 2011 o valor 
mais baixo registado em Portugal (2%), e mais uma vez, as linhagens genéticas tinham 
sido já descritas em Portugal e noutros países, com algumas diferenças na sua prevalência. 
A linhagem genética definida por T11-emm11-ST403 era agora a mais prevalente, seguida 
por T12-emm22-ST46 e T28-emm28-ST52.  
 Uma das observações foi o facto de esta situação ter sido acompanhada por um 
elevado consumo de macrólidos, conferindo assim ênfase às flutuações dos clones na 
prevalência da resistência a este antibiótico. 
 O grupo relativamente restrito de linhagens genéticas com resistência aos 
macrólidos está bem disseminado, mas pouco se sabe acerca dos motivos para o seu 
sucesso ou da sua origem - aquisição de genes de resistência seguida de expansão local, ou 
simplesmente disseminação geográfica. Para tentar perceber se a população de GAS estava 
a reflectir a população geral de S. pyogenes isolados na faringe, uma colecção de 803 
estirpes, representando 50% do total de estirpes isoladas em doentes com faringo-
amigdalite em Portugal, entre 2000 e 2005, foi analisada por todos os métodos de tipagem 
acima mencionados. Esta comparação permitiu a identificação de tipos emm específicos e 
clones de PFGE associados com cada um dos fenótipos de resistência aos macrólidos. 
Entre os tipos emm encontrados nesta colecção, os tipos emm4, emm22 e emm28 foram 
associados com a resistência aos macrólidos, enquanto os tipos emm3, emm6, emm87 e 
emm89 foram associados com a susceptibilidade a este antibiótico. A utilidade do PFGE na 
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tipagem de GAS foi reforçada neste trabalho pois esta foi a única técnica de tipagem capaz 
de diferenciar estirpes resistentes e susceptíveis dentro do mesmo tipo emm. Foram 
exemplos disso grupos de estirpes dos tipos emm1 e emm4. Adicionalmente, ambas as 
populações mostraram diferenças na diversidade, indicando que a população de GAS 
resistentes aos macrólidos tem uma dinâmica própria, independente dos padrões de 
variação da população geral.  
 Durante muito tempo, a produção das exotoxinas SpeA e SpeC foi associada ao 
desenvolvimento de escarlatina, uma das apresentações das infecções causadas por S. 
pyogenes. No entanto, a literatura é contraditória e alguns estudos não detectaram esta 
associação. Para tentar encontrar potenciais marcadores desta infecção, caracterizámos 
uma colecção de 101 estirpes associadas a escarlatina e comparámos com 202 estirpes 
associadas a faringite (sem o diagnóstico de escarlatina). Para isto, foi determinado o perfil 
de superantigénios, para além de todos os métodos de tipagem já mencionados. Os 
resultados mostraram que os genes ssa, speA e speC estavam associados a escarlatina, mas 
foi também demonstrado que as estirpes associadas a escarlatina eram menos diversas que 
as estirpes associadas a faringite, o que sugere que existam linhagens de maior propensão 
para causar esta apresentação. 
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 THESIS OUTLINE 
 
 
 The main purpose of the work presented in this thesis was the characterization of 
Streptococcus pyogenes associated with tonsillo-pharyngitis in Portugal, with a special 
focus on macrolide resistance. To achieve this, phenotypic and molecular typing methods 
were used among a large collection of isolates. 
 The study is presented in 6 chapters, organized as follows: 
 Chapter 1: General Introduction - This chapter provided a review of the main 
characteristics of this important pathogen - the infections it causes, its virulence factors, 
antimicrobial resistance, typing methods and epidemiology of macrolide resistance.  
 Chapter 2: Intrahost variation in infection - The heterogeneity among S. pyogenes 
isolates recovered from the same patient, in the course of pharyngitis is determined, in 
terms of antimicrobial resistance profiles and emm type. 
 Chapter 3: Epidemiological study of macrolide-resistant S. pyogenes isolates in 
Portugal (1998-2011) - In this chapter, the macrolide resistant GAS isolates recovered 
from tonsillo-pharyngitis in Portugal, between 1998 and 2011 are characterized. As 
explained in this chapter, this issue is divided into 4 subchapters corresponding to different 
time periods. 
 Chapter 4: Differences between macrolide resistant and susceptible Streptococcus 
pyogenes: importance of clonal properties in addition to antibiotic consumption - this 
chapter provides some clues about the origin of macrolide resistant clones in Portugal, by 
comparing a large collection of macrolide resistant and susceptible isolates. 
 Chapter 5: Scarlet fever is caused by a limited number of Streptococcus pyogenes 
lineages and is associated with the exotoxins ssa, speA and spec - in this chapter, the 
characterization of scarlet fever isolates is performed, in an attempt to identify the potential 
molecular markers for the development of scarlet fever. 
 Chapter 6: General Discussion - this chapter provides a discussion of the major 
findings obtained in this thesis, highlighting new perspectives for future work. 
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 1. Streptococcus pyogenes - general features  
 
 The presence of streptococci in patients with skin infections was first demonstrated 
in 1874 by Billroth and in 1879, Pasteur detected the presence of these microorganisms in 
the blood of a patient with puerperal sepsis. In 1883, Fehleisen established the importance 
of these chain forming organisms in human infections and the designation of Streptococcus 
pyogenes was finally applied in 1884 by Rosenbach [30]. 
 Streptococcus pyogenes is a Gram positive bacterium, identified as Lancefield’s 
group A streptococci (GAS) in 1933 [117]. Individual cells have spherical shape, with 0.5-
1 µm size, are nonmotile and normally arranged in pairs or straight chains. It is a 
facultative anaerobe microorganism, catalase and oxidase negative [147]. The Lancefield 
classification scheme distinguished these streptococci based on their group A 
carbohydrate, composed of N-acetylglucosamine linked to a rhamnose polymer backbone 
[117]. On blood agar plates, colonies form large zones of beta-hemolysis, that result from 
the production of streptolysin-O that mediates the complete lysis of erythrocytes [153] (see 
Figure 1.1).  
 
 
 1.1. Identification 
 
 Streptococcus pyogenes identification starts with the observation of beta-hemolytic 
colonies, when grown in 5% blood agar plates (Figure 1.1). Presumptive identification can 
be made using the bacitracin susceptibility test [70], but it is not a very reliable test, since 
bacitracin resistant S. pyogenes isolates were already described [132, 141, 160].  
 
 
 
 
 
 
 
 
FIGURE 1.1: β-hemolysis produced by S. 
pyogenes colonies on blood agar plates
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 Based on the serological classification developed by Rebecca Lancefield in 1933 
[117], there are commercially available kits for the presumptive species identification of 
beta-hemolytic streptococci that involve the enzymatic extraction of the carbohydrate and 
its agglutination reaction with specific sera. A positive reaction can also be seen between 
the group A serum and other beta-hemolytic streptococcal species, such as S. dysgalactiae 
subsp. equisimilis and S. anginosus group, but these are more rarely associated with human 
disease [70].  
 Other test for the identification of S. pyogenes include pyrrolidonylarylamidase 
activity, since only this species among streptococci produces the enzyme [70].  
 
 1.2. Virulence factors 
 
 Streptococcus pyogenes expresses multiple virulence factors, which are involved in 
several aspects of host-pathogen interactions.  
 
 
 
FIGURE 1.2: GAS virulence factors interact with the host at many levels. At cell and tissue level, 
the virulence factors contribute to the pathogenicity of GAS mediating adherence to host cells, 
promoting internalization and invasion and circumventing phagocytosis. At the organism level, 
these factors are involved in the dissemination throughout the host and induction of systemic 
toxicity. Many of the known GAS virulence factors are involved in more than one stage of 
infection. Reproduced from Tart et al. [203].  
 
 
 Initial contact between GAS and human epithelial cells is a very important step 
because without strong adherence, the microorganism would be removed by mucous and 
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salivary fluid flow and through the exfoliation of the epithelium [57]. Moreover, it has 
been suggested that the invasion of deeper tissues from the mucosa or skin may be 
facilitated by specific adhesions mechanisms [57]. The adherence process may also 
activate the immune system by inducing local cytokine production and inflammatory 
responses [54, 212]. 
 The adherence of this pathogen to the host cells, the invasion of host tissues, the 
interaction with the immune system and the production of several enzymes and toxins are 
important to the establishment of GAS disease in the human host and multiple virulence 
factors are involved in all stages of infection. 
 A brief description of the major virulence factors will be addressed in the next 
section. 
 
 Capsular Polysaccharide  
 
 Based on the morphology of the colonies of GAS when grown on solid media, 
Rebecca Lancefield distinguished three types of hemolytic streptococci – mucoid 
(translucent, liquid appearance), matte (irregular, collapsed appearance) and glossy 
(compact, opaque) colonies and established an association between virulence and the 
appearance of the colonies. Mucoid or matte colonies were associated with potentially 
virulent isolates for mice, while glossy colonies were formed by less virulent isolates. 
Furthermore, isolates producing mucoid or matte colonies were shown to produce higher 
levels of M protein relatively to the glossy colonies isolates [120, 208]. The M protein 
received its designation because of this association with mucoid or matte colonies [219]. In 
1959, Wilson demonstrated that the mucoid or matte morphology of the colonies was due 
to the production of a capsular polysaccharide, instead of the M protein [219]. However, 
encapsulated strains can be difficult to identify after subculture in the microbiology 
laboratory, since the expression of the capsule can be lost in some conditions, such as the 
growth in artificial media [196].  
  The GAS capsular polysaccharide is composed of hyaluronic acid, a high-
molecular weight linear polymer containing D-glucoronic acid and N-acetylglucosamine. 
The similarity between capsular hyaluronate and the one found in human connective tissue 
renders this virulence factor a poor immunogen [28]. The importance of the capsule as a 
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major virulence factor of S. pyogenes comes from the frequently reported association 
between invasive infections and rheumatic fever and mucoid strains [197].  
 Capsule production is considerably variable among GAS isolates. The capsule acts 
as a virulence factor by preventing phagocytosis, as already demonstrated by studies with 
acapsular mutants [217]. Furthermore, in highly encapsulated isolates, the treatment with 
hyaluronidase rendered them more susceptible to phagocytosis, supporting a protective 
role of the capsule [174]. The mechanism used by the capsule in preventing phagocytosis 
is the inhibition of complement activity by blocking the access of neutrophils to the 
opsonic complement components bound to the bacterial surface, rather than inhibiting C3b 
deposition [216]. 
 The hyaluronic acid capsule of GAS has been shown to enhance virulence in skin 
and soft tissue infections [5, 181], as well as in systemic infections [217]. This could be 
due to its interference with the immune system but the capsule was also shown to influence 
the attachment to the epithelium of the pharyngeal mucosa and the skin, either by 
modulating the interactions of the M protein and other adhesins or by direct binding itself 
to CD44 on human keratinocytes [180]. It was already demonstrated that the binding of the 
GAS hyaluronic acid capsule to CD44 on epithelial cells triggers cytoskeletal 
rearrangements that open intracellular junctions, in a serotype-specific manner, facilitating 
paracellular translocation of the microorganism which can be used as a possible 
mechanism of tissue invasion [58, 199]. 
 
 M protein 
 
 In 1927, Rebecca Lancefield identified the M protein as a “type-specific 
substance”, demonstrating its ability to elicit an immune response [118], that is protective 
against re-infection with the same M serotype [119]. On the bacterial surface, the proteins 
are arranged in hair-like structures that protrude away from the surface [154] (Figure 1.3) 
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FIGURE 1.3: Transmission electron micrograph of a thin sectioned S. pyogenes bacterium, with 
the hair-like structure colored in green. Reproduced from Oehmcke et al. [154] 
  
  The M protein is formed by two polypeptide chains that form an alpha-helical 
coiled-coil arrangement, anchored in the cell membrane and spanning the cell wall [28] 
(Figure 1.4). Typically, the polypeptide chains consist of four blocks (labeled A-D), which 
differ in size and aminoacid sequence (Figure 1.4). The structure of the C-terminal has an 
LPXTG motif, a signal required for the correct anchoring of the protein to the cell wall and 
this region is highly conserved among GAS strains [81]. The amino terminal region, that 
extends to the exterior is a highly variable region and constitutes the serotype specificity of 
different GAS isolates [28].  
 The repeats located in the conserved region of the protein are involved in the 
interaction with the immune system [103], and the fibrinogen binding domain of many M 
proteins is contained in the variable region [169].  
 The size of the M proteins is variable among S. pyogenes isolates, even among 
strains of the same serotype [80, 104]. This is thought to be generated by homologous 
recombination between intragenic repeats, resulting in the addition or deletion of repeats 
[104]. A recent study found that the whole surface-exposed sequence of the M protein 
shows significant size variation, ranging from 200 to 435 aa among a large collection of 
isolates, representing multiple M types [139]. This size variation is related to the variable 
number of repeats each M protein harbors. Some proteins lack “A” and “B” repeats 
entirely and sometimes the “B” repeats are present as a single repeat (Figure 1.4) [139]. As 
different regions of the M protein interact with different host proteins and components of 
the immune system, it is possible that changes in the size of the M protein can give 
individual bacteria a survival advantage, but further studies of the impact of the size of the 
M protein in the virulence potential and clinical manifestations are still needed [139].  
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 The M protein is encoded by the emm gene and analysis of the presence and 
arrangement of the emm family genes in the bacterial chromosome allowed the distinction 
of 5 dominant emm patterns (patterns A-E), with few exceptions. It was also possible to 
establish significant associations between some of these patterns and different diseases: 
pharyngeal isolates were associated with emm patterns A, B or C, and pattern D is 
associated with skin isolates. Among isolates presenting pattern E, no significant 
association could be established with any of the sites of infection (skin or throat). These 
results provided the genetic basis for the early recognized concepts of “throat” and “skin” 
strains, leading to the idea that strains with the A-C genotype tend to show a strong 
preference for throat infections (“throat-specialists”), emm pattern D strains have a 
tendency to cause impetigo (“skin-specialists”) and emm pattern E strains infect both 
tissues (“generalists”) [19]. 
FIGURE 1.4 Three representative M proteins model. Patterns A-C emm types represent the longest 
M proteins. The “A” repeats are absent from the vast majority of M proteins belonging to the 
pattern D and E. The “B” repeats are present in most A-C and D emm types, but absent from most 
of the pattern E emm types. Reproduced from McMillan et al. [139] 
 
 
 M proteins can be classified into two groups (class I and class II) based on the 
presence or absence of a conserved antigenic domain within the surface-exposed portion. 
The class I molecules show immunoreactivity with C repeat region specific antibodies, 
while the class II molecules do not react with these antibodies [21]. This classification is 
further supported by differences in the biological properties of both classes. GAS isolates 
carrying class II M proteins are usually producers of an apoproteinase called the serum 
opacity factor (SOF) that causes the aggregation of the high-density lipoprotein and 
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opacification of serum [179]. In contrast, isolates carrying class I molecules fail to produce 
SOF [57]. Moreover, class I M protein serotypes are associated with rheumatic fever and 
class II molecules are associated with acute glomerulonephritis [20, 21, 154]. 
 The M proteins are believed to be the primary antigens of GAS and anti-
streptococcal antibodies also reacting against a variety of human proteins have been 
described, such as cardiac myosin, tropomyosin, vimentin, laminin, keratin and several 
valvular proteins. This molecular mimicry of the M protein is particularly important in the 
induction of autoimmune reactions in rheumatic fever, a non-suppurative sequela caused 
by S. pyogenes infections [154].  
 The M protein was also recognized as an important adhesin [67], through the 
interaction with receptors in the host cells, such as fibronectin, membrane cofactor protein 
(CD46) and glycosaminoglycans, an interaction that depends on the M type and the target 
host cell [57, 87, 154]. The M protein has antiphagocytic properties, avoiding complement 
activation by binding at least one of the following complement factors - factor H, factor H 
like-1 (FHL-1), C4-binding proteins (C4BP) and CD46 complement regulatory protein. 
The interaction of the M protein with factor H or FHL-1 seems to occur in different regions 
of the hypervariable portion of the protein and disrupts the alternative complement 
pathway by inhibiting the deposition of C3b and reducing phagocytosis by 
polimorphonuclear leucocytes [27, 57]. Binding of C4BP to the hypervariable region of the 
M protein (an inhibitor of the classical complement pathway) has been shown to confer 
phagocytosis resistance. The M protein can also bind fibrinogen, decreasing the deposition 
of C3b in the bacterial surface, activating the alternative complement pathway or blocking 
the classical pathway [154].  
 Although considered an extracellular pathogen, GAS internalization into cultured 
human epithelial cells has already been demonstrated [121, 143] and the binding of M 
protein to host cell receptors seems to contribute to this uptake [56]. 
 
 T protein 
 
 The T protein is a tripsine-resistant surface protein of GAS, and its variability 
constitutes the basis of a typing system [92]. For a long time, the T protein was regarded 
solely as an epidemiological marker, with an unclear role in GAS virulence. However, it 
Chapter 1 
 
10 
 
was recently shown that S. pyogenes harbors, in its surface, pilus-like structures, composed 
of members of a family of extracellular matrix binding proteins (ECM-binding proteins). It 
was also demonstrated that the Lancefield T6 antigen forms the backbone of one of the pili 
and the backbone of three other pili was recognized by three different sera from the T- 
typing system, suggesting that the diversity of these pilus-like structures are the basis for 
this typing system [145].  
 GAS pili are encoded in a region termed FCT (Fibronectin-binding, Collagen-
binding  T antigen) region, and nine FCT variants have been identified so far [72]. Because 
they are members of a family of ECM- binding proteins, their contribution to virulence is 
believed to be related to adhesion and invasion of epithelial cells, but a role in biofilm 
formation was also suggested [13, 134].  Additionally, recombinant pilus proteins showed 
the capacity to induce protective immunity in a mouse model of GAS infection and 
invasive disease [145], reinforcing this importance as a virulence factor.  
 
 Fibronectin-binding proteins 
 
 The adherence and invasion of host cells by S. pyogenes are also mediated by 
fibronectin binding proteins. There are currently 11 fribronectin-binding proteins described 
in GAS, including Protein F1 (PrtF1)/SfbI, Protein F2 (PrtF2)/PFBP, SOF (serum opacity 
factor)/SfbII, FbaA and FbaB (fribronectin binding proteins A and B), the M1 protein and 
Scl1 (streptococcal collagen-like protein 1). The distribution of fribronectin binding 
proteins among GAS isolates seems to be related to the M type, while the correlation with 
clinical manifestations is not so clear [158, 220]. Moreover, it was suggested that the 
presence of some of these proteins could be an important epidemiological marker, as 
demonstrated for the higher prevalence of the prtF1 and/or the prtF2 genes among 
macrolide resistant GAS, that was suggested to represent protection of the action of 
antimicrobial treatment and of the host immune response [6, 97].  Some of the fribronectin 
binding proteins of GAS also promote evasion of phagocytosis by the inhibition of 
complement activity [220]. 
 
 In the human host, GAS encounters various barriers, including a vigorous innate 
immune response. A variety of virulence determinants allow S. pyogenes to survive in this 
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new environment, avoiding recognition and phagocytosis and establishing long-term 
survival within the host. Besides the already mentioned M protein, the hyaluronic acid 
capsule, and some fribronectin-binding proteins, S. pyogenes produces a variety of 
extracellular products important for virulence by interacting with the host immune system. 
Among these are streptococcal pyrogenic exotoxins, streptodornases (DNases), streptolysin 
O and streptolysin S, interleukine-8-protease (SpyCEP), streptococcal inhibitor of 
complement (Sic), C5a peptidase and streptokinase [52]. 
 
 Streptococcal pyrogenic exotoxins  
 
 S. pyogenes produces many virulence factors and among them are the secreted 
pyrogenic exotoxins (Spe), which act as superantigens.  These superantigens interact with 
the host major histocompatibility complex (MHC) class II molecules and with the variable 
region of the T-cell receptor β-chain. Unlike conventional antigens, this interaction occurs 
without the involvement of antigen-presenting cells. Moreover superantigens can interact 
with large numbers of T cells that share particular sequences within the variable region of 
the β chain of the T cell receptor, resulting in an extensive immune activation and 
significant release of pro-inflammatory cytokines, leading to the shock and organ damage 
seen in some severe GAS infections [113].  
 There are 11 superantigens described so far in S. pyogenes: some of these 
superantigens are chromosomally encoded (SpeG, SpeJ and SMEZ) and others are encoded 
on temperate bacteriophages (SpeA, SpeC, SpeH, SpeI, SpeK, SpeL, SpeM and SSA). The 
chromosomally encoded SpeB and SpeF are actually a cysteine protease and a DNase, 
respectively, instead of superantigens, in contrast to what was originally described [88, 
109].  SpeB is one of the best-studied virulence factors of GAS. It promotes evasion from 
the immune system, degrading a wide range of host and GAS proteins, promoting escape 
of recognition and phagocytosis and facilitating tissue invasion and spread [150].  
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Streptodornases (DNases) 
 
 NETs (neutrophil extracellular traps), secreted by host neutrophils in response to 
chemotactic signals are composed of DNA, histones, granule proteases and antimicrobial 
peptides. Their role is to facilitate the entrapment and clearance of bacteria in the initial 
site of infection, independent of phagocytic uptake. To overcome NETs, S. pyogenes 
produce one or more streptodornases (DNases). An example is the phage-encoded DNase 
(sda1), produced by S. pyogenes T1M1, frequently associated with invasive infections, 
with a demonstrated role in NET escape and virulence [40].  
 
 Streptolysin O and Streptolysin S  
 
 Streptolysin S (SLS) is an oxygen-stable, non-immunogenic hemolysin, with a 
broad cytolytic spectrum, being involved in phagocytic clearance and cell cytotoxity. The 
expression of SLS promotes virulence in animal models of invasive infection and 
contributes to GAS translocation across epithelial barriers [60, 199].  
 Streptolysin O (SLO) is an oxygen-sensitive hemolysin that binds to cholesterol in 
eucaryotic cell membranes, where it oligomerizes to produce large transmembrane pores, 
leading to cell lysis. It is immunogenic and increased titers of anti-SLO (ASO) are good 
indicators of streptococcal disease [50]. SLO facilitates the escape of GAS from the 
endosome-lysosome pathway following invasion of host cells [96], and contributes directly 
to virulence in animal models of systemic infection [207].  
 
 C5a peptidase 
 
 C5a peptidase is a proteolytic enzyme anchored to the cell wall of S. pyogenes, 
encoded by the scpA gene, which interferes with the immune system by inhibiting the 
recruitment of phagocytic cells to the site of infection, through the cleavage of C5a at its 
polimorphonuclear-binding site [57]. As a result, the infiltration of phagocytes is delayed 
and the clearance of bacteria is retarded, allowing the establishment of the infection. C5a 
peptidase is capable of inducing a strong immune response, with a good correlation to the 
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response of anti-streptolysin O (ASO) and anti-DNase B, which are considered indicators 
of GAS infection [187].  
 
 Interleukin-8 protease (SpyCEP) 
 
 SpyCEP (ScpC) is a cell wall anchored proteinase which degrades interleukin-8 
(IL-8), a chemokine that mediates neutrophils transmigration and activation, allowing 
bacterial spread and development of systemic infection [102]. However, the ability to 
degrade IL-8 differs dramatically among clinical isolates and it was already suggested that 
the contribution of this virulence factor to disease outcome depends on the site of infection 
and on host environment [190].  
 
 Streptococcal inhibitor of complement (Sic) 
 
 Sic is a highly polymorphic secreted protein, produced by very few strains of GAS, 
mostly by M1 isolates. Initially it was thought that its role in GAS virulence was related 
solely to an interference with the formation of the membrane attack complex (MAC), but it 
was recently demonstrated that it is, in fact, a polyfunctional inhibitor of the innate 
immune response, inhibiting the activity of a wide range of antimicrobial peptides and 
proteins [77].  
 
 Streptokinases 
 
 One of the proteins secreted by GAS is the streptokinase with the ability to convert 
plasminogen to plasmin [154]. The protease activity of plasmin is important in bacterial 
colonization, degrading blood clots and extracellular matrix components (ECM) and 
activating metalloproteinases. GAS can interact with human plasminogen directly through 
specific surface proteins or indirectly through fribronectin-binding proteins and the 
presence of plasminogen at the infection site, leading to increases in the local levels of 
plasmin. This was proposed to have an important role in GAS pathogenesis, demonstrated 
by increased virulence in mouse skin models and enhanced adherence and invasion in 
pharyngeal cells [154, 159].  
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 Global virulence regulators 
 
 The expression of virulence factors is controlled by transcriptional regulators, that 
respond to environmental signals present in the various niches which S. pyogenes 
encounters in the human host. With the increasing availability of complete genome 
sequences, a reasonable number of response regulators and two component signal 
transduction systems were described, summarized in a review from Kreikemeyer and 
collaborators [114]. Among the response regulators are Mga (regulating genes encoding 
adhesins and proteins involved in tissue invasion, such as emm, sof, scpA and sic, among 
others), RofA-like protein (RALP) family, regulating genes encoding fribronectin binding 
proteins, hemolysins, proteases, superantigens and other virulence regulators (Mga) and 
Rgg/RopB, that regulates the expression of SpeB, exerting a negative effect on mga 
transcription and influencing several two component system networks [114]. 
 Signal transduction through two component systems include the Ihk/Irr, with an 
essential role in GAS evasion of polimorphonuclear leucocyte (PMN) - mediated killing 
being highly expressed during acute pharyngitis and FasBCAX, involved in the down-
regulation of genes encoding adhesins and induction of genes encoding secreted 
streptolysin S (sagA) and streptokinase (ska). These two systems display homology with 
systems from Staphylococcus aureus and other streptococcal species. The best-
characterized two component system of GAS is CsrRS (csr standing for capsule synthesis 
regulator) also called CovRS (cov standing for control of virulence genes). This system 
was already shown to regulate capsule gene transcription and the expression of important 
virulence factors, such as streptolysin S, streptokinase, streptodornases and the cysteine 
protease SpeB [114].  
 
 
 1.3. Carriage  
 
 The ecological niche of Streptococcus pyogenes is quite narrow; their only known 
host are the humans. The primary sites for S. pyogenes colonization involve the nasal and 
oropharyngeal mucosal epithelium in the upper respiratory tract and the superficial layers 
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of the epidermis [18]. Since GAS has no environmental reservoir, direct transmission via 
respiratory droplets or skin contact is essential for its survival and dissemination [22].  
 Some individuals may harbor GAS continuously for months or years without 
symptoms of infection [107]. The prevalence of streptococcal carriers is a controversial 
matter, since many differences in their number were found, depending on the study 
population and the methods used [163]. A meta-analysis of the prevalence of streptococcal 
carriage in children revealed that among children younger than 5 years, the pooled 
prevalence of GAS carriage was 4%, ranging from 2% to 17%, lower than the carriage in 
children of all ages (12%, ranging from 3% to 26%) [186]. Chronic carriers can represent a 
clinical challenge, because even when the pharyngitis has a viral cause, GAS can still be 
detected by the culture of a throat swab, potentially confounding the ethiological diagnosis. 
Streptococcal carriage may not be effectively abolished by antimicrobial therapy [171] and 
there are several reasons for this, such as the internalization of the bacteria in the tonsillar 
epithelium cells [121, 149], the production of beta-lactamases by other microorganisms 
present in the oropharynx or the absence of a normal flora, capable of inhibiting GAS [39].  
 In Portugal, a study conducted between 2000 and 2006 in the Lisbon area that 
included children and adolescents attending day care centers and schools and close 
contacts, reported a rate of oropharyngeal carriage of Streptococcus pyogenes of 11% in 
children and 3.3% in adults [164].  
 
 
 1.4. Infections 
  
 Streptococcus pyogenes causes a broad spectrum of diseases, ranging from 
uncomplicated infections in the upper respiratory tract and skin to severe, life-threatening 
infections, as well as post-infectious complications [57]. 
 The global burden of GAS diseases is difficult to estimate. Some of the infections 
caused by S. pyogenes are very common in low-end economic settings and developing 
countries, where usually there are no systems to accurately estimate the disease burden. 
Given this limitation, any attempt to estimate the global prevalence of GAS infections will 
lack important information [41]. Still, with the available data, it was estimated that there 
are at least 517 000 deaths each year due to severe GAS diseases and the greatest burden is 
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due to rheumatic heart disease, with a prevalence of at least 15.6 million cases, with 
282000 new cases and 163000 deaths each year. Additionally, there are more than 111 
million cases of pyoderma and over 616 million cases of pharyngitis worldwide each year 
[41]. 
 
 1.4.1 Supurative infections 
 
 Pharingytis 
 
 Pharyngitis is one of the most common infections for which patients seek medical 
advice [50]. A variety of bacterial and viral agents can cause pharyngitis in the 
immunocompetent host. The most frequent include viral agents, of which rhinovirus, 
coronavirus and adenovirus are the most important [95]. Among bacterial agents, 
Streptococcus pyogenes is, by far, the most frequent pathogen isolated from pharyngitis, 
being responsible for 5-15% of pharyngitis cases in adults and 20-30% in children, most 
commonly in children aged 5-15 years [218]. However, under crowded conditions, such as 
schools, day care centers and military facilities, all ages are vulnerable to the spread of the 
organism [57]. Exudative pharyngitis due to streptococcal infection among children 
younger than 3 years of age is rare [218]. Other streptococci can also be responsible for 
pharyngitis, although to a lesser extent, such as group C and group G streptococci, 
presenting clinical features that are very similar to pharyngitis caused by S. pyogenes [95]. 
Other less common bacterial agents include Neisseria gonorrheae, Arcanobacterium 
haemolyticum, some species of Corynebacterium, and Chlamydial and Mycoplasmal 
species [95]. 
 The characteristic symptoms of streptococcal pharyngitis include a sudden onset of 
sore throat, pain on swallowing, fever, headache, abdominal pain and nausea and vomiting. 
Some clinical signs, such as tonsillopharyngeal exudate and erythema, soft-palate 
petechiae, beefy red and swollen uvula, anterior cervical lymphadenitis and scarlatiniform 
rash can also be present [26]. In the case of viral pharyngitis, respiratory signs and 
symptoms such as rhinorrhea, nasal congestion and cough are also present, although there 
is some evidence that these signs in patients with GAS pharyngitis may be more common 
than it was previously thought [135].  
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 Scarlet fever 
 
 Scarlet fever, also known as scarlatina, is usually associated with throat infections, 
although it can also occur due to infections at other sites and is characterized by skin rash, 
“strawberry tongue” and sore throat [57]. It is considered a toxin-mediated disease, so that 
the streptococcal superantigens have historically been referred to as erythrogenic toxins or 
scarlet fever toxins. The characteristic scarlet fever rash is believed to be due to a 
hypersensitivity reaction that results from superantigen activity [137], mainly of SpeA, 
although it has been suggested that in the absence of this pyrogenic exotoxin, SpeC could 
also cause identical symptoms [221].  
 In the 19
th
 and 20
th
 centuries, it was a significant cause of childhood morbidity and 
mortality [146], and although scarlet fever outbreaks still occur, it is currently a relatively 
rare disease [45, 69, 116, 155, 209].  
 
 Skin and soft tissue infections 
 
 S. pyogenes is responsible for a variety of clinical conditions involving the skin and 
soft tissue. Localized streptococcal purulent infections of the skin are usually referred as 
GAS pyoderma, but generally this term is used mostly to refer to streptococcal impetigo 
and ecthyma [135].  
 Impetigo is a highly contagious infection of the skin, although superficial and self-
limiting, which affects primarily exposed areas (face, arms and legs). At the skin, GAS can 
survive and replicate, reaching the subcutaneous tissues through small breaks in the skin, 
causing a strong inflammatory response resulting in the pyoderma purulent lesions. 
Systemic signs of infection are uncommon, but the spread of the infection by scratching is 
usual. GAS ecthyma occurs when lesions extend more deeply into the dermis and produce 
shallow ulcers [29, 135].  
 Erysipela is an acute inflammation of the skin that involves the skin and superficial 
lymphatic vessels. Clinically, an elevated erythematous lesion is present, and fever and 
other systemic signs of disease are common. Cellulitis is an infection that extends more 
deeply into subcutaneous tissues, with edema, redness, warmth and induration of the skin 
and/or soft tissue. As is the case with erysipelas, the presence of cellulitis may be 
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associated with systemic signs of infection and fever [29, 135]. Other species can be 
responsible for impetigo, erysipelas and cellulitis. Staphylococcus aureus is frequently 
recovered from impetigo lesions, alone or in combination with S. pyogenes, and some 
cases of cellulitis are caused by S. aureus, which has implications for empiric therapy, 
since the treatment of such infections requires the use of antimicrobial agents active 
against both species. Staphylococci are rarely responsible for erysipelas, but groups C, G 
and B streptococci can be responsible for this infection, although the majority of cases are 
caused by GAS [29].  
 
 Necrotizing fasciitis 
 
 Necrotizing fasciitis is a deep infection of subcutaneous tissue that results in the 
progressive destruction of fascia and fat. This infection is commonly associated with GAS 
bacteremia and the concomitant development of shock and organ failure, often in patients 
with streptococcal toxic shock syndrome, which will be discussed below [29]. Patients 
often have some prior history of trauma, such as an insect bite, scratch or abrasion and 
most of them have pre-existing conditions that render them more susceptible to this 
infection, such as varicella or specific conditions that result in immunosuppression such as 
diabetes mellitus, advanced age, chronic renal failure, peripheral vascular disease and drug 
misuse, although it also occurs in young and previously healthy individuals [29, 101].  
 The successful management of necrotizing fasciitis is dependent on a rapid 
diagnosis to allow for an adequate therapeutic response, requiring early and aggressive 
surgical debridement of the site of infection and antimicrobial therapy [135].  
 
 Streptococcal toxic shock syndrome  
 
 Streptococcal toxic shock syndrome (STSS) is characterized by a sudden onset of 
shock and organ failure and the presence of a culture positive for GAS. Cases have been 
observed more frequently in patients with risk factors, like those with chronic underlying 
conditions, such as diabetes mellitus, chronic cardiac or pulmonary diseases, immune-
deficiency syndromes and children with varicella [135]. However, STSS can sporadically 
be present in previously healthy persons as primary peritonitis, with septic shock and 
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multiple organ failure emerging in just a few hours, with some cases occurring in women 
of reproductive age, suggesting an association with the female genital tract [206]. In fact, a 
portal of entry from the skin or vaginal mucosa was observed in nearly 60% of the patients; 
in other cases, a transient bacteremia originating in the pharynx could be the cause of the 
condition [29, 206]. Recent data from European countries revealed an incidence of STSS 
of 13% in streptococcal infections from any source, which increased dramatically to 50% 
in patients with necrotizing fasciitis, with a 7-day mortality of 44% [115].  
 STSS represents the most fulminant expression of disease caused by toxin-
producing strains of S. pyogenes. It results from the ability of bacterial toxins to act as 
superantigens, triggering excessive and non-conventional T-cell activation, with 
concomitant activation of other cell types and stimulating massive cytokine production that 
ultimately causes tissue damage, disseminated intravascular coagulation and organ 
dysfunction [122].  
 Therapy with broad spectrum antibiotic should be instituted until the presence of 
GAS has been confirmed, with coverage for streptococci and S. aureus, and an association 
of clindamycin and a beta-lactam antibiotic is recommended to achieve a more effective 
treatment of GAS invasive disease. Penicillin is relatively ineffective in the treatment of 
soft-tissue infections given the high concentration of organisms with a slow rate of 
replication (the Eagle effect), being less susceptible to the inhibition of cell wall synthesis 
[29]. Clindamycin, with an effect on protein synthesis, has been shown to decrease the 
production of M protein and SpeA and is thought to lead to a better outcome due to 
reduction of the production of proteins interfering with the immune system [135, 193]. 
 Interestingly, not all patients colonized or infected with a toxin-producer strain of S. 
pyogenes develop STSS, suggesting a role for the interaction between specific properties 
of the pathogen and of the host immune system in the development of this syndrome. Low 
levels of protective antibodies may contribute to the susceptibility of the host to invasive 
streptococcal infection [8] and an association between human leucocyte antigen class II 
haplotype and susceptibility to superantigen toxicity was already demonstrated [128].  
   
Chapter 1 
 
20 
 
1.4.2. Post-infectious sequelae 
 
 Rheumatic fever 
 
 Rheumatic fever is a delayed consequence of group A streptococcal pharyngitis. 
The major signs of the disease are polyarthritis, carditis, chorea and less frequently 
subcutaneous nodules and erythema marginatum, with minor signs of systemic 
inflammation potentially also evident [195]. It is an autoimmune disease that results from 
the production of autoreactive antibodies and T cells shown to cross-react with components 
of the group A streptococcus and host tissues. Streptococcal components include the M 
protein, which has epitopes that cross-react with cardiac and other host tissues [195]. 
 It is now considered a rare disease, and its prevalence reflects, in part, the adequacy 
of preventive medical care. The site of the antecedent infection to rheumatic fever is 
pharyngeal, but not all pharyngitis caused by GAS progress to rheumatic fever [195]. 
Some studies have already shown that rheumatogenic strains express potentially some M 
types, with an association of some rheumatic fever epidemics to such M types, including 
M5, 3, 6, 14, 18, 9 and 24 [195]. Although some rheumatic fever outbreaks were reported 
in the 1980s, a decrease in the incidence of this disease in the last 50 years was already 
associated with the replacement of rheumatogenic types by non-rheumatogenic types in 
cases of acute pharyngitis in the USA [189].  
 Although it is believed that there is some genetic susceptibility to the disease, the 
association of rheumatic fever to specific host factors, like the human haplotypes is still not 
clear [197].  
 
 Glomerulonephritis 
 
 The clinical manifestations of glomerulonephritis, a nonsuppurative sequela of 
GAS infections include discolored or coffee-colored urine due to hematuria, edema of the 
face and extremities and circulatory congestion due to renal impairment. Unlike rheumatic 
fever, both pharyngeal and skin infections can lead to glomerulonephritis.   
 Like in the case of rheumatic fever, the nephrotoxicity of GAS seems to be related 
to specific M types, although not all strains of the same M type are nephritogenic. The 
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predominant M protein types associated with skin infections and pyoderma are M2, 49, 42, 
55, 56, 57 and 60 while M types 1, 4, 12 and 25 are associated with throat infections and 
glomerulonephritis, although M types 12 and 1 are sometimes found in association with 
skin infections too [57, 173].  
 The development of poststreptococcal glomerulonephritis is related to an 
immunological response that seems to involve immune complexes with streptococcal 
antigenic components and subsequent glomerular deposition along with complement 
activation and molecular mimicry between streptococcal and renal components, leading to 
an autoimmune response [1]. The streptococcal antigens involved in the pathogenesis of 
the disease include the M protein, a streptococcal plasmin-binding protein (NAPlr)  and 
SpeB [1, 57].  
 Previous studies have already reported associations between the incidence of 
glomerulonephritis and the presence of host susceptibility factors, including the HLA 
haplotypes [1]. 
 
 
 1.5 Microbiological diagnosis 
 
 Clinical features of GAS can be nonspecific and do not discriminate between GAS 
and viral pharyngitis although particular signs are more typical viral features like 
rhinorrhea, cough, oral ulcers, and hoarseness [188]. Recommendations for the diagnosis 
of GAS include swabbing the throat and testing with a rapid antigen detection test 
(RADT), which detects the presence of group A streptococcal carbohydrate on a throat 
swab or culture [188]. Given the high incidence of pharyngitis in children and adolescents, 
it is also recommended that in case of a negative RADT, a culture should also be 
performed [188], because some RADTs appear to be significantly less sensitive than 
culture [31]. Culture of the throat swab in blood agar plates (BAP) was first described in 
1954 by Breese and Disney [36] and remains the standard for the establishment of the 
presence of GAS in the upper respiratory tract [31], with the additional advantage of 
isolating the microorganism for epidemiological and antimicrobial resistance studies.   
 In a positive throat culture, S. pyogenes appear as beta-hemolytic colonies among 
other normal microbiota, which consists of species from the genera Streptococcus, 
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Haemophilus and Neiseria as well as Staphylococcus and other bacteria, although less 
frequently [126]. Some strategies have been described to achieve a better recovery of 
group A streptococci such as growing the microorganism under anaerobic conditions, 
improving in this way the activity of streptolysin O, and the incorporation of antibiotics 
such as sufamethoxazole-trimethoprim (SXT) in BAP in order to inhibit the growth of 
some of the normal microbiota of the upper respiratory tract [57, 142]. However, these 
approaches have to be used carefully, because in vitro resistance of S. pyogenes to SXT, 
initially believed to be common, seems to be dependent on the composition of the medium 
used [35]. 
 
 
 1.6 Typing methods 
 
 There are several typing methods available for epidemiological studies of GAS, 
including phenotypic and molecular methods. The phenotypic methods, such as 
determination of antimicrobial susceptibility patterns and resistance phenotypes, phage 
typing or T typing, present the great advantage of being simple, rapid and effective in the 
identification of isolates recovered during an outbreak, but showed to be inadequate for 
evolutionary studies. Besides their low discriminatory power, the number of GAS isolates 
non-typeable with these methods (particularly in the case of T typing), reinforced the need 
to complement these methods with molecular typing methods [75, 156]. 
 
 M- and T-typing 
 
 Apart from being a major virulence factor produced by Streptococcus pyogenes, the 
M protein is also the basis of a typing system developed by Rebecca Lancefield in 1928. M 
typing is a serological system based on antigen-antibody reaction, depending on the 
preparation of type-specific sera and extraction of the M protein from the surface of GAS 
[118].  From 1928 to 1966, 51 different M types were described and at the present, there 
are 83 GAS M serotypes serologically unique and encoded by unique emm gene sequences 
[71]. However, it was soon recognized that this typing technique presented two important 
disadvantages: the difficulty in the preparation and maintenance of the sera with a high 
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number of M types, each requiring a specific serum, and perhaps most importantly, the 
increasing number of isolates non-typeable by this method due to low expression levels of 
the M protein or lack of specific sera. To overcome these disadvantages, another typing 
method was developed, based on the production of antibodies against the opacity factor 
(SOF). Although not all S. pyogenes strains produce this apoproteinase, the opacity factor 
is antigenically specific and correlates with the M type. This was particularly important in 
the case of M sera for opacity-producing serotypes, that were of poor quality and difficult 
to prepare [136]. However, this did not solve the problem with M typing that was 
eventually superseded by emm typing. 
 The T protein, a surface protein of S. pyogenes with serological activity, is the basis 
of a different typing scheme, T-typing [92]. It is an agglutination test between the T 
antigen extracted from the cell wall upon treatment with pepsin or trypsin and a set of 
commercially available sera.  Certain T types are associated with a specific M types [9, 
10]. There are 25 different T types and unlike the M protein, the most conserved region of 
this protein is the amino-terminal region [108]. This typing method has a low 
discriminatory power and the number of non-typeable isolates is still considerable.  
 
 emm typing 
 
 In the late 1980s, the resurgence of rheumatic fever and the increase in cases of 
invasive infections caused by GAS [53, 106, 182], as well as the number of isolates that 
could not be typed by the available phenotypic methods prompted a reassessment of the 
typing strategies leading to molecular approaches. The emm gene, that encodes the M 
protein, has a hypervariable region encoding the M serospecificity and it was soon 
demonstrated that the 5’ sequences of the emm gene could efficiently predict the M type 
[11, 12, 111, 167], allowing the establishment of emm typing as an extension of the 
Lancefield M typing system.  A Website was designed, allowing the comparison of the 
sequence resulting from the amplification by polymerase chain reaction and direct 
sequencing of the hypervariable region of the gene with all known emm sequences 
deposited (http://www.cdc.gov/ncidod/biotech/strep/protocols.htm), using the BLAST 
algorithm and allowing the assignment of the emm type and subtype. There are currently 
more than 200 different emm types, of which some correspond to isolates that are M non-
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typeable. The experience with M typing resulted in emm typing becoming the most widely 
used tool for epidemiological studies of GAS. However, it was recently shown that this 
typing technique is not sufficient to unambiguously identify GAS clones and should be 
complemented with other typing methods, such as pulsed-field gel electrophoresis (PFGE) 
or multilocus sequence typing (MLST), for a better characterization of GAS clones [43].  
The determination of emm restriction patterns, involving  the multiple digestion of the 
PCR fragment used for emm typing with endonucleases can also be used 
(http://www.cdc.gov/ncidod/biotech/strep/protocol_emm-type.htm) 
 Specific emm-types were already shown to correlate well with specific emm 
patterns [138] and it was also possible to establish an association between emm patterns 
and M protein class and the production of SOF; class I and SOF-negative belonged mostly 
to patterns A-D, while class II, SOF-positive to pattern E [19]. However, although the 
association between the emm patterns and the tissue of infection reflects a global trend, 
exceptions were reported [205].  
   
 Pulsed-field gel electrophoresis (PFGE) 
 
 Pulsed field gel electrophoresis is widely used in epidemiological studies of S. 
pyogenes. It involves the enzymatic digestion of total DNA embedded in agarose, using an 
infrequently cutting endonuclease. The digested bacterial plugs are subjected to 
electrophoresis in which the polarity of the current is changed at previously specified time 
intervals, generating DNA digestion patterns. The comparison of these patterns allows the 
deduction of the genetic relationships between the isolates [156]. Figure 1.5 is an example 
of a typical S. pyogenes PFGE gel.  
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FIGURE 1.5: Pulsed-field gel electrophoresis (PFGE) profiles generated upon SmaI digestion of 
total DNA from S. pyogenes. Fragment sizes (kb) of the lambda (λ) PFGE marker (New England 
Biolabs, Beverly, USA) are presented.  
 
 The endonuclease used to generate the profiles is frequently SmaI, but isolates 
expressing the M phenotype with DNA that is resistant to digestion with SmaI were 
described [51]. To overcome this, it is common to use alternative enzymes, often SfiI, to 
characterize the two macrolide resistance phenotypes, but a direct comparison of the M and 
MLSB clones is not possible when using different enzymes. The M isolates are resistant to 
the digestion with SmaI due to a methyltransferase encoded in the same genetic element 
that carries the mef(A) gene [79]. 
 Guidelines for the interpretation of the DNA digestion patterns generated by PFGE 
were proposed by Tenover and colleagues in 1995. According to these criteria, isolates 
with the same pattern are genetically indistinguishable and represent the same strain; 
isolates with two to three band differences, resulting from a single genetic event (a point 
mutation or an insertion or deletion of DNA) are closely related. Differences of four to six 
bands (likely due to two independent genetic events) means that the isolates are possibly 
related and isolates are considered unrelated if the PFGE patterns differ in seven or more 
bands (corresponding to three or more genetic events)[204].  
 At the present time, data analysis is often accomplished by using commercially 
available software, such as Bionumerics (Applied-Maths, Sint-Martens-Latem, Belgium). 
The use of this software allows the normalization of the PGFE gels and the storage in a 
database, making it possible to compare the restriction patterns of large sets of isolates 
over time. The result is a dendrogram that represents the relationships between all the 
242.5
194.0
145.5
97.0
48.5
533.5
485.0
436.5
388.0
339.0
291.0
λ ladder
Chapter 1 
 
26 
 
isolates according to the criteria used for interpretation and comparison. Frequently, 
isolates sharing > 80% similarity on the dendrogram will be considered closely related, as 
supported by work with other streptococci [184]. PFGE is not only widely used in 
epidemiological studies of GAS, but it also presents a  high discriminatory power [43].  
 GAS virulence has been related to the presence of bacteriophages and to horizontal 
gene transfer of large DNA segments thereby creating diversity in PFGE types, since 
alterations in the number and positions of the bands in the agarose gel can arise from these 
insertions on the bacterial chromosome [43, 185, 198]. Moreover, it is a very useful tool 
for short-term epidemiological studies, because the genetic variation indexed by this 
method accumulates relatively rapidly. This rapid accumulation of variation can represent 
a disadvantage for longer term epidemiological studies that would be better served by 
genetic variation that accumulates relatively slowly.  
 
 Multilocus sequence typing (MLST) 
 
 One of the major limitations of PFGE is the difficulty in comparing results obtained 
by different laboratories, which is particularly important in global epidemiology studies. 
To overcome this, a typing scheme was developed - multilocus sequence typing (MLST) - 
that takes advantage of the unambiguous nature and portability of DNA sequence data for 
the characterization of bacterial isolates. Internal fragments of seven housekeeping genes 
(their products are involved in vital functions, being present in every organism) are 
sequenced and an allele number is assigned by comparing to other sequences deposited in a 
database (www.mlst.net) [129]. An MLST scheme for S. pyogenes was developed [68] and 
626 different STs were identified so far (spyogenes.mlst.net).  
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FIGURE 1.6: The multilocus sequence 
typing scheme: Amplification and 
sequencing of the internal fragments of 
housekeeping genes and comparison with 
known alleles, followed by assignment of the 
allele numbers and allelic profiles. Adapted 
from Spratt et al. [192] 
Although it presents some limitations, such as the difficulty of the technique and the cost, 
it has many advantages, including its high resolving power, allowing in many instances the 
discrimination of isolates of the same emm type, and as variations within the nucleotide 
sequences of housekeeping genes accumulates relatively slowly, temporally separated 
isolates of the same ST can be recovered, which can be useful in long term epidemiological 
studies. The other advantage is the possibility of different laboratories comparing 
unambiguous results without the need to exchange strains.  The clustering of isolates 
achieved by MLST is in good agreement with that obtained using other techniques [43, 
68].  
 Based on MLST results, the clonal relationships between the isolates can be 
inferred using the eBURST algorithm that divides MLST data into groups of related 
isolates and clonal complexes, providing information about the founding genotypes or the 
likely patterns of evolutionary descent within the clusters [76]. This algorithm is based on 
a simple model: a clonal complex arises from the increase in frequency of the founding 
genotype (due to a fitness advantage or random genetic drift) and from its diversification. 
In terms of MLST, the descendants of the founder will present the same allelic profile but 
over time diversification will also occur and variants in one of the seven alleles (single 
locus variants - SLVs) will arise. Eventually these SLVs will diversify further, resulting in 
double locus variants (DLVs) or triple-locus variants (TLVs) and so on. Using the 
eBURST rules, it is possible to identify potential links between STs that correspond to the 
most probable pattern of descent, within each clonal complex [76]. However, the eBURST 
algorithm is not globally optimized and such links within the clonal complexes can violate 
the rules proposed.  To overcome this, a globally optimized implementation of eBURST 
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was developed - goeBURST [82]. A software implementation of this algorithm is currently 
available (http://www.phyloviz.net), with the advantage of integrating additional 
information such as clinical or patient demographic data or other isolate information (such 
as other phenotypic and molecular characteristics) [83].  
 
 Superantigen gene profile 
 
 The profiling of the superantigen (SAg) gene content of GAS isolates - toxin 
profiling - has been used as a molecular typing method, since it allows further 
discrimination of GAS isolates of the same emm type. As mentioned above, some of the 
superantigens are encoded on temperate bacteriophages (SpeA, SpeC, SpeH, SpeI, SpeK, 
SpeL, SpeM) and the exchange and integration of these prophages among GAS isolates 
must play an important role in the genomic diversification of the species and in the 
emergence of clones associated to toxin-mediated diseases, such as scarlet fever or 
invasive GAS disease [84, 137, 221].  
 A recent method of SAg profiling was developed, using two multiplex PCR 
reactions that allow the detection of 13 gene fragments (11 superantigens - SpeA, SpeC, 
SpeH, SpeI, SpeK, SpeL, SpeM, SpeG, SpeJ and SMEZ - and SpeB and SpeF, used as 
positive controls) covering all the known allelic variants of the genes [84]. A similar typing 
method that also claims to include all the superantigens, but also other genes encoding 
virulence factors was developed, but is was already suggested that the profiling of 
additional virulence factors did not bring additional information [34]. Using SAg profiling, 
a strong association between the complete profile and emm type was reported and it was 
also suggested that variation of the SAg profile in the population occurs at a faster rate than 
some of the usually used typing methods like emm typing or MLST, being suitable in the 
identification of clones associated with specific properties, like the association to a specific 
disease or enhanced virulence [63, 85, 86, 222]. 
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 Whole-genome sequencing 
 
 The importance of recombination as a key factor in bacterial evolution has been 
recognized, and it has also been suggested that recombination rates in bacteria may be 
higher than mutation rates [74, 125, 191]. Furthermore, when recombination involves 
DNA portions that are larger than the internal gene fragments analyzed by MLST, the 
result will be the identification of the same alleles in strains with different genetic 
backgrounds [42]. To overcome this and to complement and improve the typing techniques 
described above, whole genome sequencing methods have been applied to the study of S. 
pyogenes, offering highly sensitive and unequivocal comparison at the single nucleotide 
level [14].  
 Up to now (December, 2013), the full genomes of 19 strains are available. 
(http://www.ncbi.nlm.nih.gov/genome/genomes/175). Each genome is approximately 1.9 
Mb in size, and about 10% of the overall gene content is encoded on variably present 
exogenous elements, such as prophages and integrative conjugative elements [15]. With 
the availability of these genomes, many virulence factors were identified, novel host-
pathogen interactions were elucidated and several virulence factor regulatory pathways 
were studied, providing new insights into the molecular pathogenesis of Streptococcus 
pyogenes [148].  
 The recent advances in next generation sequencing technologies, offering the 
opportunity to obtain complete or nearly complete genome sequences of large numbers of 
individual strains will allow the establishment of genetic differences, undetectable by other 
typing techniques, with recognized advantages for both outbreaks and long-term 
epidemiological studies [14, 16, 42].  
 
 Although less frequently, the epidemiological characterization of GAS was done 
using other methods, such as Multilocus Enzyme Electrophoresis (MLEE), vir typing, 
ribotyping, Random Amplified Polymorphic DNA (RAPD) and Fluorescent Amplified-
Fragment Length Polymorphism Analysis (FAFLP) [75, 99].  
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 1.7 Antimicrobial resistance and treatment of GAS infections  
 
 The treatment of patients with acute pharyngitis should be done with an antibiotic 
at an appropriate dose for a period expected to eradicate the microorganism from the 
pharynx [188]. Among the antibiotics available for the treatment of GAS pharyngitis are 
beta-lactams (such as penicillin, ampicillin and amoxicillin), many cephalosporins, 
macrolides and clindamycin [31]. Due to its efficacy, safety, narrow spectrum and cost, 
penicillin remains the treatment of choice for this type of infections [188]. The duration of 
the treatment with oral penicillin is usually 10 days, mainly to protect against the 
complication of acute rheumatic fever [4].  However, other antibiotics taken for a shorter 
duration such as cephalosporins or macrolides may have a comparable effect to penicillin 
taken for 10 days, overcoming the possible low compliance of long antibiotic course [4]. In 
Portugal, where oral penicillin is not available, macrolides and lincosamides, which are 
often recommended as suitable alternatives for patients allergic to penicillin [31], are an 
option with the  additional advantage of having an oral route of administration.  
 
 1.7.1 β-lactams 
 
 The mechanism of action of β-lactam antibiotics involves the binding and 
inactivation of bacterial proteins that are responsible for cell wall synthesis, the penicillin 
binding proteins (PBPs) [44].  
 In S. pneumoniae, penicillin resistance in natural populations is associated to 
mosaic genes, resulting from the replacement of segments of PBPs of susceptible strains by 
homologous blocks from resistant strains, most likely by natural transformation. In spite of 
extensive use of penicillin in the treatment of GAS infections, there are no reports of β-
lactam resistance detected in vivo in S. pyogenes isolates and one of the reasons for this 
could be the fact that PBPs of S. pyogenes contain no lengthy regions of similarity with 
genes from other streptococci, making it unlikely that the acquisition of penicillin 
resistance arises by homologous recombination with genes from other species [78]. Based 
on the creation of penicillin-resistant laboratory mutants, it was already suggested that in 
the case of S. pyogenes, the emergence of penicillin resistance could lead to marked 
changes in the biology of the microorganism including the expression of low-affinity 
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PBPs, physiological defects, poor growth rates, decreased production of M protein and 
morphological abnormalities [94, 105].  
 
 1.7.2. Tetracyclines 
 
 Tetracyclines bind reversibly to the 30S ribosomal subunit, blocking the binding of 
the tRNA, inhibiting protein synthesis. Resistance to tetracycline arises upon genetic 
acquisition of tet genes. Four variants of this gene were already reported in S. pyogenes, 
tet(M) and tet(O), that encode ribosomal protection proteins and less frequently, tet(K) and 
tet(L), encoding efflux pumps [46].  
 Although tetracyclines are not usually used in the treatment of GAS infections, 
their use as animal growth factors can promote the emergence of resistance in human 
pathogens [46]. Tetracycline- and macrolide-resistance genes are often carried in the same 
genetic elements and the most frequent associations are tet(M) and erm(B) or mef(E) genes 
[33, 35, 82], as well as tet(O) and mef(A) or erm(A) genes [38, 62, 91]. There are several 
genetic elements carrying these genes, and some are found among other species of the 
genus Streptococcus [66, 210], with the ability to spread within streptococcal populations 
[100, 123]. Given this, tetracycline resistance surveillance studies are important and it was 
already suggested that tetracycline use could act as a selective force driving macrolide 
resistance in Streptococcus pyogenes [151].  
 
 1.7.3 Macrolide and Lincosamides  
 
 Macrolides and lincosamides are chemically unrelated but share many biological 
properties, such as the mechanism of action and mechanism of resistance, antimicrobial 
activity and pharmacological properties. Erythromycin, produced by Saccharopolyspora 
erythraea (formerly Streptomyces erythreus), is a 14-member macrocyclic lactone ring, 
attached to two sugar moieties. Newer macrolides, such as azithromycin or clarithromycin, 
are derived from erythromycin and have a greater spectrum of action, better oral 
absorption, longer half-life and fewer side effects. Lincosamides are devoid of the lactone 
ring. Lincomycin was the first lincosamide isolated from a microorganism and its chemical 
modification produced clindamycin, with higher absorption upon oral administration [194]. 
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Macrolides and lincosamides inhibit protein synthesis due to the binding of the antibiotic 
to the 50S ribosomal subunit that results in stimulating dissociation of the peptidyl-tRNA 
molecule from the ribosomes during elongation and chain termination [172].  
 
 1.7.4 Streptogramins  
 
 Streptogramins are natural antibiotics, consisting of an association between two 
types of molecules, group A and group B streptogramins [175]. Alone, each compound 
exhibits a moderate bacteriostatic activity, but in combination they can produce a 
bactericidal effect. Streptogramin B acts on the 50S ribosomal subunit, competing with 
macrolides for the same binding sites; resistance to both classes of antibiotics arises 
through the same mechanisms. Type A streptogramins blocks peptide bond formation, 
inhibiting the peptidyl transferase reaction directly [98].  
 
 1.7.5 Macrolide resistance mechanisms in GAS 
 
 There are two described mechanisms used by S. pyogenes to resist the bacteriostatic 
action of macrolides: target site modification, by methylation or mutation that prevents the 
binding of the antibiotic to the ribosome and active efflux of the antibiotic. These 
mechanisms have already been described in macrolide and lincosamide producers, to 
protect themselves from the action of the antibiotics [124].  
 Methylation was the first mechanism of macrolide resistance and it is due to 
posttranscriptional modification of the 23S rRNA by a methyltranferase [213]. In general, 
genes encoding these methylases are designated by erm (erythromycin ribosome 
methylase) and several classes of erm genes have been described [172]. As the binding site 
in the 50S ribosomal subunit for erythromycin overlaps the binding site of the newer 
macrolides, as well as lincosamides and streptogramin B antibiotics, the modification by 
methylation reduces the binding of most macrolides, lincosamides and streptogramin B, 
resulting in the MLSB phenotype [215]. Expression of MLSB resistance can be constitutive 
or inducible, generating the cMLSB or the iMLSB phenotypes, respectively. In the case of 
the iMLSB phenotype, bacteria produce inactive mRNA that becomes active only in the 
presence of a macrolide inducer. In the presence of the inducer (usually erythromycin), 
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there are mRNA rearrangements, allowing the ribosomes to translate the methylase coding 
sequence [124]. On the contrary, in bacteria expressing the cMLSB phenotype active 
methylase mRNA is produced in the absence of an inducer. Phenotipically, iMLSB isolates 
present reduced clindamycin inhibition zone proximal to the erythromycin disk in the 
double disk test, whereas a regular circular shape is present around the clindamycin disk 
when the disks are placed apart [214].  
 Many of the erm genes are associated with conjugative or non-conjugative 
transposons which are often associated with other antibiotic resistance genes, although 
some have been found in plasmids [37, 172]. These transposons, with the capacity to 
transfer the resistance traits to susceptible isolates by conjugation [89, 90], have a wide 
host range, which can explain the observation that clinical isolates from many different 
bacterial species carry these erm genes [172].  
 The other mechanism, responsible for resistance to 14- and 15-membered 
macrolides and susceptibility to 16-membered ring macrolides, lincosamides and 
streptogramin B (the M phenotype), is mediated by a membrane associated protein that 
pumps the antibiotic out of the cell, keeping intracellular concentrations low and 
preventing the binding of antibiotics to the ribosome. This membrane associated pump is 
encoded by mef genes (macrolide efflux) [200]. Several mef genes have already been 
characterized of which mef(A) is the most frequently found [49].  The mef(E) determinant, 
first described in S. pneumoniae, shares 90% DNA and 91% aminoacid identity with 
mef(A) [202] and its presence in S. pyogenes isolates was already confirmed [32]. The 
discrimination between mef(A) and mef(E) is epidemiologically important because they are 
carried in different genetic elements and their dissemination is also different [61, 62]. 
Other mef genes were found in S. pyogenes, such as mef(I), mef(O), a mef mosaic variant, 
in which the 5’ region was identical to that of mef(A) and the 3’ region was identical to that 
of mef(E), and another mef variant [32, 178]. The mef(A) gene is usually associated with a 
chimeric element composed of a transposon inserted into a prophage [7], while the mef(E) 
genes are often associated with mega elements, in association with other resistance genes 
in composite transposons [62]. The genetic elements carrying the mef genes have already 
shown the ability to be transferred between different S. pyogenes isolates [90, 110]. 
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 Other mechanisms of resistance such as alterations of ribosomal proteins were also 
described, but are not frequently observed in GAS isolates responsible for infections and 
have little clinical impact [25].  
 
 1.7.6 Epidemiology of macrolide resistance 
 
 Less than 20 years after the isolation of erythromycin from Saccharopolyspora 
erythraea in 1952 and its introduction in the clinical practice, resistance to this antibiotic 
became apparent in some clinical isolates. In 1968, the first group A streptococci resistant 
to erythromycin were reported in England, in the Unites States and in Canada [65, 112, 
177]. Since then, increases in macrolide resistance were reported in many countries, 
although each country may retain specificity regarding resistance rates, prevalence of the 
macrolide resistance phenotypes and phenotypic and molecular characteristics of the 
resistant isolates. 
 A relationship between the decrease in macrolide resistance and the decrease in 
macrolide consumption was already demonstrated [3, 17, 59, 211]. Some studies showed 
an association between specific macrolides (intermediate acting and long-acting 
macrolides) in the selection of resistance and of a particular macrolide resistance 
phenotype [131, 144]. However, the relationship between macrolide consumption and 
resistance is not always so obvious. In Slovenia, after an increase in macrolide 
consumption (mainly long-acting macrolides), paralleled by a significant increase in the 
macrolide resistance rate from 0 % to 7.4% in the period 1994-1999, resistance rates 
doubled in S. pyogenes, reaching a value of 20% in 1999-2004, despite a 21% decrease in 
macrolide consumption [47, 48]. In Spain, a decrease in macrolide resistance rate was 
reported with no significant changes in macrolide consumption [157]. Macrolide use must 
be the main driver of macrolide resistance in Streptococcus pyogenes; however, natural 
clonal fluctuations may also play a role.  
 
 In Spain, high macrolide resistance rates have been reported. Between 1996 and 
2007 in four studies, including 2,287 S. pyogenes isolates, the antimicrobial resistance rates 
and phenotypes of resistance, as well as their temporal trends were analyzed. Over this 11-
year period, 19% of the isolates were resistant to erythromycin, with a clear predominance 
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of the M phenotype (64.5%). Among the MLSB isolates, the great majority expressed the 
cMLSB phenotype (94.9%), while the iMLSB phenotype was expressed by only 5.1% of the 
isolates. In this period, a temporal increasing trend in the prevalence of the MLSB isolates 
was reported (from 14% in 2001-2002 to 35.5% in 2006-2007), probably due to the 
replacement of macrolide resistant clones. Interestingly, a decreasing macrolide resistant 
trend was detected in this same period (24.3% in 2001-2002 to 19.0% in 2006-2007, 
p<0.001), that was undetectable when analyzing the whole study period [161]. A higher 
resistance rate was reported in this country, between 1994 and 2006 (33%), still with a 
clear dominance of the M phenotype (77%). Isolates presenting the MLSB isolate presented 
mostly the constitutive form of this phenotype (20%) while 3% expressed the iMLSB 
phenotype. Among the cMLSB isolates, erm(B) was the most prevalent resistant 
determinant and erm(TR) was associated to the iMLSB phenotype. The M isolates carried 
mef(A/E), with no distinction made between these two genetic elements [176]. However, 
this study included GAS isolates recovered from a wide spectrum of clinical 
manifestations, including severe GAS infections, skin infections, scarlet fever, rheumatic 
fever and tonsillo-pharyngitis, as well as asymptomatic carriers, and macrolide resistance 
rates are different in different types of infection [55, 86].  
 Another survey in Spain including mostly pharyngeal isolates detected a high 
macrolide resistance rate (21%), with annual variations of 14.3% to 28.9% between 1999 
and 2005 and an increase in the prevalence of MLSB isolates was also noted, from 3% in 
1999 to 13% in 2005. Although there were fluctuations in the prevalence of isolates 
presenting the M phenotype, their tendency since 2003 was to decrease [162].  
 Temporal and geographical variations in macrolide resistance rates and phenotypes 
are frequent and sometimes local variations within the same country can occur. In 
Cantabria, Spain, macrolide resistance reached a maximum of 53.6% between July and 
December of 2002, but a rapid decrease in the last quarter of 2003 was reported and in 
2004 the macrolide resistance rate was as low as 3.7%. In this period there was also a rapid 
inversion of macrolide resistance phenotypes, with a decrease in the prevalence of the M 
phenotype, paralleled by an increase in the proportion of isolates expressing the MLSB 
phenotype, without significant changes in macrolide consumption [157].  
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 In Greece, macrolide resistance in GAS has also reached high values. In a survey 
conducted in Western Greece, between January 1999 and December 2002, including only 
GAS recovered from children with tonsillo-pharyngitis, a resistance rate of 24% was 
reported, without a clear dominance of any of the macrolide resistance phenotypes. 
However, it was not known if the macrolide resistance rates or the prevalence of the 
macrolide resistance phenotypes were stable throughout the study period [93]. Another 
study, carried out between January 2003 and December 2006, detected a lower value of 
resistance (15%), as well as an increase in macrolide resistance rate from 12% in 2003 to 
19% in 2006. Once again, there was no considerable dominance of any of the macrolide 
resistance phenotypes (53.7% expressed the M phenotype and 46.3% the MLSB 
phenotype). However, this study included mostly tonsillo-pharyngitis patients, but also 
other types of infection from only one Greek hospital and when considering pharyngeal 
isolates only, macrolide resistance was significantly higher [140]. 
 A more recent survey revealed a macrolide resistance rate of 24%, stable during the 
study period (January 2007 and June 2009), but an increase in the prevalence of the MLSB 
phenotype was noted with a concomitant decrease in the prevalence of the M phenotype. In 
this work, the authors attributed the appearance of resistant isolates to the emergence of 
particular clones [133]. 
 
 In Italy, macrolide resistance in S. pyogenes between 1993 and 1996 remained low, 
below 5%. However, from 1995 to 1996 an increase in macrolide resistance from 2.6% to 
17.1% was reported, and the M phenotype was the most frequent, with 73% of the isolates 
expressing this phenotype [23]. In 2000, high macrolide resistance rates (35.8%) were 
reported, although this study included only 127 GAS recovered from the same hospital. 
The most frequent macrolide resistance phenotype was MLSB, expressed by 83 isolates 
(65%) [64]. More recent data reported a significant decrease in macrolide resistance from 
28.1% in 2001 to 15.6% in 2006. The overall macrolide resistance in this period was 
22.6% (n=320), without the dominance of any of the macrolide resistance phenotypes. This 
study was conducted in a central Italian region and the authors found a correlation between 
this decrease and the consumption of a specific class of macrolides, namely long-acting 
macrolides [144].  
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 Lower values of macrolide resistance were reported in Germany. Between 1999 and 
2002 and between 2002 and 2004, the macrolide resistant rate was constant, with a value 
of 14%, but from one period to another, an increase in the prevalence of isolates expressing 
the M phenotype was reported [165, 166]. In the first study, 55.6% of the isolates 
presented the M phenotype and carried the mef(A) gene; iMLSB isolates represented 31.5% 
of the population (carrying the erm(A) gene) and only 13% of the isolates presented the 
cMLSB phenotype and carried the erm(B) gene [165]. In 2002-2003, a dramatic increase in 
the prevalence of isolates presenting the mef(A) genotype was reported, reaching the value 
of 94%, in spite of the same resistant rate [166]. However both studies included a low 
number of isolates (possibly due to short study periods) and one included throat and skin 
isolates [165], while the other included solely isolates from community-acquired 
respiratory tract infections [166]. In recent years, a decrease in the macrolide resistance 
rate was reported to 8.2% (n=29) in 2005-2006 [33] and to 2.6% (n=9) in 2006-2009 [73]. 
However the latter was performed in one medical centre and can represent a particular 
situation of lower macrolide resistance that the authors attributed to a more restrictive use 
of macrolides in that region [73]. The number of resistant isolates is low in both studies, 
without any dominant macrolide resistant phenotype.  
  
 In France, macrolide resistance increased from 6% (n=93) to 22% (n=72) between 
1996-1999 and 2002-2003. Both studies included pharyngeal isolates recovered from 
pediatric patients. The MLSB phenotype was the most prevalent, although in 2002-2003, 
the difference in the prevalence of both phenotypes was more evident. The M isolates 
carried the mef(A) gene and the great majority of the MLSB isolates carried the erm(B) 
resistant determinant [24, 25]. However, from October 2009 to May 2011, only 19 isolates 
from a collection of 585 GAS isolates collected from children with pharyngitis were 
resistant to erythromycin, indicating a decrease in macrolide resistance in France, reaching 
the value of 3.2%, that was attributed by the authors to a decrease in antimicrobial 
consumption in this country [59]. A significant decrease in macrolide resistance, 
significantly correlating with a decrease in antimicrobial consumption was also reported in 
Belgium, where the prevalence of macrolide resistant S. pyogenes decreased from 13.5% to 
3.3% during 1999-2006 and remained low from 2006 onward. Interestingly, this decrease 
was accompanied by an increase in the proportion of erm(A) positive isolates among the 
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resistant population, from 1.2% (n=81) to 76.6% (n=36) in 2009 and a decrease in the 
proportion of mef(A) and erm(B) isolates [211].  
 
 In Finland, there was also a statistically significant decrease in macrolide resistance 
rate among GAS isolates, after a reduction in the use of macrolide antibiotics. An increase 
in macrolide resistance was reported until 1993, when resistance rates reached high values 
(19%), but resistance diminished to a value of 8.6% in 1996 [183]. In a study conducted 
between 1994 and 1995, the majority of the isolates expressed the M phenotype (61%, 
n=242), and only 4 of the MLSB isolates presented the constitutive form of this phenotype, 
while 150 isolates expressed the iMLSB phenotype [110]. In the period between 1997 and 
2001, macrolide resistance in GAS presented a decreasing trend, although it did not reach 
statistical significance [17]. In 2004-2005, macrolide resistance in Finland was low, below 
5%, although no information about the prevalence of macrolide resistance phenotypes was 
available [168]. Low macrolide resistance rates were also reported in Norway, the 
Netherlands and Sweden [127, 168].  
 
 Besides the geographical and temporal differences in macrolide resistance rates and 
in the prevalence of particular macrolide resistance phenotypes and genotypes, differences 
in the dominant emm types were also documented. Usually, the majority of these emm 
types shared the same resistance determinants and presented the same ST, which suggests a 
wide geographical dissemination of a few clones. However, isolates fully susceptible to 
macrolides that share the same pulsed-field gel electrophoretic profiles (PFGE) or the same 
sequence types (STs) as these major clones have been described, and several resistant 
determinants have been associated with each resistant lineage [59, 64, 130, 133, 162, 165, 
201, 223]. Taken together, these data imply that independent acquisition of resistance 
genes by the same prevalent clones followed by local expansion could have also played a 
role in conditioning the successful macrolide resistance phenotypes and clones in particular 
geographic locations. 
 An association between certain emm types and macrolide resistance was already 
documented [2, 46, 110, 119, 136, 182], but in most of these studies the characterization of 
the S. pyogenes isolates was limited to emm typing. Moreover, it is still not clear if the 
macrolide resistant population has its own dynamics or if this is simply the reflex of 
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molecular characteristics of the general GAS population. The question of whether some 
genetic backgrounds are more prone to acquire and carry macrolide resistant genes or the 
high prevalence of a particular emm type in the macrolide resistant population is just the 
result of an equally high prevalence in the general population remains unanswered.  
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Aims of the Thesis 
  
 Macrolides are suitable alternatives for the treatment of infections caused by 
Streptococcus pyogenes. There are large geographical and temporal differences in 
macrolide resistance rates in S. pyogenes causing tonsillo-pharyngitis. Several studies have 
found a relationship between antibiotic consumption and macrolide resistance, with some 
specific classes of macrolides being more implicated than others in the selection of 
resistance and of particular resistance phenotypes. However, natural fluctuations of the 
clones can also play a role in the prevalence of macrolide resistance rates, although the 
contribution of each factor remains unclear. 
 The main purpose of the work presented in this thesis was the characterization of S. 
pyogenes associated with tonsillo-pharyngitis in Portugal, with a special focus on 
macrolide resistance. This included the determination of macrolide resistance among GAS 
causing tonsillo-pharyngitis, as well as their macrolide resistance phenotypes and evolution 
in a large period of time and the characterization of the clonal composition of the 
population. The knowledge of the macrolide resistance rates is important for the empiric 
treatment of GAS infections, since they provide an alternative to penicillin. Understanding 
the dynamics of the resistant population is equally important, in order to track the 
dissemination of specific clones in close geographic areas or to identify particularly 
successful clones. The knowledge of the molecular characteristics of the population will 
also provide some insights into the contribution of fluctuations of the clonal composition to 
the overall macrolide resistance rate. For this purpose, the macrolide susceptibility among 
GAS isolates recovered from patients with tonsillo-pharyngitis in several laboratories 
located throughout Portugal was determined and a collection of 620 macrolide resistant 
GAS were studied by phenotypic and molecular techniques, which included the 
determination of macrolide resistance phenotypes and genotypes, T typing, emm typing, 
PFGE restriction profiling and MLST. All the genetic lineages identified were compared 
with the ones described in other European countries.  
 Another important contribution for the main purpose of this thesis involved a study 
to determine the relative contributions of geographic dissemination of macrolide resistant 
clones and genetic acquisition of macrolide resistance genes followed by local spread. To 
do this, a collection of 803 GAS isolates, isolated between 2000 and 2005, representing 
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50% of the total pharyngeal isolates recovered in Portugal was characterized and 
compared. All the isolates were characterized using T typing, emm typing, PFGE profiling 
and MLST. Statistical tests were used to ascertain the differences between the two 
populations. 
 Another important goal of this thesis was to characterize the S. pyogenes isolates 
causing scarlet fever in Portugal, given the recent outbreak reports. The large collection of 
pharyngeal isolates available allowed us to use the same approach used to study macrolide 
resistant GAS - a comparison between scarlet fever isolates and pharyngitis isolates, in an 
attempt to identify molecular markers of this syndrome. Besides the usual typing 
techniques indicated above, SAg profiling was also performed, given the frequent, 
although contradictory association of some exotoxins produced by S. pyogenes to scarlet 
fever. 
 Lastly, we aimed to find out if the strategy used in the microbiology laboratory of 
isolating and subculturing one single colony from the primary swab plate was the most 
acceptable for antimicrobial susceptibility testing and other epidemiological studies. This 
study was prompted by recent reports of heterogeneity among colonies recovered from a 
single patient. For this purpose, we analyzed colonies isolated from the same primary plate 
of 35 pharyngitis patients, from the same hospital - originating a total of 321 isolates, by 
antimicrobial susceptibility testing and emm typing.  
 62 
 
  
 
CHAPTER 2 
 
 
INTRAHOST VARIATION IN INFECTION 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Intrahost variation in infection 
 
65 
 
 INTRODUCTION 
 
 The human oropharynx is heavily colonized and it is the site for carriage of many 
important human pathogens, including Streptococcus pneumoniae, Streptococcus 
pyogenes, Haemophilus influenzae, Neisseria meningitidis, Moraxella catarrhalis and 
Staphylococcus aureus [15]. 
 In the microbiology laboratory, the identification of the bacterial causative agent of 
tonsillo-pharyngitis involves the culture of the throat swab in blood agar plates [3]. The 
presence of beta-hemolytic colonies among other normal flora in a throat culture, 
associated to a diagnosis of tonsillo-pharyngitis is indicative of Streptococcus pyogenes as 
the ethiological agent involved. In order to identity the agent and further characterize the 
bacteria, it is standard procedure to isolate and subculture one single colony, with the 
underlying assumption that the infection is caused by a single clone. However, it is well 
known that different genotypes or phenotypes can be found within a bacterial population in 
carriage and infection [20, 24]. 
 Co-colonization, or the presence of more than one strain in the nasopharynx seems 
to be required for horizontal gene transfer between different pneumococcal strains [4, 16, 
21], which may lead to changes in capsular serotype or antimicrobial susceptibility. Using 
culture-based techniques, S. pneumoniae co-colonization rates were determined to range 
from 1% to 20% [9, 12, 21, 25], and using molecular techniques higher rates were reported 
[25]. Most of these studies described the serotype diversity among Streptococcus 
pneumoniae [4, 9, 12, 25], while others also addressed the genetic diversity of these 
isolates and found differences in the serotype, PFGE type, prophage content and 
antimicrobial susceptibility patterns in carriage [21]. It was recently demonstrated that 
genetic exchange in conditions similar to those found in vivo is extremely efficient [16]. 
Moreover, it is well known that horizontal gene transfer events are important in the 
emergence of novel virulence traits as well as in the dissemination of antimicrobial 
resistance determinants and epidemiological studies indicate that the source of these 
antimicrobial resistance genes seems to be the other colonizing strains, rather than invasive 
isolates [7]. However, contrary to S. pyogenes, S. pneumoniae is naturally transformable, 
incorporating foreign DNA by transformation, in which the horizontal gene transfer 
between different strains co-existing in the same niche is more likely to occur [16].  
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 In Streptococcus pyogenes, there are few studies addressing the occurrence of more 
than one strain in a single host. In a study conducted in an area where acute tonsillo-
pharyngitis is endemic, recovering 5 isolates from each sample, a single clone of S. 
pyogenes was detected in each case of infection using pulsed-field gel electrophoresis [19]. 
Also in the oropharynx of healthy carriers, a single clone of S. pyogenes was detected 
giving the first indication that co-colonization is rare [19].  However, antibiotic resistance 
heterogeneity in streptococcal isolates was recently described in different S. pyogenes 
colonies from the same throat swab [26]. This study included 16 pediatric patients, and 
heterogeneity was found both in antimicrobial susceptibility pattern (in 3 patients) and 
emm subtype (in one patient). The differences in antimicrobial susceptibility included the 
acquisition of the transposon Tn916, carrying the tet(M) gene, conferring tetracycline 
resistance in one isolate among nine susceptible isolates and the gaining of the transposon 
Tn1207, originating macrolide resistance through the action of the mef(A) gene [26]. In 
spite of this, all the resistant and susceptible isolates from the same patient shared the same 
emm type and multilocus sequence type (MLST) sequence types (ST). In the only case 
where differences were observed solely on the emm subtype level, all the isolates shared 
the same ST and antimicrobial resistance profile. This heterogeneity among isolates of the 
same genetic background raised the question of whether culture-based techniques that rely 
on the assumption that an infection is caused by a single clone are adequate to perform 
antimicrobial susceptibility testing and epidemiological studies. According to the authors, 
if only a minority of colonies carries resistance genes, the classical antimicrobial 
susceptibility testing would consider the strain as susceptible, but the proliferation of the 
resistant isolates after initiation of antibiotic treatment could have as a consequence a 
therapeutic failure. Moreover, single-colony based epidemiological studies could be 
measuring antimicrobial resistance rates that were underestimated [26]. 
 The aims of this study were to evaluate the potential bacterial molecular 
heterogeneity and diversity in antimicrobial resistance profiles in GAS isolates recovered 
from single throat swabs of patients associated with a diagnosis of tonsillo-pharyngitis, in a 
large teaching hospital in Lisbon.  
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 MATERIALS AND METHODS 
 
 Bacterial isolates  
 Bacterial isolates were recovered from 44 patients with a diagnosis of tonsillo-
pharyngitis, from September 2006 to April 2007 in the microbiology laboratory of Hospital 
de Santa Maria in Lisbon. For each throat swab culture, ten β-hemolytic colonies 
(presumably GAS colonies) were selected from the primary plates and subcultured to a 
secondary plate for conservation and further testing. In some cases, it was not possible to 
isolate 10 colonies for some primary plates; when less than 8 colonies were recovered, the 
primary plate was excluded from the study (n=9). The final collection included 321 GAS 
isolates, from 35 patients, in which 15 samples originated 10 isolates, 11 samples 9 isolates 
and 9 samples 8 isolates. 
  
 Antimicrobial susceptibility testing and macrolide resistance phenotype  
 Susceptibility to erythromycin, clindamycin, tetracycline, norfloxacin and 
trimetropim- sulfametoxazole (Oxoid, Basingstoke, UK) was tested using disk diffusion 
according to CLSI recommendations [6]. The macrolide resistance phenotype was 
determined according to a double disk test previously described [18].  
 
 DNA extraction 
 Total bacterial DNA was isolated according to the methodology described by the 
Centers for Disease Control and Prevention (CDC) 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). 
 
 emm typing 
 emm typing was performed as described by the CDC 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). Amplification products were 
purified using the High Pure PCR purification kit (Roche, Mannheim, Germany) according 
to the manufacturer’s instructions and sequenced using primer emmseq2, and the DNA 
sequences were searched against the emm sequences deposited in the CDC database 
(http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm). 
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 RESULTS 
 
 Antimicrobial susceptibility testing 
 Among the colonies isolated from each of the primary plates, there were no 
differences in the antimicrobial resistance profiles. Given this homogeneity, results of 
antimicrobial susceptibility testing will be presented by sample and not by individual 
colonies.  
 Among the 35 samples, erythromycin resistance was found in isolates from 5 
samples and clindamycin in isolates from 3 isolates samples. Three samples yielded the 
cMLSB phenotype, while 2 presented the M phenotype. Tetracycline resistance was 
expressed by isolates from one sample. Two samples presented isolates expressing 
resistance to norfloxacin and all the isolates were susceptible to trimethoprim-
sulphamethoxazole.  
 
 emm typing 
 Similarly to the antimicrobial resistance profiles, there were no differences in the 
emm type presented by all the colonies from the same primary plate. Furthermore, the 
amplification and sequencing of the emm gene revealed the same emm subtype among 
GAS isolates originated from the same plate.  
 The most frequent emm type was emm4.0 (20%, n=7), followed by emm44.0 (14%, 
n=5). The characteristics of the samples included in this study, are summarized in Table 
2.1  
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TABLE 2.1: Characteristics of the 35 samples included in this study 
emm type (no. of 
samples) 
Samples (no. of colonies) 
Resistance profile (no. of samples)
a 
 
[Macrolide resistance phenotype (no. of samples)] 
4.0 (7) 2(10); 2(9); 3(8) Fully susceptible
 
(7) 
44.0 (5) 3(10); 2(8) Fully susceptible
 
(5) 
1.0 (4) 2(10); 1(9); 1(8) Fully susceptible
 
(4) 
12.0 (4) 3(10); 1(8) Fully susceptible
 
(3); Ery
R
 Cli
S
 Te
S
 Nor
S 
(1) [M(1)] 
28.0 (3) 1(10); 1(9); 1(8) Fully susceptible
 
(1); Ery
R
 Cli
R
 Te
S
 Nor
S 
(2) [MLSB (2)] 
75.0 (3) 1(10); 2(9) Fully susceptible
 
(2); Ery
R
 Cli
S
 Te
S
 Nor
S 
(1) [M(1)] 
89.0 (3) 2(10); 1(9) Fully susceptible
 
(3) 
6.0 (2) 1(10); 1(9) Fully susceptible
 
(1); Ery
S
 Cli
S
 Te
S
 Nor
R 
(1) 
6.4 (1) 1(9) Ery
S
 Cli
S
 Te
S
 Nor
R
 (1) 
11.0 (1) 1(9) Ery
R
 Cli
R
 Te
R
 Nor
S 
(1) [MLSB (1)] 
3.1 (1) 1(9) Fully susceptible
 
(1) 
87.0 (1) 1(8) Fully susceptible
 
(1) 
a) All the samples were susceptible to trimethoprim-sulphamethoxazole, so it was not discriminated. Ery - erythromycin, Cli - 
clindamycin, Te- tetracycline, Nor - norfloxacin, R - resistant, S- susceptible 
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 DISCUSSION 
  
 Differences in the antimicrobial resistance profiles among colonies recovered from 
the same patient, with a diagnosis of tonsillo-pharyngitis were recently reported, implying 
that the single colony strategy used in the microbiology laboratory could lead to an 
incorrect measurement of antibiotic resistance rates, as well as failures in the treatment. All 
the differences detected were found among isolates presenting the same genetic 
background, implying that the heterogeneity arose from horizontal gene transfer of some 
resistant determinants to a minor population of the infecting organism [26].  
 Our results are contrary to these, even with a larger collection. We detected no 
differences in antimicrobial resistance profile among all the colonies isolated from each 
primary plate, which suggested that in our collection, horizontal gene transfer is not 
frequent in the course of an infection. Our results are in agreement with another study 
which demonstrated that GAS has a clonal nature in carriage and infection. In that study all 
the colonies from the same throat swab were analyzed by PFGE. Although we have 
previously shown that PFGE is a good typing technique with high resolving power, 
differentiating macrolide resistant and susceptible isolates [22], it is possible that some 
differences remain undetected using this typing method, such as emm type or subtype.  
 All the isolates in the Belgium study, in which differences in the antimicrobial 
resistance profiles or other molecular differences, such as a different emm subtype were 
found, presented  emm3 [26] and in our collection only one isolate expressed this emm 
type. Furthermore, we have previously showed that emm3 is highly prevalent in the general 
GAS population in Portugal, but very rare among the resistant population [22]. In other 
studies, this emm type was reported to be rarely associated with macrolide resistance [1, 
28]. The infrequent association of macrolide resistance to emm3 isolates could be related to 
an intrinsic feature of these isolates, rendering them more resistant to acquisition of 
macrolide resistance determinants, although this remains to be established. Macrolide and 
tetracycline resistance determinants are carried in mobile genetic elements and some 
studies indicate that M proteins could function as barriers to horizontal gene exchange [5, 
23]. However, recent studies suggested that extensive lateral gene transfer occurred among 
GAS isolates of different M types [2, 27]; the role of M protein as a barrier to horizontal 
gene exchange is still to be completely elucidated.  
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 In the literature there are some reports of intrahost sequence variation of some GAS 
proteins. The M protein was soon recognized to exhibit large differences in size and 
antigenic variation between different serotypes [8, 14]. This size variation, believed to be 
generated by homologous recombination between intragenic repeats, was detected among 
laboratory cultures of group A streptococcal strains [13] and it was also reported in a single 
patient, diagnosed with rheumatic fever caused by GAS [11], although the multiple 
colonies analyzed were obtained in consecutive days.  
 More recently, a study including GAS recovered from pharyngitis patients detected 
intrahost sequence variation of the gene that encodes for another protein - the streptococcal 
inhibitor of complement (Sic), present mostly in emm1 isolates [17]. This study detected 
mixed infections with strains containing 2 distinct sic alleles in five out of the 20 patients 
analyzed; for each patient, a total of 100 colonies were screened. In all cases where mixed 
infections were detected, there was a major (>90%) and a minor (<10%) sic allele. Within 
the same host, all the isolates had the same genetic background, suggesting that the 
variation in the sic gene arose from one single infecting emm1 organism [17]. 
 According to the authors, these differences in size and sequence variation of the 
proteins could provide a survival advantage to the organism. In the case of the M protein, 
differences in size would lead to antigenic differences, due to different number of epitopes 
available per M molecule. Likewise, the Sic protein was already shown to contain epitopes 
detected by human antibodies [10], and its variation resulting in mixed infections could 
potentially contribute to pathogen survival by immune avoidance [17]. Although we have 
found no heterogeneity in our collection regarding antimicrobial resistance profiles or emm 
type and subtype, it would be interesting to analyze the size and sequence of the M 
proteins, in order to detect any intrahost size variation that would potentially lead to 
antigenic diversity in an infecting population.  
 From our results, the single colony strategy, commonly used in the microbiology 
laboratory seems to be reliable and will not lead to an underestimated measurement of the 
macrolide resistance rate. In the course of a single infection, horizontal gene transfer 
resulting in the emergence of a subset of isolates with antibiotic resistance among a 
susceptible population is probably rare, although we do not know if such heterogeneity is 
present in carriage, as it is for S. pneumoniae [4, 16, 21]. However, in such a large 
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collection it would be interesting to see if spontaneous protein size mutants are being 
generated and its implications for the immune system.  
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 Brief introduction 
 
 A study conducted in Portugal between January 1998 and June 1999 revealed a 
high macrolide resistance rate in Streptococcus pyogenes in Portugal - 35.8% [1]. The 
macrolide resistant population presented mostly the cMLSB phenotype (approximately 
80%), while only 17% presented the M phenotype and the remaining isolates presented the 
iMLSB phenotype. This high macrolide resistance rate prompted continuing surveillance of 
antibiotic resistance, the prevalence of macrolide resistance phenotypes and genotypes and 
the clonal composition of the population. With this aim, a study was conducted between 
1998 and 2003, including 325 macrolide resistant S. pyogenes isolates, associated with a 
diagnosis of tonsillo-pharyngitis, recovered from several laboratories located throughout 
Portugal. The characterization of these isolates originated two publications: the first 
consisted of the determination of the macrolide resistance rate, a phenotypic and a brief 
molecular characterization of the resistant isolates, including the prevalence of the 
macrolide resistance phenotypes and genotypes, as well as emm and T typing. The second 
publication included the molecular characterization of the same isolates by pulsed-field gel 
electrophoresis (PFGE) and multilocus sequence typing (MLST). In this thesis, chapters 
3.1 and 3.2 are the result of these two publications. The results of these two studies 
revealed that in Portugal, the overall level of macrolide resistance in S. pyogenes between 
1998 and 2003 was high, but stable (27%), accompanied by a rapid inversion of the 
dominant phenotypes, with a marked decrease in the prevalence of MLSB isolates and a 
concomitant increase in isolates presenting the M phenotype. The molecular 
characterization revealed a diverse population, with eight major PFGE clones circulating 
among the macrolide resistant isolates, most of them previously identified in other 
European countries. The high rate of macrolide resistance, as well as the rapid and unusual 
inversion of the macrolide resistance phenotypes motivated the continuing of the 
surveillance study, and the isolates recovered between 2004 and 2006 were analyzed and 
published in a third paper, that in this thesis corresponds to chapter 3.3. In this study, a 
decline in macrolide resistance was noted, due to the decrease in the prevalence of isolates 
presenting the M phenotype while the proportion of MLSB isolates remained stable. The 
clonal composition of the population was also very diverse, with the appearance of new 
clones and the association of different macrolide resistant determinants to previously 
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identified clones. More importantly, with the inclusion of this subset of isolates in our 
collection it was possible to detect a decreasing trend in macrolide resistance since 1999, 
not previously identified, that could not be attributed to differences in the diversity of 
isolates presenting each of the macrolide resistance phenotypes. Macrolide consumption, 
known to be a major driving force in macrolide resistance, was reported to be high in 
Portugal, and in spite of this, erythromycin resistance reached a low value. To find out if 
the decreasing trend continued and to identify the circulating clones in Portugal after 2006, 
we conducted another study, which included macrolide resistant isolates recovered in the 
period 2007-2011 that in this thesis  is described in chapter 3.4.  
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SUMMARY 
 
In Portugal, erythromycin resistance of 26.6% (n=352) remained constant during 1998 to 
2003, however in 1998 the MLSB phenotype dominated (85%), whereas in 2003 the M 
phenotype prevailed (77%). A decline in T12/emm22 MLSB isolates could partially explain 
the drop in this phenotype, but the rise of the M phenotype was not due to clonal 
expansion. 
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 Although penicillin remains the antibiotic of choice in the treatment of Lancefield 
group A streptococci (GAS) infections, macrolides and lincosamides are recommended as 
suitable alternatives for patients allergic to penicillin [5]. Newer macrolides, such as 
azithromycin, may be given once a day, making this an attractive option for the treatment 
of pharyngitis due to Streptococcus pyogenes. In Portugal, where penicillin V is not 
available, macrolides and lincosamides have the additional advantage of being a 
therapeutic option with an oral route of administration. High macrolide resistance in GAS 
was previously identified in Portugal [13] in line with other European countries [1, 4, 6] 
but in contrast to others [14, 16]. The aims of this study were to determine the prevalence 
of macrolide resistance phenotypes and its temporal trends and to evaluate the correlation 
with T and emm-types. 
 A total of 1,321 GAS from clinical infections were collected from 30 laboratories, 
geographically distributed throughout Portugal, from January 1998 to December 2003. The 
isolates were distributed in the study period as follows: 153 in 1998, 240 in 1999, 213 in 
2000, 216 in 2001, 270 in 2002, and 229 in 2003. The laboratories were asked to submit all 
nonduplicate GAS isolated from outpatients during the study period. Antimicrobial 
susceptibility testing, T-typing, and macrolide resistance phenotype and genotype were 
determined as previously described [7, 13]. Strains were emm typed according to the 
recommendations of the Centers for Disease Control and Prevention (CDC) 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). The sequences of representatives 
of each restriction profile were searched against GenBank as well as the emm CDC 
database (http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm). An isolate was 
considered to be of a given emm type if it had >95% identity over the 160 bases considered 
[3].  
 Among this collection, 352 isolates (26.6%) were erythromycin resistant. Although 
there was a higher prevalence of resistant isolates recovered in 1998 (34.6%), the variation 
of the overall prevalence in the following years (19.6% in 1999, 27.7% in 2000, 25.5% in 
2001, 23.7% in 2002, and 20.5% in 2003) was not significant (χ2 test, P = 0.22) (Fig. 1). 
Only the 325 erythromycin-resistant isolates recovered from throat swabs associated with a 
diagnosis of pharyngitis were characterized further. 
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FIGURE 3.1.1 Erythromycin resistance and prevalence of macrolide resistance phenotypes in Portugal 
during 1998-2003 
 
 
 Resistance to tetracycline was expressed by 38.7% (n=126) of the isolates 
(MIC90=96µg/ml, MIC range, 12 to 512µg/ml). The distribution of tetracycline-resistant 
isolates among the study years was as follows: 84.9% of the isolates recovered in 1998, 
70.2% in 1999, 28.8% in 2000, 30.9% in 2001, 12.5% in 2002, and 12.8% in 2003. The 
cMLSB phenotype was expressed by 170 isolates (52.3%), 151 (46.4%) presented the M 
phenotype, and only 4 isolates (1.2%) the iMLSB phenotype. Erythromycin resistance 
determinants were detected in all isolates by multiplex PCR. All isolates presenting the M 
phenotype carried the mef(A) gene, including one which carried both mef(A) and erm(B) 
genes. Nine of the isolates presenting the MLSB phenotype (4.9%) carried both the mef(A) 
and erm(B) resistance determinants whereas all other isolates presenting this phenotype 
yielded a single PCR product consistent with the presence of the erm(B) gene. Three 
isolates presenting the iMLSB phenotype carried the erm(A) gene, and one carried the 
erm(B) gene. 
 A summary of the number of T/emm-type associations with the two macrolide 
resistance phenotypes and their distribution over the different years of the study period is 
presented in Table 1. The majority (90%) of the tetracycline-resistant isolates were 
included in the T12/emm22 group. 
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TABLE 3.1.1 Distribution of T and emm types and macrolide resistance phenotypes among 325 pharyngitis 
associated erythromycin-resistant GAS in Portugal during 1998-2003 
T types 
emm types 
Total 
22 12 28 1 77 75 4 9 11 2 89 
12 125/2* 2/23 4/0 1/0   0/1 0/1 2/0 0/1  134/28 
28   29/1   0/1  0/1  0/1  29/4 
1  0/2  0/35  0/1 0/2     0/40 
13 3/0 0/1  0/2 3/0  0/3  1/0   7/6 
25 1/0     0/10      1/10 
4       0/32     0/32 
B3264       0/2    0/2 0/4 
5/27/44       0/2     0/2 
14/49       0/1     0/1 
NT 1/0 0/7 2/0 0/2   0/1     3/10 
2  0/1     0/2   0/2  0/5 
6      0/1 0/1     0/2 
9        0/7    0/7 
Total 130/1 2/34 35/1 1/39 3/0 0/13 0/47 0/9 3/0 0/4 0/2 325 
* The number of strains associated to each macrolide resistant phenotype (MLSB/M) is indicated 
 
 
 The situation found in 1998 and 1999, where strains expressing the MLSB 
phenotype accounted for approximately 80% of all macrolide-resistant isolates (Figure 
3.1.1), was similar to that found among a group of erythromycin-resistant isolates 
recovered in Italy in 2000 [6] and in France (2002 to 2003) [4]. However, the dominance 
of the MLSB phenotype was in sharp contrast to the situation found in neighboring Spain 
where isolates collected around the same years (1996 to 1999) expressed overwhelmingly 
(95%) the M phenotype (1). The tendency for the strains expressing the MLSB phenotype 
to present a limited number of T/emm-type associations and for at most two associations 
(T12/emm22 and T28/emm28) to account for more than 80% of isolates recovered in each 
year was a constant during the study period. The only exception was 2001 when, not only 
was an unusually high number of associations identified (n=9) but three different 
associations were necessary to account for 80% of the isolates (compare to 2000 when, for 
the same number of isolates, only three associations were identified) (Table 3.1.1). This 
indicates that other T/emm type associations expressing the MLSB phenotype existed that 
could replace the T12/emm22 group; however none rose to significant numbers. In the 
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following years there was an increase in prevalence of isolates expressing the M 
phenotype, that accounted for 76.6% of erythromycin resistant isolates in 2003 (Figure 
3.1.1). In sharp contrast to the data presented here, the increases in occurrence of strains 
expressing the M phenotype documented elsewhere were also paralleled by an increase in 
the overall macrolide resistance rate [8, 9, 11]. Contrary to isolates expressing the MLSB 
phenotype, those expressing the M phenotype were found among a diverse group of 
T/emm-type associations and usually at least one-half of the total number of associations 
found each year was necessary to account for 80% of the isolates. This increased diversity 
is better illustrated by the strains exhibiting the M phenotype recovered in 2003, when 17 
different T/emm-type associations were found among the 36 isolates (Table 3.1.1). Unlike 
these findings studies from elsewhere in Europe have documented similar numbers of 
T/emm-type associations among isolates expressing the two phenotypes [4, 6]. The contrast 
to the situation in Spain, where only four emm types accounted for 85% of the isolates 
expressing the M phenotype [1], indicates that, despite the geographic proximity, 
macrolide-resistant GAS isolated in the two countries constitute two different populations. 
Moreover, it suggests that the rise in isolates of the M phenotype was not due to invasion 
of the few emm groups prevalent in Spain.  
 The decrease observed in tetracycline resistance paralleled the decline of isolates 
presenting the MLSB phenotype, namely, those associated with the T12/emm22 types. This 
could be explained by the presence of erm and tetracycline resistance genes in the same 
transposon [12] in this group of isolates.  
 Although a situation where either phenotype dominates is not unusual, such a rapid 
shift in prevalence of the different phenotypes, while maintaining the same overall 
erythromycin resistance rate (Figure 3.1.1), was not previously described in GAS to the 
best of our knowledge. This shift could not be attributed simply to the reduction in the 
number of isolates defined by T12/emm22 and the absence of other T/emm-type 
associations expressing the MLSB phenotype that could take its place, or by the emergence 
of a limited number of highly successful strains expressing the M phenotype and specific 
T/emm-type associations as documented in North America  [8, 11]. Since the data 
presented do not offer firm clues, we can only speculate as to the reasons behind this shift. 
Although Portugal is among the largest antibiotic consumers in Europe 
(www.ua.ac.be/ESAC), it is not remarkable for its macrolide consumption. Decreases in 
Chapter 3.1  
 
90 
 
macrolide use were associated to a reduction of macrolide resistant GAS [16]. However, 
there was only a slight decrease in consumption for human use in the ambulatory setting 
during the study period in Portugal (www.ua.ac.be/ESAC). If, as suggested by Nielsen et 
al. [15], tetracycline use together with macrolide use could be correlated to macrolide 
resistance, especially the MLSB phenotype, then the slight reduction in tetracycline use 
(www.ua.ac.be/ESAC) could have an additive effect. These factors, as well as a possible 
immunity developed by the human population against the limited number of T antigens 
and M proteins associated with the MLSB phenotype, could explain the observed reduction 
in prevalence. The diversity among the strains expressing the M phenotype could be 
explained by a higher mobility of the genetic element containing the mef(A) gene [10]. 
Interestingly, an unusual chimeric genetic element combining a transposon and a 
bacteriophage, that could mediate the transfer of the mef(A) gene by a process similar to 
transduction, was recently described [2]. The data presented documents a major shift in the 
prevalence of macrolide resistance phenotypes in an unusual short time period, not 
paralleled elsewhere in Europe and without a concomitant change in the frequency of 
macrolide resistance. Continued surveillance is needed to establish if this shift will 
stabilize and if the major groups of isolates sharing the same T/emm-types are also found 
elsewhere. 
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 SUMMARY 
 
 Although the overall level of macrolide resistance (27%) has remained stable in 
Portugal, a rapid inversion in the dominant phenotypes has been noted, with a sharp 
decrease in the MLSB phenotype paralleled by an increase in the M phenotype. To gain 
further insight into these changes, 325 macrolide resistant isolates were characterized using 
a combination of pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing 
(MLST). The use of Cfr9I, an isoschizomer of SmaI, to digest M phenotype isolates that 
were refractory to SmaI digestion allowed direct comparison of MLSB and M isolates. The 
results from PFGE and MLST were highly concordant and identified eight major clones, 
accounting for 92% of the isolates, each of which was associated exclusively with a single 
macrolide resistance phenotype. Two major clones were found among MLSB isolates, 
characterized by sequence types (ST) 46 (T12-emm22) and ST52 (T28-emm28), whereas 
clones characterized by ST39 (T4-emm4) and ST28 (T1-emm1) dominated among M 
isolates. The clone defined by ST52 corresponded to a bacitracin resistant clone circulating 
in Europe, and a novel variant expressing other surface antigens (T12-emm22) was 
detected. The presence of the four major clones has been reported previously in other 
European countries, suggesting Europe-wide dissemination of a few macrolide-resistant 
lineages. 
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 INTRODUCTION 
 
 Two mechanisms of resistance to macrolide antibiotics have been described in 
Streptococcus pyogenes: one caused by the presence of a methylase encoded by the erm(B) 
or erm(A) genes that results in resistance to most macrolides, lincosamides and 
streptogramin B (the MLSB phenotype); and a second caused by the presence of an efflux 
pump encoded by the mef(A) gene that results in resistance to 14- and 15-membered 
macrolides, while susceptibility to clindamycin and streptogramin B antibiotics is retained 
[14]. Isolates carrying both erm and mef(A) resistance determinants expressing either the 
MLSB or the M phenotype have also been described previously [2].  
 Macrolide resistance is increasing among S. pyogenes isolates in several European 
countries, and this has often been accompanied by an alteration in the prevailing 
phenotypes [21]. In Portugal, macrolide resistance remained almost constant during 1998–
2003 (27%) [20], but surprisingly, this was not associated with a stable population of 
macrolide-resistant S. pyogenes strains. Indeed, the predominance of the MLSB phenotype, 
which accounted for c. 80% of isolates in 1998, was completely reversed in 2003, when 
76.6% of the isolates expressed the M phenotype [20]. This change is puzzling, since there 
was no significant alteration in macrolide use during this period, and sustained use could 
be expected to select for isolates expressing the MLSB phenotype, since this phenotype is 
associated with higher resistance in vitro. One possibility is that the introduction of a 
highly successful clone or clones, particularly from neighboring Spain, where the M 
phenotype predominates (95%) [1], could have displaced a local clone. However, rapid 
changes in S. pyogenes isolates associated with pharyngitis, not attributable readily to any 
single factor, but thought to represent natural fluctuations, have also been described 
previously [9].  
 Comparison of the profiles generated by pulsed-field gel electrophoresis (PFGE) 
has long been used to distinguish clones of S. pyogenes [3]. The endonuclease used to 
generate the profiles is frequently SmaI, but the emergence of isolates expressing the M 
phenotype with DNA that is resistant to digestion with SmaI [3] has led to the use of 
alternative enzymes, often SfiI, to characterize the two macrolide resistance phenotypes 
[10], thereby preventing a direct comparison of the M and MLSB clones. More recently, 
sequence based typing methods have been developed that rely on determining the 
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nucleotide sequences of internal fragments of housekeeping genes [5]. These sequencing 
methods, known as multilocus sequence typing (MLST), provide unambiguous results that 
are easily portable and accessible in a central database, thereby facilitating comparison of 
results obtained in different laboratories. 
 In order to gain a better insight into the dynamic behavior exhibited by macrolide-
resistant S. pyogenes isolates in Portugal, and to clarify the relationship of the major clones 
involved with those reported from other European countries [10, 18, 21], the present study 
characterized 325 macrolide-resistant S. pyogenes isolates from Portugal [20] by PFGE, 
using enzymes suitable for the direct comparison of M and MLSB isolates, and MLST.  
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 MATERIALS AND METHODS 
 
 Bacterial isolates 
 A collection of non-duplicate 325 macrolide-resistant S. pyogenes isolates 
recovered from throat swabs and associated with a diagnosis of tonsillo-pharyngitis 
between 1998 and 2003 was analyzed. The isolates, provided by 30 laboratories distributed 
throughout Portugal, comprised 53 from 1998, 47 from 1999, 59 from 2000, 55 from 2001, 
64 from 2002, and 47 from 2003. Results of antimicrobial susceptibility tests using CLSI 
(formerly NCCLS) interpretative criteria [16], T-typing results, macrolide-resistant 
phenotypes and genotypes, and emm typing results, have been reported previously [20]. 
 
 PFGE and MLST 
 Chromosomal DNA of macrolide-resistant isolates was prepared with a 
modification of a method described previously [7]. In brief, the composition of the lysis 
solution was altered to include mutanolysin 5 U/mL, lysozyme 1 mg/mL and ribonuclease 
A 30 µg/mL (Sigma-Aldrich, Steinheim, Germany). After digestion with SmaI or Cfr9I 
(Fermentas, Vilnius, Lithuania), the fragments were resolved by PFGE as described 
previously [7]. All MLSB isolates produced multiple bands following digestion with SmaI; 
however, the DNA of most isolates with the M phenotype (n = 150; 46.2%) did not digest 
with SmaI, and in such cases the isoschizomer Cfr9I (Fermentas) was used. Bionumerics 
software (Applied-Maths, Sint-Martens- Latem, Belgium) was used to create UPGMA 
(unweighted pairgroup method with arithmetic mean) dendrograms of the SmaI or Cfr9I 
fragment patterns. The Dice similarity coefficient was used, with optimization and position 
tolerance settings of 1.0 and 1.5, respectively. PFGE clusters were defined as isolates with 
≥ 80% similarity, as described previously for Streptococcus pneumoniae [19]. A PFGE-
based cluster was considered to be a major lineage if it included ten or more isolates, or if 
it included five or more isolates recovered in the same year. MLST analysis was performed 
with representatives of each major lineage, as described previously [5], and allele and 
sequence type (ST) identification were performed using the S. pyogenes MLST database 
(http://spyogenes.mlst.net). 
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 Bacitracin susceptibility testing 
 Bacitracin susceptibility was determined for all isolates by disk diffusion, using 
disks containing bacitracin 0.05 U (Oxoid, Basingstoke, UK) and Tryptic Soy Agar 
(Oxoid), supplemented with sheep blood 5% v/v, according to the manufacturer’s 
instructions. Any zone of inhibition around the bacitracin disk was interpreted as being 
indicative of susceptibility. 
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 RESULTS 
 
 PFGE and MLST 
 All 325 isolates included in this study were typeable by PFGE, and 40 (12.3%) 
isolates were analyzed by MLST. Eight major lineages were found, containing 297 
(91.4%) of the isolates. The PFGE patterns of representative isolates from each major 
clone are shown in Figure 3.2.1. The remaining isolates were included in minor PFGE 
groups (containing six or fewer isolates) or had unique PFGE profiles. In most cases, all 
isolates belonging to the same PFGE-defined cluster had the same ST by MLST. For the 
two exceptions, the STs were single-locus variants of each other, indicating a close genetic 
relationship between the isolates. Similarly, most isolates belonging to the same PFGE 
cluster had the same emm type and the same resistance phenotype and genotype. The 
characteristics of the eight lineages found in this study, as well as their distribution during 
the study period, are summarized in Table 3.2.1. 
 
TABLE 3.2.1. Properties of macrolide-resistant Streptococcus pyogenes responsible for pharyngitis isolated 
in Portugal during 1998-2003 
            Year 
 
 
 
PFGE 
cluster 
No. of 
isolates (%) 
T/emm Phenotype Genotype ST 1998 1999 2000 2001 2002 2003 
A 118 (36.3) 12/22
a
 MLSB erm(B)
b
 46
c
 44 32 17 13 7 5 
B 46 (14.2) 28/28
d
 MLSB erm(B)
e
 52 0 2 12 12 14 6 
C 48 (14.8) 4/4
f
 M mef(A) 39
g
 5 3 7 3 10 20 
D 20 (6.2) 12/12
h
 M mef(A) 36 1 4 3 5 5 2 
E 10 (3.1) 12/12 M mef(A) 36 0 2 3 1 2 2 
F 35 (10.8) 1/1
i
 M mef(A) 28 0 1 5 7 16 6 
G 12 (3.7) 25/75 M mef(A) 150 0 0 0 3 5 4 
H 8 (2.5) 9/9 M mef(A) 75 0 0 6 0 2 0 
Other
j
 28 (8.6)         3 3 6 11 3 2 
a13/22 (n=3), 25/22 (n=1) 
b All the isolates presented the MLSB, phenotype, and 111 isolates expressed the erm(B) gene, while 7 isolates carried 
both erm(B) and mef(A). 
cST45 (n=1) 
d12/22 (n=9) 
 e All the isolates presented the MLSB, phenotype, and 45 isolates expressed the erm(B) gene, while only one isolate 
carried both erm(B) and mef(A)  
fSeven other T types were found, (T5/27/44, T6, T1, TB3264, T12, T13 and T25), including one isolate presenting 
T12/emm22. 
gST38 (n=1) 
h13/12 (n=1); 2/12 (n=1) 
i13/1 (n=1) 
jFifteen T/emm type combinations were found among 13 PFGE clusters 
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FIGURE 3.2.1 Pulsed-field gel electrophoresis (PFGE) analysis of macrolide-resistant Streptococcus 
pyogenes isolates from Portugal. (A) Dendrogram showing cluster analysis of the PFGE profiles of the 325 
macrolide-resistant isolates by the unweighted pair-group with arithmetic mean (UPGMA) method. For each 
of the major clones, a triangle proportional to the number of isolates is shown in the dendrogram, followed by 
the capital letter designating the PFGE cluster. (B) PFGE profiles generated following SmaI (A, B) or Cfr9I 
(C–H) digestion of DNA isolated from representatives of each major clone. Capital letters identifying each 
lane correspond to the clone designations 
 
 
 The largest cluster (cluster A; 118 (36.3%) isolates) comprised exclusively MLSB 
isolates. MLST was performed for nine of these isolates, and all except one belonged to 
ST46, with the remaining isolate belonging to ST45, which is a single-locus variant. This 
cluster also included most (n=7) of the isolates that carried the erm(B) and mef(A) 
resistance determinants simultaneously. These seven isolates were recovered from two 
hospitals in the same region during1998 and 1999. 
 Cluster B accounted for 46 (14.2%) of the isolates (all MLSB), most of which were 
T28/emm28. However, a significant proportion (n=9; 19.6%) of the isolates in this cluster 
had a different T and emm type (T12-emm22). Ten (21.8%) of these 46 isolates, 
representing both T-emm combinations present in this cluster, were analyzed by MLST. 
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All ten isolates characterized by MLST, defined either by emm22 or emm28, belonged to 
ST52.  
 The most heterogeneous cluster found in this study (cluster C) accounted for 48 
(14.8%) of the isolates, all of which expressed the M phenotype. Although almost all of 
these isolates were emm4, the T types present in this cluster were very diverse. The 
dominant T type was T4, but other T types, such as 5/27/44, T6, T1, B3264, T12, T13 and 
T25, accounted for 34.8% of the isolates in this cluster. Despite this diversity, three of the 
four isolates analyzed by MLST were ST39; the exception, a T12-emm4 isolate, belonged 
to ST38. However, these STs are single-locus variants of each other, supporting the overall 
grouping revealed by PFGE analysis. Isolates presenting with emm12 were divided into 
two PFGE clusters (clusters D and E; Figure 3.2.1), but this distinction was not supported 
by the other methods used. All the isolates in these two clusters expressed the M 
phenotype, and almost all had the same T type (T12). Moreover, a single ST (ST36) was 
associated with both clusters, suggesting that clusters D and E represent subgroups of the 
same genetic lineage, together accounting for 30 (9%) of the isolates.  
 Cluster F (n = 35; 10.8%) included emm1 isolates, all of which expressed the M 
phenotype. The four isolates from this cluster that were analyzed by MLST included one 
with a T type different from T1, namely T13, but all were found to belong to ST28. Two 
smaller PFGE clusters (clusters G and H) included 12 and eight isolates, respectively 
(Table 3.2.1). 
 A small proportion (n = 28; 8.6%) of isolates did not belong to any of the clusters 
described above. Five had a unique PFGE pattern, and although the emm types of most 
(n=4) of these were represented in the major clones (i.e., emm1, 9, 22 and 75), these 
isolates had diverse genetic backgrounds. 
 
 Bacitracin susceptibility 
 All isolates grouped in PFGE cluster B were resistant to bacitracin, as shown by the 
absence of an inhibition zone around the bacitracin disk, whereas the remaining 279 
isolates were bacitracin- susceptible. 
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 DISCUSSION 
 
 Although the overall level of erythromycin resistance remained constant during the 
study period, the MIC50 for the isolates recovered during 1998 was >512 mg/L, compared 
with 16 mg/L in 2003, suggesting that changes had occurred in the clonal composition of 
the macrolide-resistant population. The strains analyzed represented diverse genetic 
lineages corresponding to 21 PFGE profiles. A large diversity among macrolide- resistant 
isolates, notably among isolates presenting the M phenotype, is not unusual [4, 22]. 
Nevertheless, eight clones accounted for most (92%) of the isolates, and the four most 
frequent lineages (PFGE clusters A, B, C and F) represented 76% of the isolates analyzed. 
Despite significant yearly variations, six of the major clones identified were detected 
during five of the six study years, indicating their persistence in the population. Also 
noteworthy, and in agreement with previous studies, was the strong association between 
emm type and ST [5], as well as between PFGE cluster and macrolide resistance 
phenotype. Although the latter association has been reported previously [24], these 
comparisons were frequently incomplete because of the existence of isolates expressing the 
M phenotype that were not digested by SmaI, which is the endonuclease used most 
frequently for PFGE analysis [10]. The data reported here confirm the above findings for 
all isolates, since use of the isoschizomer Cfr9I allowed direct comparison of all M and 
MLSB isolates. Most of the isolates grouped in each PFGE cluster also shared the same 
emm type, with the notable exception of cluster B, in which a significant fraction (n=9, 
19.6%) were emm22. Although these isolates did not form a PFGE subgroup within cluster 
B, they also shared a T type (T12) that was different from that of other isolates in cluster B, 
and were indistinguishable, according to these surface markers, from clone A. However, 
MLST analysis confirmed the inclusion of these isolates in clone B, since the T28-emm28 
and T12-emm22 isolates shared ST52, having no alleles in common with ST46, which is 
characteristic of clone A. Moreover, all these isolates shared the unusual property of being 
resistant to bacitracin, a test used traditionally in the presumptive identification of S. 
pyogenes [23]. The first outbreak involving macrolide-resistant (MLSB) S. pyogenes 
isolates resistant to bacitracin was described in the USA [23], but no data regarding T and 
emm type are available. Recently, macrolide- and bacitracin-resistant S. pyogenes isolates 
with T28-emm28 have been described in Europe [11, 15], including Spain, where these 
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isolates were associated with ST52 [17], the same ST of the isolates found in Portugal. A 
report from Sweden [6] also identified T28-emm28 isolates belonging to ST52 as the 
dominant clone among invasive isolates; however, the macrolide and bacitracin 
susceptibility of the isolates involved was not reported. The variant reported in the present 
study, sharing the same surface antigens as the dominant MLSB clone T12-emm22, has not 
been reported previously, and perhaps resulted from transfer of the necessary genetic 
determinants into the ST52 background, as has been suggested to account for the presence 
of multiple emm types associated with the same ST [9]. The substantial temporal variations 
in clonal prevalence among macrolide-resistant S. pyogenes, as documented in Portugal 
[20], highlight the pitfalls of comparing the data from various studies conducted in Europe. 
Moreover, there are few studies that have characterized the genetic backgrounds of 
macrolide-resistant S. pyogenes by MLST, and studies using PFGE frequently resort to 
different endonucleases (usually SfiI) to characterize M phenotype isolates. Further 
complicating the comparison among studies is the inclusion of isolates responsible for 
different types of infection, since an association between emm type and particular disease 
manifestations [13] could create a bias towards different emm types. Despite these 
limitations, three surveys of STs among macrolide-resistant S. pyogenes in European 
countries with a lower rate of macrolide resistance than Portugal identified similar clones. 
Thus, in a survey in Germany, in which isolates with the M phenotype predominated 
(n=30), the most common clone was ST39-emm4, with other important clones including 
ST28-emm1 and ST36-emm12 [18], i.e., similar to the present findings in Portugal. In 
Poland, ST36-emm12 accounted for three of five isolates expressing the M phenotype [21]. 
However, in both Germany and Poland, isolates expressing the MLSB phenotype carried 
the erm(A) gene, unlike the situation in Portugal, and the few isolates carrying the erm(B) 
gene were unrelated to the major clones identified in Portugal. It is noteworthy that three of 
the four isolates from Portugal with an inducible MLSB phenotype shared the same emm 
gene as one of the dominant clones expressing this phenotype in both Poland and Germany 
(ST63-emm77). A strong parallel between the data reported here and a study of macrolide-
resistant S. pyogenes isolates recovered in Belgium during a similar period was also noted. 
Although only data concerning PFGE clustering, emm type and macrolide resistance 
phenotype and genotype are available for comparison, the major clones identified in 
Belgium seem to correspond to those found in Portugal. Two PFGE clusters, containing 
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emm22 and emm28 isolates, respectively, accounted for the majority of erm(B) isolates, 
and two PFGE clusters, containing emm1 and emm4 isolates, respectively, accounted for 
the majority of mef(A) isolates [10]. This strong similarity existed despite an overall lower 
level of macrolide resistance in Belgium and the temporal variations in the prevalence of 
the different phenotypes compared with Portugal [10, 20]. These observations argue in 
favor of Europe wide dissemination of a limited number of macrolide-resistant clones, 
although each country may retain specificity regarding the prevalence of the different 
genotypes and clones. It is currently unclear whether these resistant clones are spreading 
throughout Europe, or whether they result from independent acquisition of resistance genes 
by the same prevalent STs, followed by local dissemination. Whenever these clones 
account for the majority of macrolide-resistant isolates, they frequently share the same 
resistance determinants, regardless of the country of origin, suggesting geographical 
dissemination. Nevertheless, local acquisition of resistance genes must also play a role, 
since isolates fully susceptible to macrolides that share the same STs as these major clones 
have been described [12], and either of the resistant determinants has been associated with 
each lineage, both in the present report and in previous studies [18, 21]. This hypothesis is 
further supported by previous observations showing that conjugal transfer of elements 
carrying either the erm or the mef(A) resistance determinants among S. pyogenes can occur 
in vitro [8]. The alterations in the prevalence of macrolide resistance differ significantly 
among different European countries and cannot be correlated directly with use of 
macrolides [10, 20]. As expected, a situation in which macrolide resistance is changing can 
be accompanied by changes in the prevalent clones [10], but such changes can also occur 
when macrolide resistance is stable [20], suggesting that other factors, such as natural 
fluctuations in the prevalence of clones [9], may be important determinants of macrolide 
resistance and the associated phenotypes.  
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 SUMMARY 
 
 Macrolide resistance among Streptococcus pyogenes (group A streptococci) in 
Portugal was stable during 1998–2003, but a rapid inversion in the dominant phenotypes 
was noted in the same period, with a sharp decrease in the proportion of isolates presenting 
the MLSB phenotype and a concomitant increase in isolates presenting the M phenotype. 
The characterization of group A streptococci recovered during 2004–2006, which is 
reported here, revealed that resistance was not stable during this period and that the decline 
in erythromycin resistance observed during 2004–2006 was due to a decrease in the 
prevalence of isolates presenting the M phenotype, while the proportion of isolates 
expressing the MLSB phenotype remained stable. Characterization by emm typing, T 
serotyping, pulsed-field gel electrophoresis (PFGE) profiling and multilocus sequence 
typing revealed a very diverse population. Several of the major PFGE clusters identified 
had already been found in the 1998–2003 study period, but others were found for the first 
time, e.g. T11-emm11-ST403, carrying the erm(B) gene, and T3/13-emm3-ST315, carrying 
the mef(A) gene. The clone defined as T12-emm12-ST36, previously found to be 
associated with mef(A), was now found to be predominantly associated with erm(B). The 
clonal dynamics of macrolide-resistant group A streptococci emphasizes the importance of 
considering factors other than antibiotic consumption in explaining the prevalence of 
resistant isolates. 
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 INTRODUCTION 
 
 Streptococcus pyogenes, Lancefield group A streptococci (GAS), is an important 
human pathogen causing a wide variety of infections, from severe life-threatening diseases 
to pharyngitis, an infection for which it is the most common bacterial etiological agent. β-
lactams remain the antibiotics of choice in the treatment of GAS pharyngitis, and 
macrolides and lincosamides are the first line alternatives. Although macrolide resistance 
in GAS remained at low levels for a long time, a number of recent studies have reported an 
increase in resistance. Two different mechanisms have been recognized in macrolide-
resistant S. pyogenes: target site modification and active efflux. Target site modification 
occurs in the ribosome via an erythromycin resistance methylase (Erm) protein, blocking 
the binding of macrolides, lincosamides and streptogramin B (generating the MLSB 
phenotype) [19]. In GAS, the MLSB phenotype can be mediated by two classes of 
methylase genes, the erm(B) determinant and the erm(TR) determinant (belonging to the 
erm(A) class) [27]. The expression of the erm genes can be either constitutive or inducible, 
generating the cMLSB phenotype or the iMLSB phenotype, respectively, the latter 
frequently being associated with the erm(A) class. Both classes of erm genes were found to 
be associated with transposons that were shown to have the capacity to transfer the 
resistance traits to susceptible isolates by conjugation [8]. The second mechanism 
conferring macrolide resistance in GAS is mediated by a membrane-associated pump 
encoded by the mef genes, leading to resistance to 14- and 15-membered ring macrolides 
(generating the M phenotype) [28]. The mef(A) and mef(E) variants are widely distributed 
in streptococci [4], although the mef(A) variant associated with a phage-like element was 
found in the majority of GAS with the M phenotype [15]. Other mechanisms of resistance 
resulting from mutations, such as alterations of the ribosomal proteins, are infrequently 
observed in isolates responsible for infections, and currently have little clinical impact [7].  
 The factor most frequently associated with increases in antimicrobial resistance is 
antimicrobial consumption [1, 6]. An association between macrolide consumption and 
resistance in GAS was shown in ecological studies [6, 17], with intermediate-acting (e.g. 
clarithromycin) and, particularly, long-acting (e.g. azithromycin) macrolides being 
implicated in enhanced resistance selection [11]. Further supporting this association, it was 
noted that a sharp decrease in macrolide prescribing was accompanied by a decline in 
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macrolide-resistant GAS [29]. More recently, studies at the individual level confirmed and 
extended these findings by showing a causal relationship between both clarithromycin and 
azithromycin treatment and selection for macrolide-resistant streptococci [21]. 
Furthermore, the latter study implicated clarithromycin, but not azithromycin, in the 
selection for the erm(B) gene. In spite of the recognized importance of antibiotic 
consumption in the selection of resistant strains, the largely clonal structure of most 
bacterial populations [22], including GAS [16, 22], suggests that the circulating clones 
may also contribute significantly to both the prevalence of resistance phenotypes and the 
overall level of resistance. The transmissibility of the genetic elements carrying the 
resistance determinants may also influence their prevalence in the population, with the 
more easily disseminated elements having an advantage over less mobile genetic 
determinants [20].  
 We have previously shown that, although erythromycin resistance in GAS 
remained above 20% in Portugal from 1998 to 2003, this was not associated with a stable 
population of macrolide resistant S. pyogenes [31]. Indeed, the predominance of the MLSB 
phenotype, which accounted for c. 80% of isolates in 1998, was completely reversed in 
2003, when almost 77% of the isolates expressed the M phenotype [31]. We have also 
found these changes to be associated with the decline of a particular clone expressing the 
MLSB phenotype and the emergence of several clones expressing the M phenotype [30]. 
Here we report the continuing fluctuations in macrolide resistance phenotypes and a 
decline in overall erythromycin resistance.  
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 MATERIALS AND METHODS 
 
 Bacterial isolates and identification 
 In total, 1184 S. pyogenes isolates recovered from throat swabs and associated with 
a diagnosis of tonsillo-pharyngitis were collected from 31 microbiology laboratories 
located throughout Portugal from January 2004 to December 2006. The laboratories were 
asked to submit all non-duplicate S. pyogenes isolates from outpatients during the study 
period. The isolates were collected in the study period as follows: 284 in 2004, 392 in 
2005, and 508 in 2006; only a little over 5% of the isolates were recovered from adults 
(>18 years). The proportion of isolates submitted by laboratories from each of the major 
regions of Portugal was constant relative to the previous study period [31]. Isolates were 
identified to the species level by colony morphology, β-haemolysis on horse blood agar, 
and a commercial latex agglutination technique (Slidex Strepto A; BioMérieux, Marcy 
l’Etoile, France). In this collection, 156 isolates (13.2%) were erythromycin-resistant, and 
only these isolates were characterized further. 
 
 Antimicrobial susceptibility testing and macrolide resistance phenotype  
 Susceptibility to erythromycin, clindamycin and tetracycline (Oxoid, Basingstoke, 
UK) was tested using disk diffusion according to CLSI recommendations [10]. The 
macrolide resistance phenotype was determined according to a double disk test previously 
described [23].  
 Bacitracin susceptibility was determined for all isolates by disk diffusion using 
disks containing 0.05 U of bacitracin (Oxoid, Basingstoke, UK) as previously described 
[30]. The absence of an inhibition zone around the disk was interpreted as resistance. 
 
 PCR determination of the macrolide and tetracycline resistance genotype 
 Total bacterial DNA was isolated according to the methodology described by the 
CDC (http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). PCR reactions to 
determine which of the macrolide resistance determinants (erm(B), erm(A) or mef) was 
present were performed as described previously [14]. To discriminate between mef(A) and 
mef(E), mef was amplified by PCR using primers MEFR (5’-CCAATGA 
TTTACACCGATT-3’), MEF1 (5’-AATACAACAATTGGAAACTT-3’) and MEF2 (5’-
Shifts in macrolide-resistant clones 
 
117 
 
AAGGAGTTGTGGTTCTGA-3’), as previously described (Gómez E, de la Pedrosa G, 
van derLinden M et al. Presented at the 47th Interscience Conference on Antimicrobial 
Agents and Chemotherapy (ICAAC), Chicago, 17–20 September 2007).  
 PCR reactions for the detection of the tetracycline resistance determinants tet(K), 
tet(L), tet(M) and tet(O) were performed for all isolates included in this study, as 
previously described [32]. The Streptococus dysgalactiae subsp. equisimilis strains SH533, 
SH523 and 645040, carrying tet(M), tet(O) and tet(L), respectively, and an Escherichia 
coli strain carrying the pST181 plasmid with the tet(K) gene were used as positive 
controls. 
 
 T and emm typing 
 T typing was done by slide agglutination using sera for types 1, 2, 3, 4, 6, 8, 9, 11, 
12, 13, 18, 22, 23, 25, 28, 5 ⁄ 27 ⁄ 44, 14 ⁄ 19, B3264 and Imp. 19 (Hemolytic streptococcus 
Typing Antisera for Group A (T-typing), Seiken, Denka Seiken, Tokyo, Japan), according 
to the manufacturer’s instructions. emm typing was performed as described by the CDC 
(http:// www.cdc.gov/ncidod/biotech/strep/protocols.htm). Amplification products were 
purified using the High Pure PCR Product Purification Kit (Roche, Mannheim, Germany), 
according to the manufacturer’s instructions, and sequenced using primer emmseq2 [5], 
and the DNA sequences were searched against the emm sequences deposited in the CDC 
database (http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm). An isolate was 
considered to be of a given emm type if it had >95%identity over the 160 bases considered 
[5].  
 
 Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing 
(MLST)  
 PFGE was performed as previously described [9]. All isolates were digested with 
SmaI, and the isoschizomer Cfr9I was used only for the isolates with the M phenotype, 
which were not digested by SmaI, due to the presence of a methyltransferase encoded in 
the same genetic element that carries the mef(A) gene [15, 30]. Bionumerics software 
(Applied-Maths, Sint-Martens- Latem, Belgium) was used to create UPGMA (unweighted 
pair-group method with arithmetic mean) of the SmaI- or Cfr9I- generated fragment 
patterns. The Dice similarity coefficient was used, with optimization and position tolerance 
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settings of 1.0 and 1.5, respectively. PFGE clusters were defined as isolates with ≥ 80% 
similarity [9]. A PFGE-based cluster was considered to be a major lineage if it included 
more than five isolates. MLST analysis was performed in representatives of each major 
lineage, as previously described [12], and allele and sequence type (ST) were attributed 
using the S. pyogenes MLST database (spyogenes.mlst.net). 
 
 Statistical analysis 
 Wallace coefficients (W) were used to compare partitions. This coefficient 
indicates the probability that two isolates sharing the same characteristic, as established 
using a given typing method, will also be grouped together when a different typing method 
is used [9]. Simpson’s index of diversity (SID) and corresponding 95% CIs were used to 
evaluate the clonal diversity of the isolates presenting the M and the MLSB phenotypes [9]. 
Statistically significant differences in proportions of resistant isolates were detected using 
the two-tailed Fisher exact test, trends in macrolide resistance were evaluated using the 
Cochran–Armitage test for trend [2], and 95% CIs were calculated using the Wilson 
method [3]. 
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 RESULTS 
 
 Antimicrobial susceptibility 
 During the 3 years of the study, the overall rate of erythromycin resistance was 
13.2%, lower than that documented previously (26.6%, Fisher’s exact test, p <10-6) [31]. In 
2004, 50 isolates were erythromycin-resistant (17.6%), the highest resistance rate, followed 
by 11% (n=43) in 2005 and 12.4% (n=63) in 2006, with a significant decreasing trend 
(Cochran-Armitage test for trend, p <10
-4
). Inspection of Figure 3.3.1 shows that the 
decline in resistance in the 2004-2006 period was due to a decline in isolates of the M 
phenotype, and that this trend of decreasing erythromycin resistance could have started 
before 2004. In fact, the Cochran-Armitage test for trend, which was unable to detect a 
trend in the period 1999–2003 (p = 0.22), is significant if one considers the entire period 
1999–2006 (p <10-4).  
 
 
FIGURE 3.3.1. Erythromycin resistance and prevalence of macrolide resistance phenotypes in Portugal 
during the period 1998–2006. Open circles and solid lines represent the proportion of erythromycin-resistant 
group A streptococci among those causing pharyngitis and corresponding 95% CIs. Broken lines represent 
the proportion of each phenotype in the population. Solid triangles represent the proportion of isolates of the 
M phenotype. Open triangles represent the proportion of isolates of the MLSB phenotype. 
 
 
 The majority of the isolates (n=80; 51.3%) presented the cMLSB phenotype, 74 
(47.4%) presented the M phenotype, and only two isolates (1.3%) presented the iMLSB 
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phenotype; however, the prevalence of the macrolide-resistance phenotypes was not 
constant during the study period (Figure 3.3.1). Resistance to tetracycline was found in 
19.9% (n = 31) of the macrolide-resistant isolates, all expressing the MLSB phenotype; in 
fact, the macrolide resistance phenotype was a good predictor of tetracycline resistance 
(W=0.739). The distribution of tetracycline-resistant isolates during the study years was as 
follows: 20.0% (n=10) of the isolates recovered in 2004, 11.6% (n=5) in 2005, and 25.4% 
(n=16) in 2006. 
 Resistance to bacitracin was found in 43 isolates, all presenting the cMLSB 
phenotype. 
 
 Genotypic characterization 
 Erythromycin resistance determinants were detected in all isolates using multiplex 
PCR. With the exception of seven isolates, all carried a single macrolide resistance 
determinant (Table 3.3.1). All isolates of the M phenotype carried mef(A) and none the 
mef(E) variant, including two that carried both mef(A) and erm(B) and an isolate that 
carried mef(A) and erm(A). Four of the isolates presenting the cMLSB phenotype (4.9%) 
carried both erm(B) and mef(A), whereas all other isolates presenting this phenotype 
yielded a single PCR product consistent with the presence of erm(B). One of the two 
isolates presenting the iMLSB phenotype carried erm(A) and the other erm(B). The tet(M) 
gene was found among all tetracycline resistant isolates. None of the other tet determinants 
was found among the studied isolates, including all phenotypically tetracycline susceptible 
isolates. 
 
 Clonal characterization 
 The emm types most frequently found in this study were emm28 (28%), emm4 
(25%) and emm11 (11%). Other emm types accounted for 37% of the isolates, but each for 
less than 10% (emm1, emm2, emm3, emm4, emm6, emm12, emm22, emm44–61 and 
emm75). The most prevalent T types were T28 (25%), T4 (21%), T12 (17%) and T3/13 
(12%), and the remaining 24% of the isolates were T1, T6, T11, T25 or were T non-
typeable. 
 All 156 isolates were typeable by PFGE using either SmaI or Cfr9I, and 25 (16%) 
of the isolates were analyzed using MLST. Eight major lineages were identified, 
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containing 139 isolates (89%), and the remaining isolates (n=17) were included in minor 
PFGE clusters (containing four or fewer isolates) or had unique PFGE patterns. The PFGE 
patterns of representative isolates from each major clone are shown in Figure 3.3.2 and the 
characteristics of the eight major lineages found in this study, as well as their distribution 
during the study period, are summarized in Table 3.3.1.  
 
 
 
 
FIGURE 3.3.2 Pulsed-field gel electrophoresis (PFGE) analysis of macrolide-resistant Streptococcus 
pyogenes isolates from Portugal. (a) Dendrogram showing cluster analysis of the PFGE profiles of the 156 
macrolide-resistant isolates by the unweighted pair-group with arithmetic mean (UPGMA) method. Dice 
coefficients (percentages) are indicated in the scale above the dendrogram. For each of the major clones, a 
triangle proportional to the number of isolates is shown in the dendrogram, followed by the capital letter 
designating the PFGE cluster. (b) PFGE profiles generated following SmaI (MLSB isolates) or Cfr9I (M 
isolates) digestion of DNA isolated from representatives of each major clone. Capital letters identifying each 
lane correspond to the clone designations. m, lambda ladder PFGE marker (New England Biolabs, Beverly, 
MA, USA). 
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TABLE 3.3.1. Properties of macrolide-resistant Streptococcus pyogenes responsible for pharyngitis isolated 
in Portugal during the period 2004–2006 
 
PFGE 
cluster 
No. of 
isolates 
(%) 
T/emm Phenotype Genotype ST 
Year 
2004 2005 2006 
A 42 (26.9) 28/28
a
 cMLSB erm(B)
b
 52 10 17 15 
B 39 (25) 4/4
c
 M mef(A)
d
 39 18 14 7 
C 16 (10.3) 11/11
e
 cMLSB erm(B) 403 4 3 9 
D 11 (7.1) 12/22 cMLSB erm(B)
f
 46 5 1 5 
E 10 (6.4) 3/13/3 M mef(A) 315 0 0 10 
F 8 (5.1) 25/75 M mef(A) 150 3 1 4 
G 7 (4.5) 12/12 cMLSB
g
 erm(B)
g
 36 1 2 4 
H 6 (3.8) 1/1 M mef(A)
h
 28 3 3 0 
Other
i
 17 (10.9)     6 2 9 
PFGE, pulsed-field gel electrophoresis; ST, sequence type. 
a
NT/28 (n = 2); 12/28 (n = 2). 
b
Two isolates carried both erm(B) and mef(A). 
c
3/13/4 (n = 5); 3/13/2 (n = 1); 3/13/3 (n = 1). 
d
One isolate carried both erm(B) and mef(A) and one isolate carried both mef(A) and 
erm(A). 
e
12/11 (n = 3). 
f
Two isolates carried both erm(B) and mef(A). 
g
One isolate had the iMLSB phenotype and carried erm(A). 
h
One isolate carried both mef(A) and erm(A). 
i
Twelve T/emm type combinations were distributed among ten PFGE clusters. All three macrolide resistance 
phenotypes were found among these isolates: M phenotype (n = 10), all carrying the mef(A) gene; cMLSB 
phenotype (n = 6), all carrying the erm(B) gene and iMLSB phenotype (n = 1), carrying the erm(B) gene. 
 
 
 The PFGE cluster classification was an excellent predictor of both the macrolide 
resistance phenotype and the emm type (W=0.995 and W=0.958, respectively).  
 PFGE cluster A accounted for 27% (n=42) of the isolates and included exclusively 
the cMLSB phenotype. All isolates in this cluster carried the emm28 allele and the erm(B) 
gene, including two isolates that additionally carried mef(A), and all were susceptible to 
tetracycline and, unusually, resistant to bacitracin. Most isolates in this cluster were T28, 
with the exception of two isolates that were non-typeable and two isolates that were T12. 
All the isolates characterized by MLST (n=4), including one with the T12 serotype, 
belonged to ST52. A single bacitracin-resistant isolate was not grouped into any of the 
major PFGE clusters but had the same characteristics as these isolates (T28-emm28-ST52). 
 Cluster B included only isolates of the M phenotype and they were susceptible to 
tetracycline, and accounted for 25% (n=39) of the isolates. All the isolates carried mef(A), 
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including two isolates that, in addition, also carried either erm(B) or erm(A). Although 
almost all the isolates were T4, a significant proportion (n=7; 17.9%) of the isolates were 
T3/13. However, only two of these seven isolates were of different emm types, namely 
emm2 and emm3, whereas all other isolates of the cluster carried emm4. All isolates 
analyzed by MLST (n=6), including the two isolates of different emm types, were found to 
belong to ST39.  
 All the isolates included in cluster C (n=16, 10.3%) presented the cMLSB 
phenotype, were resistant to tetracycline, and carried erm(B). Most isolates included in this 
cluster were T11-emm11, with the exception of three isolates, characterized by the 
combination T12-emm11. All isolates of this PFGE cluster for which the sequence type 
was determined (n=4), including one T12-emm11 isolate, belonged to ST403.  
 Cluster D comprised 11 cMLSB isolates (7.1%), which were resistant to tetracycline 
and had the same combination of surface antigens, namely T12-emm22. Two isolates 
carried both erm(B) and mef(A), and those remaining carried only erm(B). The three 
isolates included in this PFGE cluster analyzed by MLST were found to belong to ST46.  
 All of the isolates grouped in cluster E (n=10, 6.4%) presented the M phenotype, 
were susceptible to tetracycline, and carried only mef(A). The T antigen expressed by all of 
the isolates was T3/13, and all of them carried the emm3 allele. MLST was performed for 
two isolates, and both belonged to ST315.  
 Three smaller clusters (F, G and H) comprised eight, seven and six isolates, 
respectively. Cluster F included tetracycline-susceptible isolates displaying the M 
phenotype and the T25-emm75 surface antigens and carrying mef(A). One isolate was 
analyzed by MLST and belonged to ST150. Cluster G comprised tetracycline-susceptible 
cMLSB isolates, carrying erm(B), with the exception of one isolate that presented the 
iMLSB phenotype and carried erm(A). All seven isolates were T12-emm12, and the two 
isolates analyzed by MLST were ST36. The smaller cluster, designated H, included 
tetracycline-susceptible isolates presenting the M phenotype, and all except one carried 
only mef(A) (the exceptional isolate carried both mef(A) and erm(A)). All of the isolates 
were T1-emm1, and the ST found in this cluster was ST28 (n=2). 
 A small proportion (n=17, 10.9%) of the isolates was not grouped into any of the 
clusters described above. Whereas six had a unique PFGE pattern, the emm types of 
another six were found in major clusters (emm1, emm12 and emm3). The prevalence of the 
Chapter 3.3 
 
124 
 
major clusters was not stable during the study period (Table 3.3.1), and these fluctuations 
were reflected in the changes observed in the frequency of the macrolide resistance 
phenotypes (Figure 3.3.1). To evaluate whether the diversity of the clones expressing each 
of the main macrolide resistance phenotypes— MLSB and M—varied during the period 
1998–2006, SID and the corresponding 95% CIs were calculated for each year. The results 
are summarized in Figure 3.3.3. 
 
 
FIGURE 3.3.3 Simpson’s index of diversity for the population of macrolide-resistant group A streptococcus 
(1998–2006). Simpson’s index of diversity and corresponding 95% CIs were calculated for the PFGE 
clusters of macrolide-resistant Streptococcus pyogenes isolates from each study year. 
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 DISCUSSION 
 
 The erythromycin resistance rate among GAS during the period 2004–2006 
decreased significantly, and included the lowest value found during the last decade in 
Portugal. Excluding 1998, when the overwhelming dominance of a single clone could have 
influenced the overall rate of resistance to erythromycin [30], a re-evaluation of the trend 
in the period 1999–2006 revealed a significant decrease in the entire period, contrary to our 
previous findings for the period 1999–2003 [31]. This steady decrease in resistance, 
accompanied by changes in the prevalence of the macrolide resistance phenotypes, was 
due to a clonal instability that continued during the period reported here. The emergence of 
clones not detected previously, such as the PFGE clusters characterized by T11-emm11-
ST403 and T3/13-emm3-ST315, accounting for a large fraction of resistant isolates, was 
accompanied by a change in the prevalence of the clones previously described and even the 
disappearance of some clones. Most clusters retained the same macrolide resistance 
determinant found in the period 1998–2003, apart from the unusual PFGE cluster 
characterized by T12-emm12-ST36, which was now exclusively associated with the MLSB 
phenotype and the erm(B) gene, instead of with the M phenotype detected in the period 
1999-2003. With the exception of a macrolide-resistant clone not previously described 
(T3/13-emm3-ST315), all clones identified among macrolide-resistant GAS in Portugal 
appear to be present in other European countries, suggesting wide geographical spread of a 
few successful clones [13, 18, 24, 25, 28]. However, the diversity of the clones detected in 
a single geographical region and the variability of macrolide resistance determinants 
carried by otherwise undistinguishable isolates strongly suggest that acquisition of 
macrolide resistance determinants is also ongoing. 
 The changes in the clonal composition of the population could have a profound 
impact on the prevalence of the macrolide resistance phenotypes as well as on overall 
resistance. To test whether a reduced diversity of the population could be implicated in the 
changes in macrolide resistance, the SID and 95% CIs for each study year in the period 
1998-2006 were calculated (Figure 3.3.3). As expected, the initial overwhelming 
dominance of the T12-emm22-ST46 clone [30] resulted in the lowest SID being 
determined for the population expressing the MLSB phenotype; this then increased steadily 
until 2000, in parallel with the decrease in the prevalence of this clone. The second decline 
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in the prevalence of the MLSB phenotype, occurring between 2001 and 2003 (Figure 
3.3.1), was associated with stable and higher SIDs, indicating that this decrease could not 
be attributed solely to changes in the prevalence of a single clone, as occurred in 1998, or 
to a lack of clonal diversity of the MLSB isolates (Figure 3.3.3). The SID of the population 
presenting the M phenotype was significantly higher than that of the population presenting 
the MLSB phenotype up to 2001, during a period of increased prevalence of the M 
phenotype, but the two populations remained undistinguishable for the remainder of the 
study period (SIDs with overlapping CIs).  
 This latter observation does not support a difference in mobility of the genetic 
elements carrying each of the macrolide resistance determinants, which would be expected 
to result in a higher diversity of the population associated with the more mobile genetic 
elements. It is noteworthy that the steady, although not significant, decline in the diversity 
of the populations displaying both macrolide resistance phenotypes from 2001 to 2003, 
occurring in a population increasingly dominated by a few clones, was followed by a 
period of greater variability that paralleled the changes in the prevalence of each 
phenotype. However, large changes in the diversity of the population, apparent in the 
fluctuations of SID, continued to occur in the somewhat stable situation concerning 
macrolide resistance and phenotypes reached in the period 2005–2006. This suggests that, 
although the clonal composition of the population and the prevalence of the macrolide 
resistance phenotypes are certainly related, the overall make-up of the population probably 
results from the dynamic interaction between these two factors, and neither can be assumed 
to be the cause of the changes observed in the other.  
 This study has several limitations that may have influenced the results presented. In 
spite of the location of the laboratories throughout Portugal, which covered a large fraction 
of the population, only close to 1200 isolates were recovered. Two major factors are 
behind the relatively small number of isolates: (i) the management of pharyngitis relies 
mainly on rapid antigen tests and clinical criteria, with culture being infrequently 
performed; and (ii) although the laboratories were asked to submit all GAS associated with 
the diagnosis of pharyngitis, an audit to ensure compliance, which may vary in this type of 
study, was not undertaken [26]. The increase in the number of isolates that was particularly 
apparent in the period 2005-2006 was found among all participating laboratories, and we 
attribute this mainly to increased compliance with our request to send all GAS isolated in 
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pharyngitis cases. The alternative explanation would be that there is an increased incidence 
of infections caused by macrolide susceptible GAS which, consequently, would bias the 
estimates of macrolide resistance. However, this seems unlikely, because outbreaks of 
macrolide-susceptible GAS would probably be restricted to a few regions and would not be 
a national phenomenon, and no changes were observed in the proportions of isolates from 
each of the major regions considered. More importantly, the proportion of isolates 
expressing the MLSB phenotype remained approximately constant in spite of the increase 
in the total number of isolates, whereas only the proportion of isolates expressing the M 
phenotype decreased in recent years (Figure 3.3.1). 
 This study showed a decline in macrolide resistance among GAS causing 
pharyngitis in Portugal. These changes were accompanied by clonal variations, but the 
great diversity of the populations displaying each of the macrolide resistance phenotypes 
precludes the simple explanation that these could be solely attributed to strong fluctuations 
in a few resistant clones. The results underscore the importance of considering both the 
clonal structure of the bacterial population and antibiotic consumption when attempting to 
explain the prevalence of resistant isolates. 
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 SUMMARY 
 
 Macrolide resistance among Streptococcus pyogenes (Group A streptococci – GAS) 
in Portugal decreased in 1999-2006, and this was accompanied by alterations in the 
prevalence of macrolide resistance phenotypes and clonal composition of the population. 
The aims of this study were to gain further insights into the changes in overall macrolide 
resistance, of the fluctuations of macrolide resistance phenotypes and of the clonal 
structure of the macrolide resistant population of GAS recovered in 2007-2011 in Portugal. 
We report continuing changes in macrolide resistance phenotypes and a persistent decline 
in overall erythromycin resistance, despite continued high macrolide use and increased 
consumption. Characterization by emm typing, T typing, pulsed-field gel electrophoresis 
(PFGE) profiling and multilocus sequence typing revealed a marked increase in T11-
emm11-ST403 cMLSB isolates, the disappearance of the T3-emm3-ST315 M clone, and 
changes in the prevalence of previously identified GAS clones. Unexpectedly, the decline 
in erythromycin resistance and the decreasing prevalence of the MLSB phenotype were 
accompanied by a high consumption of long-acting and intermediate-acting macrolides 
that are known to select for resistance and the erm(B) gene. In spite of high macrolide 
consumption, the decline in macrolide resistance detected since 2000 continued to occur, in 
a population with high clonal instability, emphasizing the importance of considering 
factors other than antibiotic consumption in explaining the prevalence of resistance.  
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 INTRODUCTION 
 
 Streptococcus pyogenes or Lancefield group A streptococcus (GAS) is an important 
human pathogen causing a broad spectrum of infections from acute pharyngitis to severe 
invasive disease. Macrolides and lincosamides constitute suitable alternatives to the 
treatment of streptococcal infections, especially in patients allergic to β-lactams.  
 Two mechanisms of resistance to macrolides have been described in Streptococcus 
pyogenes: target site modification and active efflux. Target site modification is caused by 
the presence of a methylase encoded by the erm(B) gene or erm(TR) gene [belonging to 
the erm(A) class], that results in resistance to most macrolides, lincosamides and 
streptogramin B (the MLSB phenotype) [17]. The expression of the erm genes can be 
constitutive or inducible, generating the cMLSB phenotype and the iMLSB phenotype, 
respectively. Both classes of erm genes were found associated with transposons with the 
capacity to transfer the resistance traits to susceptible strains by conjugation [6]. The other 
mechanism, responsible for resistance to 14- and 15-membered ring macrolides (the M 
phenotype) but not to clindamycin, is mediated by a membrane associated pump encoded 
by the mef determinants.  Although the majority of GAS presenting the M phenotype 
carried the mef(A) variant [13], mef(E) was also detected in S. pyogenes [10].  
 In some countries, like Spain, Greece, Italy, Slovenia and Portugal, high macrolide 
resistance rates in S. pyogenes have been reported [8, 19, 21, 24, 26] while lower resistance 
rates were reported in other European countries [26, 32]. Likewise, some differences were 
also found in the prevalence of macrolide resistance phenotypes and the clonal 
composition of macrolide resistant GAS populations.  
 Increases in macrolide resistance are often associated with high antimicrobial 
consumption  and several studies have already shown a correlation between the decrease in 
macrolide resistance and the decrease in antibiotic consumption [2, 27, 32]. Moreover, 
some studies showed an association between specific macrolides (intermediate-acting and 
long-acting macrolides) in selecting for resistance and in the selection of a particular 
macrolide resistance phenotype [18]. However, the circulating clones and the fluctuations 
in the clonal composition of the population can also be responsible for alterations in the 
prevalence of macrolide resistance and of the macrolide resistance phenotypes [8, 29].  
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 In Portugal, a steady decline in macrolide resistance in GAS was reported between 
1999 and 2006, from 20% in 1999 to 12% in 2006. This was accompanied by fluctuations 
of the macrolide resistance phenotypes and of the clonal composition of the population 
[29]. However, these fluctuations did not simply reflect fluctuations of the overall GAS 
population. In a study comparing the macrolide resistant and susceptible GAS populations 
in Portugal, we found that particular emm types and PFGE clusters were associated with 
macrolide resistance while others were associated with macrolide susceptibility and the 
changes in macrolide resistance were accompanied by fluctuations in emm types and their 
associated lineages [28]. The differences found between the macrolide resistant and 
susceptible populations indicated that the macrolide resistant population has its own 
dynamics.  
 The aims of this study were to document any changes in macrolide resistance and in 
the characteristics of resistant isolates in 2007-2011. We report ongoing fluctuations of 
macrolide resistance phenotypes and a continuing decline in overall erythromycin 
resistance, despite continued high macrolide use and discuss their possible causes.  
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 MATERIALS AND METHODS 
 
 Bacterial isolates and identification 
 A total of 2632 S. pyogenes recovered from throat swabs, associated with a 
diagnosis of tonsillo-pharyngitis were collected from 32 microbiology laboratories located 
throughout Portugal from January 2007 to December 2011.  The laboratories were asked to 
submit all non-duplicate S. pyogenes isolated from outpatients during the study period. The 
isolates were distributed in the study period as follows: 519 in 2007, 491 in 2008, 551 in 
2009, 558 in 2010 and 513 in 2011. Isolates were identified to the species level by colony 
morphology, β-hemolysis on sheep blood agar, and a commercial latex-agglutination 
technique (Slidex Strepto A, BioMérieux, Marcy l’Etoile, France). In this collection, 139 
isolates (5.3%) were erythromycin-resistant, and only these isolates were characterized 
further. 
 
 Antimicrobial susceptibility testing and macrolide resistance phenotype 
 Susceptibility to erythromycin, clindamycin and tetracycline (Oxoid, Basingstoke, 
UK) was tested using disk diffusion according to CLSI recommendations [9]. The 
macrolide resistance phenotype was determined according to a double disk test previously 
described [20]. Bacitracin susceptibility was determined for all isolates by disk diffusion 
using disks containing 0.05 U of bacitracin (Oxoid, Basingstoke, UK) as previously 
described [30].  
 
 PCR determination of the macrolide and tetracycline resistance genotype 
  Total bacterial DNA was isolated according to the methodology described by the 
Centers for Disease Control and Prevention (CDC) 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). PCR reactions to determine 
which of the macrolide resistant determinants [erm(B), erm(A) or mef] was present, were 
performed as described previously [12]. To discriminate between mef(A) and mef(E) 
genes, the mef gene was amplified by PCR as previously described [29].  
 PCR reactions for the detection of tetracycline resistant determinants, tet(K), tet(L), 
tet(M) and tet(O) were performed for all isolates included in this study, as previously 
described [29]. Streptococcus dysgalatiae subs. equisimilis SH533, SH523 and 645040 
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carrying tet(M), tet(O) and tet(L) respectively and an Escherichia coli strain carrying the 
pST181 plasmid with the tet(K) gene were used as positive controls.  
 
 T and emm typing 
 T typing was performed by slide agglutination using sera for types 1, 2, 3, 4, 6, 8, 9, 
11, 12, 13, 18, 22, 23, 25, 28, 5/27/44, 14/19 and Imp.19 (Hemolytic streptococcus Typing 
Antisera for Group A (T-typing) SEIKEN, Denka Seiken, Tokyo, Japan), according to the 
manufacturer’s instructions. emm typing was performed as described by the CDC 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). Amplification products were 
purified using the High Pure PCR Purification Kit (Roche, Mannheim, Germany) 
according to the manufacturer’s instructions, sequenced using primer emmseq2 and the 
DNA sequences were searched against the emm sequences deposited in the CDC database 
(http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm).  
 
 Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing 
(MLST)  
 PFGE was performed as previously described [30]. The MLSB isolates were 
digested with SmaI, and the isoschizomer Cfr9I was used for the isolates with the M 
phenotype, which were not digested by SmaI [30]. Bionumerics software (Applied-Maths, 
Sint-Martens-Latem, Belgium) was used to create UPGMA (unweighted pairgroup method 
with arithmetic mean) dendrograms of the SmaI or Cfr9I fragment patterns. The Dice 
similarity coefficient was used, with optimisation and position tolerance settings of 1.0 and 
1.5, respectively. PFGE clusters were defined as isolates with ≥ 80% similarity [7].  
 A PFGE-based cluster was considered to be a major lineage if it included more than 
five isolates. MLST analysis was performed in at least 60% of randomly selected isolates 
of each emm type that was represented by more than 3 isolates (n=96) as previously 
described [11] and allele and sequence type (ST) were attributed using the MLST database 
(spyogenes.mlst.net). The relationships between the MLST STs were determined using the 
goeBURST [14] algorithm implemented in PHYLOVIZ [15] with the complete S. 
pyogenes database available at spyogenes.mlst.net.  
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 Statistical analysis 
 Trends in macrolide resistance were evaluated using the Cochran-Armitage test for 
trend [3]. The Simpson’s index of diversity and corresponding 95% confidence intervals 
were used to evaluate the clonal diversity of the isolates for each year since 1998 [7].   
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 RESULTS 
 
 Antimicrobial susceptibility testing and macrolide and tetracycline resistance 
phenotype 
 During the five years of the study, the overall rate of erythromycin resistance was 
5.3%, a lower value than the one reported in 2004-2006 (13.2%). A decreasing trend in 
macrolide resistance was noted in the period 2007-2011(10% to 2%, Cochran-Armitage 
test for trend, p<0.001).  
A total of 95 of the 139 macrolide resistant isolates (68.3%) presented the cMLSB 
phenotype, 43 (30.9%) the M phenotype and only one isolate (0.8%) presented the iMLSB 
phenotype. The decline in macrolide resistance in this period was due to the decline of 
isolates presenting both macrolide resistance phenotypes, (p<0.001 and p=0.037 for MLSB 
and M isolates, respectively (Figure 3.4.1).  
 
 
FIGURE 3.4.1 Erythromycin resistance and prevalence of macrolide resistance phenotypes in Portugal 
during the period 1998–2011. Open circles and solid lines represent the proportion of erythromycin-resistant 
group A streptococci among those causing pharyngitis. Broken lines represent the proportion of each 
phenotype in the population. Solid triangles represent the proportion of isolates of the M phenotype. Open 
squares represent the proportion of isolates of the MLSB phenotype. Solid squares represent the macrolide 
consumption, measured by defined daily doses/1000 inhabitants/day [1]. The shaded area represents 
previously published data [29, 31] 
 
 
 Resistance to tetracycline was found in 59% (n=82) of the isolates. With the 
exception of two isolates expressing the M phenotype, all the tetracycline resistant isolates 
expressed the MLSB phenotype.  The distribution of the tetracycline resistant isolates 
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among the study years was as follows: 33 in 2007, 21 in 2008, 7 in 2009, 17 in 2010 and 4 
in 2011. Resistance to bacitracin was found in 11 isolates, all expressing the cMLSB 
phenotype.  
 
 Identification of resistance determinants 
  All isolates tested carried a single macrolide resistant determinant. Among the 
cMLSB isolates, all but one carried the erm(B) gene. The exception was one isolate 
carrying the erm(A) determinant. This was also the resistant determinant carried by the 
single isolate presenting the iMLSB phenotype included in this collection. Almost all the M 
isolates carried the mef(A) gene, the exception was one isolate that yielded a PCR product 
indicating the presence of the mef(E) gene. This isolate was also also tetracycline resistant 
and carried the tet(M) determinant.   
 Among the tetracycline resistant isolates, tet(M) was found in 90.2% of the isolates 
(n=74), while 2 isolates (2.4%) carried the tet(O) gene. These two isolates also carried the 
erm(A) resistance determinant and belonged to the same emm type and PFGE cluster (see 
below). In six of the tetracycline resistant isolates, no resistant determinant was detected by 
PCR. None of the other tet determinants was found among the isolates studied.  
 
 Clonal characterization 
 The characteristics of 139 GAS isolates included in this study are summarized in 
Table 3.4.1. All 139 isolates were typable by PFGE using either SmaI or Cfr9I and nine 
major lineages were identified, containing 118 isolates (84.9%), while the remaining 21 
isolates (15.1%) were included in minor PFGE clusters (containing four or fewer isolates) 
or had unique PFGE patterns. The PFGE patterns of representative isolates from each 
major cluster are shown in Figure 3.4.2 and the characteristics of the major lineages found 
in this study are shown in table 3.4.1. 
 MLST analysis was performed in 96 isolates (70%). We identified 3 novel alleles 
among the genes used in MLST, one in gki (gki116), and two in gtr (gtr91 and gtr92). The 
gtr allele 92 presented a 1-nt deletion that was predicted to result in a truncated form of the 
protein. New allele combinations producing novel STs were also noted and were assigned 
ST numbers 657 to 659. The new alleles and the novel STs were submitted to the S. 
pyogenes MLST database (spyogenes.mlst.net). Among the 96 isolates, 18 STs were 
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found.  In all cases, isolates of the same emm type presented the same ST or STs of the 
same clonal complex (Table 3.4.1) 
  
Table 3.4.1. Characteristics of the 139 macrolide resistant GAS in Portugal 
emm type (no. 
of isolates) 
PFGE 
cluster
a
 
T  types (no. of 
isolates)
b
 
Macrolide resistance phenotype [genotype]               
(no. of isolates) 
Tetracycline resistance 
phenotype 
[genotype] (no. of isolates)
c 
ST (no. of isolates)
d
 
11(61) A53(53) 11(50), NT(2), 9(1) cMLSB [erm(B)] (53) R [tet(M)](49), [ND] (3); S(1) [403(35), 562(1)] 
G7(7) 11(7) cMLSB [erm(B)] (7) R [tet(M)](7)  403(5) 
Other (1) 11(1) M [mef(A)](1) R [ND](1) ND 
22(16) C10(9) 12(9) cMLSB [erm(B)] (9) R [tet(M)](8), [ND] (1) 46(7) 
Other (7) 12(7) cMLSB [erm(B)] (9) R [tet(M)](6), [ND] (1) 46(4) 
12(15) E8(8) 12(5), NT(2), 9(1) M [mef(A)](8) 
 
S(8) 36(5) 
Other (7) 12(5), NT(2) M [mef(A)](4)[mef(E)](1); cMLSB [erm(B)](2) 
(53) 
 
R [tet(M)](1); S(6) 36(5) 
28(11) B11(11) 28(11) cMLSB [erm(B)] (11) S(11) 52(8) 
4(8) F8(8) 4(8) M [mef(A)](8) 
 
S(8) [39(5), 658(1)] 
1(7) H7(7) 1(7) M [mef(A)](7) 
 
S(7) [28(1), 618(1), 659(3)] 
75(6) I6(6) 25(6) M [mef(A)](6) 
 
S(6) 657(4) 
6(4) D8(4) 25(6) M [mef(A)](3), cMLSB [erm(B)](1) 
 
S(4) [382(2), 411(1)] 
9(4) D8(3) 9(2), NT(1) M [mef(A)](3) 
 
S(3) 75(2) 
Other (1) 9(1) M [mef(A)](1) 
 
S(1) 75(1) 
Other
e
 Multiple
f
 Multiple
g
 cMLSB [erm(B)] (4) [erm(TR)](1); 
 iMLSB [erm(TR)](1); M [mef(A)](1) 
 
R [tet(M)] (3), [tet(O)] (2); S(2) Multiple
h
 
a 
Each major lineage is designated by a capital letter, followed by a number in subscript that indicates the number of isolates grouped in that lineage; whenever a PFGE 
cluster included less than 5 isolates of that particular emm type, it was not discriminated and it was designated by “other”. 
b
 NT, non-typeable 
c
 ND (Not determined): Did not yield any amplification product for the genes tested 
d 
Brackets indicate STs that belong to the same clonal complex defined by the goeBURST algorithm (http://goeburst.phyloviz.net/) with the complete S. pyogenes 
database available at spyogenes.mlst.net 
e 
6 emm types (7 isolates): 77(2), 3(1), 44(1), 73(1), 78(1) and 87(1) 
f
 5 PFGE clusters 
g
 6 T types: 13(2), 11(1), 28(1), 5/27/44(1), 9(1), NT(1) 
h
4 STs: 63(2), 406(1), 409(1), 62(1)  
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The prevalence of the major emm types was not stable during the study period, and 
this instability was noted in the previously studied periods (1998-2006) (Figure 3.4.3). To 
evaluate if the diversity of the emm types varied during the period 1998-2011, the 
Simpson’s Index of diversity and the corresponding 95% confidence intervals were 
calculated for each year. The results are summarized in Figure 3.4.4.  
 
 
 
 
FIGURE 3.4.3. Proportion of each of the major lineages (defined by macrolide resistance phenotype and 
emm type) that accounted for >5% of macrolide-resistant Streptococcus pyogenes isolated in Portugal 
between 1998 and 2011. Whenever an emm type was expressed by fewer than 5% of the isolates recovered in 
that year, it was not discriminated and it was designated by “other”.  
 
 
 
 
 
 
FIGURE 3.4.4. Simpson’s index of diversity for the population of macrolide-resistant group A 
Streptococcus (1998–2011). Simpson’s index of diversity and corresponding 95% CIs were calculated for the 
emm types of macrolide-resistant Streptococcus pyogenes isolates from each study year. 
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DISCUSSION 
 
 From 2007 to 2011, a decrease in erythromycin resistance rate among S. pyogenes 
responsible for pharyngitis was reported. The decreasing trend in macrolide resistance 
already detected in the period 1999-2006 [29], continued in this study period (2007-2011), 
reaching the lowest value of macrolide resistance in GAS recorded in Portugal (2% in 
2011).  
 In Portugal, tetracycline resistance among macrolide resistant GAS is usually 
associated with the cMSLB phenotype and in pharyngitis isolates, the tetracycline resistant 
determinant found was always tet(M) [30]. In this study, we documented for the first time 
in Portugal, the presence of the mef(E) gene in a GAS isolate, that also carried tet(M). The 
tet(O) was found in two MLSB isolates (one iMLSB and one cMLSB isolate), which also 
carried erm(A) and presented T13 and emm77. Because macrolide and tetracycline 
resistance determinants are carried in the same genetic elements, it was suggested that co-
selection could explain changes in macrolide resistance among S. pyogenes [22] and we 
have already demonstrated that between 1998 and 2003 the decrease in tetracycline 
accompanied the decrease in the proportion of cMLSB isolates [31]. Among all the S. 
pyogenes isolates recovered from tonsillo-pharingytis patients in Portugal, a significant 
decrease in tetracycline resistance from 8% in 2007 to 2% in 2011 was noted (p<10
-6
, 
Cochran Armitage test for trend), which could be attributed to a 54% decrease in 
ambulatory tetracycline consumption from 2000 to 2009 [25]. However, macrolide 
consumption in 2000, measured in defined daily doses (DDD)/1000 inhabitants/day, was 
twice as high as tetracycline consumption and in 2009 it was fivefold higher [25]. The high 
rates of tetracycline resistance among the macrolide resistant isolates in the last years of 
the study could simply be reflecting the high proportion of T11-emm11-ST403 isolates, 
carrying erm(B) and tet(M) determinants.  
 Ecological studies have associated changes in macrolide consumption with the 
prevalence of resistant isolates [16, 27, 32]. A randomized, double-blind, placebo-
controlled study showed that azithromycin (a long-acting macrolide) was more efficient 
than clarithromycin (an intermediate-acting macrolide) in the selection of macrolide 
resistant streptococci of the oral commensal flora, although only the latter selected for the 
erm(B) gene [18]. The importance of this finding resides in the fact that the same genetic 
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elements conferring macrolide resistance are widely spread among streptococci [6, 13] and 
that commensal streptococci are able to transfer these elements to pathogenic species 
constituting a reservoir of resistance genes [23].  
 The situation documented in Portugal is in contrast with these findings. If we 
consider the entire period from 1998 to 2011, we are now able to show that the increase in 
macrolide consumption in the country was accompanied by a decrease in overall macrolide 
resistance in GAS. The macrolide consumption increased 35% from 3.20 DDD/1000 
inhabitants/day in 1998 to a peak of 4.34 in 2005 [1]. From then on, consumption remained 
high and approximately constant until 2009 [1]. Moreover, the consumption of 
intermediate-acting and long-acting macrolides increased steadily during this period such 
that in 2009 Portugal was the third biggest consumer of long acting macrolides in Europe 
with 1.47 DDD/1000 inhabitants/day, which represents a 50% increase relatively to the 
values of 1998 (0.98 DDD/1000 inhabitants/day) [1].  The consumption of intermediate-
acting macrolides was also high in this period, peaking in 2005 at 2.60 DDD/1000 
inhabitants/day [1]. Moreover, the increase in consumption of intermediate-acting 
macrolides, shown to select for the erm(B) gene, coincided with a decrease in the 
proportion of isolates presenting the MLSB phenotype and an increase in the M phenotype 
observed in the period 1999-2003, and with the decrease of both phenotypes from 2004 
onwards (Figure 3.4.1). It could be argued perhaps that there was insufficient selective 
pressure to maintain a high macrolide resistance rate in GAS, but consumption in Portugal 
has remained well above the value of 2 DDD/1000 inhabitants/day, believed to trigger an 
increase in macrolide resistant GAS [16]. Although we have no data concerning macrolide 
consumption since 2009, it seems unlikely that a rapid decline in macrolide use, especially 
of long- and intermediate-acting macrolides would explain the variations seen in 2009-
2011, because any changes in macrolide use are expected to have a delayed effect on 
resistance rate [16]. Moreover, mathematical models predict that once resistance was 
selected [5], only drastic reductions in antibiotic use can be hoped to lead to reduced 
resistance rates, and this was not the case, since overall macrolide consumption remained 
high, and at levels of use above the threshold for selection  of resistance, at least until 
2009.  
 Changes in the clonal composition, already described in the period 1998 to 2006 
[29, 30] continued in the period 2007 to 2011. The most notable change is the increase of 
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T11-emm11-ST403 isolates, which accounted for 10% of the isolates in the period of 2004-
2006, and represent 44% of the GAS isolates in the period 2007 to 2011. A high 
prevalence of the T11-emm11-ST403 lineage was also reported in Spain, but its spread was 
associated with an increase in macrolide resistance [4], contrary to our findings in 
Portugal. Other differences include the disappearance of the T3-emm3-ST315 lineage, 
which was associated with macrolide susceptibility in Portugal [28] and rarely described 
among macrolide resistant GAS in other countries. All the genetic lineages identified 
among macrolide resistant GAS appear to be disseminated in other European countries [4, 
19].  
 In Belgium, a decrease in macrolide resistance rate was noted after a reduction of 
macrolide consumption and in a situation of low levels of resistance, the proportion of 
isolates of a single clone (erm(A)-emm77 isolates), with a low fitness cost, increased 
significantly [32]. The analysis of the prevalence of the major emm types circulating in 
Portugal (Figure 3.4.3) showed that between 1998 and 2011, each emm type seems to be 
dominant for periods of 3-4 years, without a clear decrease in the proportion of a single 
clone accompanying the decrease in macrolide resistance. To test if the decrease in 
macrolide resistance was accompanied by a decrease in the diversity of the population we 
calculated the SID of the emm types and 95% confidence intervals for each study year 
between 1998 and 2011 (Figure 3.4.4). As already reported [31], the dominance of the 
emm22 in the two first years of the study resulted in lower SIDs; between 2000 and 2009, 
the SIDs were higher but not stable with no significant yearly variation (showing 
overlapping confidence intervals). Finally, in 2010 and 2011, the population showed a 
lower diversity again, with a great predominance of emm11 isolates. However, this 
decrease in the diversity of the population cannot be invoked to explain the decrease in 
macrolide resistance because in these two years the number of resistant isolates was very 
low and, more importantly, because the decrease in macrolide resistance was noted even 
when the SIDs were stable (2000-2009).  
 Macrolide consumption still stands as the main driver of macrolide resistance in 
streptococci and this is well documented [16, 27, 32]. However, the association between 
clonal fluctuations in the population and macrolide resistance phenotypes must have a role 
in the dynamics of macrolide resistant GAS population, as already recognized [8, 28].  
Here we showed a decline of macrolide resistance among GAS associated with pharyngitis 
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to a level as comparable to the lowest in Europe (including countries with low 
consumption) [1, 26, 32] . This decrease occurred in spite of a high macrolide use, 
especially of intermediate-acting and long-acting macrolides previously implicated in 
selection of resistance. Particularly, the increase in the M phenotype observed in some 
years and the decrease in the MLSB phenotype observed since 2001 was unexpectedly 
accompanied by an increase in the consumption of long-acting macrolides, which have a 
high potential for selection of the erm(B) gene.  
 These changes were accompanied by variations in the clonal composition of the 
population, which are part of the natural dynamics of the macrolide resistant GAS, 
independently of the behavior of the general GAS population. All these results underscore 
the importance of considering both the clonal structure of the bacterial population as well 
as antibiotic consumption when attempting to explain the prevalence of resistant isolates.  
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 SUMMARY 
 
 A steady decline in macrolide resistance among Streptococcus pyogenes (group A 
streptococci [GAS]) in Portugal was reported during 1999 to 2006. This was accompanied 
by alterations in the prevalence of macrolide resistance phenotypes and in the clonal 
composition of the population. In order to test whether changes in the macrolide-resistant 
population reflected the same changing patterns of the overall population, we characterized 
both macrolide-susceptible and -resistant GAS associated with a diagnosis of tonsillo-
pharyngitis recovered in the period from 2000 to 2005 in Portugal. Pulsed-field gel 
electrophoresis (PFGE) profiling was the best predictor of emm type and the only typing 
method that could discriminate clones associated with macrolide resistance and 
susceptibility within each emm type. Six PFGE clusters were significantly associated with 
macrolide susceptibility: T3-emm3-ST406, T4-emm4-ST39, T1-emm1-ST28, T6-emm6-
ST382, B3264-emm89-ST101/ST408, and T2-emm2-ST55. Four PFGE clusters were 
associated with macrolide resistance: T4-emm4-ST39, T28-emm28-ST52, T12-emm22-
ST46, and T1-emm1- ST28. We found no evidence for frequent ongoing horizontal transfer 
of macrolide resistance determinants. The diversity of the macrolide-resistant population 
was lower than that of susceptible isolates. The differences found between the two 
populations suggest that the macrolide-resistant population of GAS has its own dynamics, 
independent of the behavior of the susceptible population. 
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 INTRODUCTION 
 
 Streptococcus pyogenes (Lancefield group A streptococci [GAS]), is the most 
common bacterial agent implicated in acute pharyngitis and can also cause a variety of skin 
and soft tissue infections, as well as severe invasive disease. Although penicillin remains 
the antibiotic of choice in the treatment of GAS infections, macrolides and lincosamides 
are recommended as suitable alternatives for patients who are allergic to penicillin [4].  
 High macrolide resistance in GAS was reported in most southern European 
countries, such as Spain, Greece, Italy, and Portugal [14, 15, 19, 22, 25, 27], but this was 
not a characteristic of all European countries [22]. Although differences in the prevalence 
of particular macrolide resistance genotypes and emm types were documented, the majority 
of these emm types shared the same resistance determinants, suggesting a broad 
geographical dissemination of a few clones. Isolates fully susceptible to macrolides that 
share the same pulsed-field gel electrophoresis (PFGE) profiles or the same sequence types 
(STs) as these major clones have been described, and several resistance determinants have 
been associated with each resistant lineage. Taken together, these data imply that 
independent acquisition of resistance genes by the same prevalent clones followed by local 
dissemination could have also played a role in conditioning the successful macrolide 
resistance phenotypes and clones in particular geographic locations.  
 An association between certain emm types and macrolide resistance was 
documented [1, 7, 16, 17, 23, 28], but in most of these studies the characterization of the S. 
pyogenes isolates was limited to emm typing. However, it was recently shown that this 
typing technique is not sufficient to unambiguously identify GAS clones. For the precise 
identification of genetic lineages, emm typing should be complemented with other typing 
methods, such as PFGE or multilocus sequence typing (MLST) [5]. In Portugal, we noted a 
steady decline in macrolide resistance among S. pyogenes isolates in 1999 to 2006, 
decreasing from 20% in 1999 to 12% in 2006 [25]. This was accompanied by large 
fluctuations of the macrolide resistance phenotypes, as well as changes in the clonal 
composition of the population [25–27]. Given these results, we hypothesized that the 
changing patterns of macrolide resistance could also be reflecting fluctuations in the 
overall population, implying that important causes for this fluctuation lay outside antibiotic 
usage and reflected other selective forces acting on the entire GAS population. 
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  The aims of this study were to characterize the macrolide-susceptible population of 
GAS and to compare it with the macrolide resistant population to determine how much the 
dynamics of macrolide- resistant isolates could be mirroring the behavior of the overall 
GAS population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
162 
 
 MATERIALS AND METHODS 
 
 Bacterial isolates and identification 
 A total of 1,606 S. pyogenes isolates recovered from throat swabs and associated 
with a diagnosis of tonsillo-pharyngitis were collected from 32 microbiology laboratories 
located throughout Portugal from January 2000 to December 2005. In this period, 
erythromycin resistance declined from 28% in 2000 to 11% in 2005 [25]. Pharyngitis is 
frequently managed in Portugal without a microbiological investigation, with these being 
performed mostly for epidemiological purposes. On the other hand, the availability of rapid 
antigen tests means that an isolate will not always be recovered, even when an etiological 
diagnosis is sought. The participating laboratories were asked to submit all nonduplicate S. 
pyogenes isolates obtained from outpatients during the study period, but no audit was 
performed to ensure compliance, and this is known to be variable in this kind of study. The 
combination of these factors may have contributed to a lower number of isolates than 
anticipated, but we have no reason to suspect that there was a bias in the isolates that were 
submitted. The isolates were distributed in the study period as follows: 214 in 2000, 216 in 
2001, 270 in 2002, 230 in 2003, 284 in 2004, and 392 in 2005. Isolates were identified to 
the species level by colony morphology, beta-hemolysis on sheep blood agar, and a 
commercial latex agglutination technique (Slidex Strepto A; bioMérieux, Marcy l’Etoile, 
France). A total of 803 isolates, randomly chosen and representing 50% of the total 
collection, were characterized. Among this group were 155 macrolide resistant isolates 
(19.3%). The distribution of the macrolide-resistant isolates included in this study was as 
follows: 23 in 2000, 19 in 2001, 23 in 2002, 38 in 2003, 30 in 2004, and 22 in 2005. These 
isolates represent a subset of the total number of macrolide-resistant isolates found during 
2000 to 2005 (n=318). 
 
 Antimicrobial susceptibility testing 
 Susceptibilities to erythromycin and clindamycin were tested by disk diffusion 
according to the recommendations of CLSI [6] and were reported previously [25–27]. The 
macrolide resistance phenotype was determined according to previously published 
procedures [27]. 
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 DNA extraction 
 Total bacterial DNA was isolated according to the methodology described by the 
Centers for Disease Control and Prevention (CDC) 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). 
 
 T and emm typing 
 emm typing was performed as described by the CDC 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). Amplification products were 
purified using the High Pure PCR purification kit (Roche, Mannheim, Germany) according 
to the manufacturer’s instructions and sequenced using primer emmseq2 [2], and the DNA 
sequences were searched against the emm sequences deposited in the CDC database 
(http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm). 
 
 Pulsed-field gel electrophoresis (PFGE) and Multilocus sequence typing MLST 
 Pulsed-field gel electrophoresis (PFGE) was performed as previously described 
[26]. All the macrolide-susceptible isolates were digested with SmaI, and isoschizomer 
Cfr9I was used only for isolates presenting the M phenotype [26]. The BioNumerics 
software (Applied-Maths, Sint-Martens-Latem, Belgium) was used to create unweighted-
pair group method with arithmetic mean (UPGMA) dendrograms of the SmaI or Cfr9I 
fragment patterns. The Dice similarity coefficient was used, with optimization and position 
tolerance settings of 1.0 and 1.5, respectively. PFGE clusters were defined as groups of 
isolates with ≥ 80% similarity in the dendrogram [5]. A PFGE-based cluster was 
considered to be a major lineage if it included ≥ 10 isolates. Clusters that included between 
5 and 10 isolates were considered minor PFGE clusters. Major lineages were identified by 
uppercase letters and minor clones by lowercase letters. The subscript number in the PFGE 
cluster designation identifies the number of isolates included in the cluster.  
 Multilocus sequence typing (MLST) analysis was performed for at least 30% of 
randomly selected isolates of each emm type that was represented by more than 10 isolates 
(n=282) as previously described [8], and allele and sequence type (ST) were attributed 
using the S. pyogenes MLST database (spyogenes.mlst.net). The relationships between the 
MLST STs were determined using the goeBURST algorithm [9] implemented in 
PHYLOViZ [10] with the complete S. pyogenes database available at spyogenes.mlst.net. 
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Statistical analysis 
 In order to compare the probability of a given emm type or PFGE clone being more 
associated with macrolide resistance or susceptibility, the odds ratios (OR) and the 
corresponding p values, corrected for multiple testing through the false-discovery rate 
(FDR) linear procedure [3], were calculated by reference to all other emm types and PFGE 
clones.  
 Adjusted Wallace (AW) coefficients were used to compare partitions, and 
Simpson’s index of diversity (SID) and the corresponding 95% confidence intervals (CIs) 
were used to evaluate the clonal diversity of the macrolide-susceptible and -resistant 
isolates [5, 24]. Trends were evaluated using the Cochran-Armitage test of trend, and 
yearly variability was tested using the Fisher exact test. p values of <0.05 were considered 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Erythromycin-resistant and -susceptible GAS 
 
165 
 
 RESULTS 
 
 Clonal characterization 
 The characteristics of the 803 isolates included in this study, as well as their 
distribution during the study period, are summarized in Table 4.1. Among the 34 different 
emm types found, the most frequent were emm4 (15.2%, n=122), emm1 and emm3 (9.6%, 
n=77 each), emm12 (9.3%, n=75), emm6 (7.2%, n=58), and emm89 (7%, n=56). The 
remaining 28 emm types accounted for 42.1% of the isolates (n=338). Among the 16 T 
types found in the collection, the most prevalent were T4 (13.8%, n=111), T12 (12.5%, 
(n=100), T1 (9.7%, n=78), T28 (8.5%, n=68), and B3264 (8.3%, n=67). Slightly under 8% 
of the isolates (n=64) were T nontypeable.  
 The 803 isolates were classified into 62 PFGE clusters, including 19 major lineages 
representing 684 isolates (85%) (Figure 4.1). Nine minor PFGE clusters were found, 
grouping 60 isolates (7.5%). In most cases, each PFGE cluster had a dominant macrolide 
resistance phenotype (susceptible, MLSB, or M), emm type, T type, and STs belonging to 
the same clonal complex (Table 1). The MLSB isolates were grouped mainly into PFGE 
cluster H38 (48%, n=30) and cluster K27 (33%, n=21), while 49% of isolates presenting the 
M phenotype (n=45) were included into cluster G49. MLST analysis was performed for 282 
isolates (35.1%). We identified 4 novel alleles among the genes used in MLST, two in gki 
(gki108 and gki109), one in mutS (muts63) and one in recP (recp101). New allele 
combinations producing novel STs were also noted and were numbered ST559 to ST569 
and ST634 to ST639. The new alleles and the novel STs were submitted to the S. pyogenes 
MLST database (spyogenes.mlst.net). Isolates of the same emm type presented mostly the 
same ST or STs of the same clonal complex (Table 4.1).  
  
TABLE 4.1– Properties of the 803 GAS isolates collected from tonsillo-pharyngitis in Portugal 
emm (no. 
isolates) 
PFGE 
clusters 
(R/S)a 
T type b (no. isolates) 
ST(no.  
isolates)c 
2000 2001 2002 2003 2004 2005 
4 (122) B66 (1/64) 
 
4(63), 3(1), NT(1) 
 
[39(12), 566(1), 635(1)] 
 
2 2 10 12 10 29 
G49 (45/2) 
 
4(39), B3264(2), 13(1), 2/4(1), 5/27/44(1), 6(1), 12(1), 1(1) 
 
[39(16), 561(1), 637(1), 638(1)] 4 0 6 16 13 8 
Other (2/8) 4(8), 6(1), 2(1) 39(6), 15(1), 55(1) 0 0 1 2 0 7 
1(77) C62(0/62) 
 
1(61), NT(1) 
 
[28(16), 567(1)] 
 
7 6 8 7 20 14 
R12 (12/0) 
 
1(10), 13(1), NT(1) 
 
28(7) 
 
1 2 4 4 0 1 
Other (1/2) 1(3) 28(1) 0 1 2 0 0 0 
3(77) A76 (0/76) 
 
3(40), NT(18), 3/13(17), 5/27/44(1) 
 
[406(14), 315(5), 15(4), 560(1)] 
 
1 8 30 4 3 30 
Other (0/1) NT(1) 15(1) 0 0 0 0 0 1 
12(75) D59 (8/42) 
 
12(40), NT(9), 2(1) [36(14), 551(1)] 9 10 6 11 5 9 
S10 (5/5) 12(9), NT(1) 36(5) 1 2 1 2 3 1 
A9 (0/8) 
 
12(6), NT(2) 36(3) 1 0 2 2 1 2 
Other (4/3) 12(6), 25(1) 36(3), 150(1) 3 0 4 0 0 0 
6(58) E58 (1/56) 6(51), NT(4), 5/27/44(1), 2(1) [382(18), 411(1)] 13 10 8 4 2 20 
Other (0/1) 6(1) 382(1) 1 0 0 0 0 0 
89(56) F53 (1/51) B3264(50), 3/13(1), 28(1) [101(5), 408(5), 553(1), 568(3)] 1 8 5 11 15 12 
Other (0/4) B3264(3), 5/27/44(1) [101(2), 568(1)] 555(1) 0 1 0 0 1 2 
75(49) L25 (8/16) 25(24) [150(7), 563(1)] 3 6 8 6 1 0 
Q13 (0/13) 25(13) [150(3), 564(1), 639(1)] 1 1 2 2 5 2 
Other (4/8) 25(11), NT(1) 150(5), 481(1) 1 1 0 3 5 2 
28(45) H38 (26/7) 28(32), NT(1) 52(9) 4 8 5 3 5 8 
P13 (1/9) 28(10) 52(5) 0 2 3 1 3 1 
Other (0/2) 28(1), NT(1) [52(1), 456(1)] 0 0 2 0 0 0 
  
aPFGE clones deﬁned as major lineages are designated by uppercase letters, and minor PFGE clones (10> n≥ 5) are designated by lowercase letters. Whenever a PFGE clone included fewer than 5 isolates of that 
particular emm type, it was not discriminated, and all such isolates were grouped under “other.” The numbers of resistant (R) and susceptible (S) isolates are indicated in parenthesis. 
bNT, nontypeable. 
cBrackets indicate STs that belong to the same clonal complex deﬁned by the goeBURST algorithm (http://goeburst.phyloviz.net/) with the complete S. pyogenes database available at spyogenes.mlst.net. 
d18 emm types (47 isolates): 11 (9), 102 (9), 58 (5), 48 (3), 74 (2), 18 (2), 29 (2), 68 (2), 53 (2), st7700 (2), 118 (2), 43 (1), 73 (1), 70 (1), 64 (1), 25 (1), 5 (1), and st38 (1). 
eTwenty-one PFGE clones. 
f12 T types: NT (15), 11 (8), 13 (5), 3/13 (5), B3264 (3), 28 (3), 9 (2), 3 (2), 25 (1), 12 (1), 18 (1), and 1 (1). 
g17 STs: 60 (3), 403 (2), 562 (2), 410 (2), 247 (1), 331 (1), 161 (1), 176 (1), 402 (1), 552 (1), 559 (1), 167 (1), 565 (1), 569 (1), 120 (1), 63 (1), and 12 (1)
emm (no. 
of 
isolates) 
PFGE clones 
(R/S)a T type b ST(n)c 2000 2001 2002 2003 2004 2005 
2(38) I32 (0/30) 2(29), 4(1) [55(7), 634(1)] 4 6 3 3 9 5 
Other (2/6) 2(7), 12(1) [55(4), 636(1)] 1 1 1 1 1 3 
22(35) K27 (21/4) 12(25) [46(6), 389(1)] 7 7 1 4 5 1 
Other (6/4) 12(10) [46(2), 389(1) ], 52(2) 0 2 1 5 2 0 
44/61(33) J32 (1/30) 5/27/44(28), NT(2), 12(1) [25(10), 554(1)] 0 0 0 2 14 15 
Other (0/2) 5/27/44(2) 555(1) 0 0 1 0 0 1 
87(25) N20 (0/18) 28(16), NT(2) 62(6) 4 3 2 3 3 3 
i5 (0/5) 28(3), 1(1), NT(1) 62(2) 0 0 0 1 0 4 
Other (0/2) 28(1), 6(1)  0 0 0 0 0 2 
9(23) M24 (0/19) 9(19) 75(4) 8 3 3 1 2 2 
Other (3/1) 9(4) 75(4) 2 0 1 0 0 1 
77(17) b8 (0/8) 13(8) 63(3) 2 1 1 2 2 0 
Other (0/9) 13(5), NT(2), 28(1), 2(1) 63(3) 1 2 5 0 0 1 
78(15) O15 (0/15) 11(15) [253(5), 409(1)] 
 
5 2 1 0 2 5 
94(11) D59 (0/9) B3264(7), 1(1), NT(1) 89(4) 2 1 1 1 1 3 
Other (0/2) B3264(2)  0 0 2 0 0 0 
Other d Multiple e Multiple f Multiple g 18 12 5 2 9 1 
Chapter 4 
 
168 
 
  
FIGURE 4.1 Dendrogram showing the PFGE profiles of the 803 GAS 
isolates. The dendrogram was constructed using the unweighted-pair group 
with arithmetic mean (UPGMA) method. Dice coefficients (percentages) are 
indicated in the scale above the dendrogram. For each PFGE cluster, a triangle 
proportional to the number of isolates is shown in the dendrogram. The 
clusters are designated by letters, with major clusters (n ≥ 10) identified by 
uppercase letters and minor PFGE clusters (10 > n ≥ 5) identified by 
lowercase letters. The subscript numbers indicate the number of isolates 
included in the cluster. 
Erythromycin-resistant and -susceptible GAS 
 
169 
 
 Differences between PFGE clusters and emm types between macrolide-
resistant and -susceptible isolates 
 The SID values of all typing methods and the corresponding 95% CIs were 
determined for the macrolide-resistant and -susceptible subsets to ascertain whether there 
were differences in the diversities of the two populations (Table 4.2). For all the typing 
methods used to characterize the entire collection, the diversity of the macrolide-resistant 
population was lower than the diversity of the susceptible population. 
This not only is evident from the lower number of different types found among macrolide-
resistant isolates but also is reflected in the significantly lower SID values (Table 4.2). For 
the subset of isolates analyzed by MLST, the diversity of the macrolide- resistant 
population was also lower.  
 
TABLE 4.2 - Simpson’s index of diversity and 95% Confidence intervals (CI95%) of the typing methods used 
in the analysis of the 155 macrolide resistant isolates and 648 macrolide susceptible GAS isolates 
Typing method 
SID (CI95%) [no. of partitions] 
Macrolide resistant isolates (n=155)  Macrolide susceptible isolates (n=648) 
PFGE 0.851 (0.817-0.884) [22]  0.938 (0.932-0.944) [58] 
emm typing 0.823 (0.792-0.854) [12]  0.927 (0.922-0.933) [34] 
T typing 0.819 (0.787-0.850) [14]  0.924 (0.920-0.928) [16] 
MLST 0.889 (0.853-0.924) [17]  0.959 (0.951-0.966) [52] 
 
 Among the emm types that were represented by more than 10 isolates, none 
included solely resistant isolates. However, some were found only in macrolide-susceptible 
isolates: emm3, emm87, emm77, emm78, and emm94. The calculation of OR supported the 
association of emm3 and emm87 with macrolide susceptibility (p< 0.001 and p= 0.007, 
respectively, both of which are significant for FDR) but not that of emm77, emm78, and 
emm94. emm types 6 and 89 were also associated with macrolide susceptibility, although 
both included one resistant isolate (both with a p value of <0.001, which is significant for 
FDR). On the other hand, emm types 4, 22, and 28 were associated with macrolide 
resistance (all with a p value of <0.001, which is significant for FDR). 
  Nine PFGE clusters that included only susceptible isolates were also identified 
(Table 4.1). In contrast, only one PFGE cluster, R12 (mostly T1-emm1-ST28), grouped 
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exclusively resistant isolates. All the other PFGE clusters included both susceptible and 
resistant isolates. 
 Similarly to what was found for emm types, the calculation of OR for the PFGE 
major clusters supported only the association of some clusters with the macrolide 
resistance phenotype. The association with susceptibility of PFGE clusters A76 (mostly T3-
emm3-ST406), C62 (mostly T1-emm1-ST28), and I32 (mostly T2-emm2-ST55) was 
statistically supported (p<0.001, p<0.001, and p=0.002, respectively, all of which are 
significant for FDR). Additionally, PFGE clusters B66 (mostly T4-emm4-ST39), E58 
(mostly T6- emm6-ST382), and F53 (mostly B3264-emm89-ST101/ST408), all including 
one resistant isolate, were also found to be associated with susceptibility (all with a p value 
of <0.001, which is significant for FDR). In contrast, PFGE clusters G49 (mostly T4-emm4- 
ST39), H38 (mostly T28 -emm28-ST52), K27 (mostly T12-emm22- ST46), and R12 (mostly 
T1-emm1-ST28) were associated with macrolide resistance (all with a p value of <0.001, 
which is significant for FDR). 
 
 Correspondence between typing methods and differences between macrolide-
susceptible and -resistant isolates 
 The AW coefficient calculated for the relationship between PFGE and macrolide 
susceptibility was high (AWPFGE  Ery=0.715; 95% CI, 0.642 to 0.788), while it was 
extremely low for emm type (AWemm   Ery=0.095; 95% CI, 0.016 to 0.175). The AW 
coefficients also indicated that among the typing methods used in this work, PFGE was the 
best predictor of emm type. This was valid considering all the isolates included in the 
collection and the macrolide-resistant and -susceptible subsets (AWPFGE    emm, all=0.914; 
95% CI, 0.889 to 0.939). The inverse relationship was significantly weaker (AWemm     PFGE, 
all = 0.598; 95% CI, 0.565 to 0.630). When considering only the macrolide-resistant or -
susceptible subsets, the relationship was much stronger (AWemm     PFGE, Ery
r
=0.754 [95% CI, 
0.658 to 0.850]; AWemm    PFGE, Ery
s
 =0.787 [95% CI, 0.747 to 0.827]), reflecting the 
discrimination by PFGE of macrolide-resistant and macrolide-susceptible lineages of the 
same emm types. For the subset of isolates analyzed by MLST (n=282), the ST was an 
excellent predictor of emm type (AWST   emm=0.963; 95% CI, 0.937 to 0.988), but the 
inverse relationship was significantly weaker (AWemm     ST =0.678; 95% CI, 0.602 to 
0.753). 
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 Changes of macrolide resistance within emm types with time 
 Since particular genetic lineages were found to be associated with macrolide 
resistance, we tested whether the distribution of macrolide-resistant isolates changed with 
time within each of the emm types with ≥ 10 isolates in the studied period. Changes were 
noted in emm1 (p= 0.016) and emm4 (p< 0.001), but only the latter was significant for 
FDR. This indicates that while the proportion of macrolide-resistant isolates remained 
stable in time for most emm types, that for emm4 changed significantly. An increase in 
emm4 isolates was noted during the study period (Cochran-Armitage test for trend, 
p<0.001). However, this increase reflects the underlying dynamics of its two major PFGE 
clusters. The increase in recent years of the macrolide-susceptible PFGE cluster B66, which 
peaked in the last year of the study, is in contrast to the dramatic increase of the macrolide-
resistant PFGE cluster G49 in the early years, to a peak in 2003, and its current decline 
(Table 4.1). 
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DISCUSSION 
 
 The changes in the prevalence of macrolide resistance phenotypes noted in Portugal 
were accompanied by alterations in the clonal composition of the population [25]. At this 
point, it remained unclear whether all these changes were a reflection of large fluctuations 
in the overall GAS population or whether macrolide-resistant S. pyogenes isolates have 
their own dynamics. In this work, we compared macrolide-resistant and -susceptible GAS 
isolates in the period from 2000 to 2005 in order to gain new insights into the reasons 
behind the fluctuations reported for the resistant population.  
 In this study, a statistically significant association was found between macrolide 
resistance and emm4, emm22, and emm28, of which emm4 and emm22 were also found in 
association with macrolide resistance elsewhere [1, 16, 23, 29]. However, our findings are 
in contrast to a report from Korea that indicated a relationship between these emm types 
and macrolide susceptibility [12]. It was also possible to establish significant associations 
between macrolide susceptibility and emm3, emm6, emm87, and emm89. While emm3 was 
also previously reported in association with macrolide susceptibility in Spain [1] and in 
Italy [29], emm89 was previously found in association with macrolide resistance [29], 
contrary to our findings. Associations between certain emm types and macrolide resistance 
and susceptibility were reported in other studies but were not detected in Portugal, such as 
for emm12 and emm2, which were often associated with macrolide resistance [7, 17, 29], 
and emm1 isolates, which were frequently found in association with macrolide 
susceptibility [1, 16].  
 PFGE was the only typing method capable of differentiating resistant isolates of the 
same emm type. For emm4 and emm1, PFGE grouped the isolates into two major PFGE 
clusters (B66 and G49 for emm4 isolates and C62 and R12 for emm1 isolates), associated with 
macrolide susceptibility and resistance, respectively. Associations between some PFGE 
clusters and macrolide susceptibility that could not be detected by emm type alone were 
identified. This was the case for clusters C62 and R12, including emm1 macrolide-
susceptible and -resistant isolates, respectively, and for cluster I32, including emm2 isolates. 
None of these emm types was statistically associated with macrolide susceptibility. These 
observations reinforce the usefulness and the importance of using PFGE to characterize 
GAS isolates. 
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  In order to compare the two populations, the SID values for all the typing methods 
used in this study were calculated (Table 4.2). There were differences in the number of 
types and SID values between the macrolide-resistant and -susceptible subsets for PFGE, 
emm typing, and T typing. The diversity of the resistant population was lower than that of 
the susceptible subset by all three methods. The SID values for the fraction of the isolates 
characterized by MLST were also lower in the macrolide-resistant population. 
 The association of certain emm types and PFGE clones with macrolide resistance or 
susceptibility and the differences in the diversity of the two groups indicate that the 
macrolide-resistant isolates represent lineages distinct from the susceptible population. The 
discrepancies in associations between emm types and macrolide resistance found in 
different geographical regions could be due to the circulation of different lineages 
expressing these emm types in different areas.  
 If the diversity of the resistant population previously reported [25–27] was a 
reflection of the diversity of the overall GAS population, the emm types and the PFGE 
clusters would not show these associations, and the diversities of the two populations 
would be approximately the same. Some emm types are never or rarely found in resistant 
isolates, even though their prevalence in susceptible isolates is high. This is the case for 
emm3, emm6, and emm89. In 2002 and 2005, 22% and 15% of the isolates, respectively, 
were emm3, and no macrolide-resistant isolates were detected. Fifty seven out of the 58 
emm6 isolates were macrolide susceptible, and while in 2005, 10% of the isolates 
presented this emm type, no acquisition of macrolide resistance determinants was detected. 
The same situation occurred with emm89, which increased throughout the study period, but 
a single resistant isolate was found. Taken together, these data suggest that there is limited 
ongoing transfer of macrolide resistance determinants.   
 The narrow group of resistant lineages is quite stable and has disseminated widely 
[11, 13, 18, 20, 21, 28]. Whether their success is dependent solely on their association with 
macrolide resistance or may also reflect other clonal properties remains to be shown. The 
characterization of contemporaneous macrolide- resistant and -susceptible isolates revealed 
distinct populations that changed independently in the study period.  
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 SUMMARY 
 
Background: Several outbreaks of scarlet fever caused by Streptococcus pyogenes were 
recently reported. Historically considered a toxin-mediated disease, dependent on the 
production of the exotoxins SpeA and SpeC, a strict association between scarlet fever and 
these exotoxins is not always detected. The aims of this study were to characterize the 
scarlet fever isolates recovered in a Lisbon hospital and to identify any distinctive 
characteristics of such isolates. 
Methods: We characterized a collection of 303 pharyngeal S. pyogenes collected between 
2002 and 2008. 101 were isolated from scarlet fever patients and 202 were associated to a 
diagnosis of tonsillo-pharyngitis. Isolates were characterized by T and emm typing, pulsed 
field gel electrophoresis (PFGE) profiling and superantigen gene profiling. 
Results: The diversity of the scarlet fever isolates was lower than the pharyngitis isolates. 
Specific lineages of emm87, emm4 and emm3 were overrepresented in scarlet fever isolates 
but only one PFGE major lineage was significantly associated with scarlet fever. 
Multivariate analysis indicated associations of ssa, speA and speC with scarlet fever. 
Conclusions: In non-outbreak conditions, scarlet fever is caused by a number of distinct 
genetic lineages. The lower diversity of these isolates and the association with specific 
exotoxin genes indicates that some lineages are more prone to cause this presentation than 
others even in non-outbreak conditions. 
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 INTRODUCTION 
 
 Streptococcus pyogenes or Lancefield group A streptococcus (GAS) is an important 
human pathogen responsible for a wide range of infections including relatively mild 
infections such as tonsillo-pharyngitis, scarlet fever and impetigo, as well as severe 
infections such as streptococcal toxic shock syndrome and necrotizing fasciitis [11]. 
Scarlet fever is usually associated with streptococcal throat infection, but it may also occur 
due to infections at other sites and is characterized by skin rash and a “strawberry tongue” 
[11]. In the 19
th
 and early 20
th
 centuries, it was seen as a significant cause of childhood 
morbidity and mortality [21] with a significant cyclical behavior [13]. Although currently 
considered a relatively rare and mild disease, a number of scarlet fever outbreaks were 
recently reported [5, 14, 18, 22, 27]. In Shangai, 114 cases of scarlet fever in children were 
reported over a 1-month period in June 2011 [5], while in Hong Kong more than 900 cases 
of scarlet fever were recorded between January and July 2011[19]. These recent outbreaks 
motivated an increased interest in this syndrome and in the possible bacterial factors 
involved.  
 S. pyogenes produces many virulence factors and among them are the secreted 
pyrogenic exotoxins (Spe), which act as superantigens.  Some of these superantigens are 
also believed to be responsible for some of the clinical signs of scarlet fever. Early studies 
indicated that the skin rash characteristic of scarlet fever is caused by the production of 
SpeA, but in its absence, SpeC could also cause identical symptoms [30]. However, other 
studies did not detect an association of these exotoxins with scarlet fever [5, 12, 30, 31]. In 
Canada, the combined presence of  SpeA and SpeC was more frequently found in scarlet 
fever isolates than in pharyngitis isolates [28]. A correlation between scarlet fever and 
SpeA, but not SpeC was reported in the USA [30, 31]. The recent outbreak reported in 
China failed to associate SpeA with scarlet fever, although a significant association 
between SpeC, SpeJ, SSA and SMEZ and scarlet fever was detected [5, 27]. 
 It was suggested that the acquisition of mobile elements, carrying specific 
superantigen combinations, could be related to the occurrence of scarlet fever outbreaks 
[27]. 
 The sequencing of the hypervariable region of the emm gene (emm typing) [2] 
which encodes the M protein, a major virulence factor produced by S. pyogenes, has been 
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the most widely used tool for epidemiological studies of GAS. However, it was recently 
shown that this typing technique is not sufficient to unambiguously identify GAS clones 
and should be complemented with other typing methods, such as pulsed-field gel 
electrophoresis (PFGE) or multilocus sequence typing (MLST), for a better 
characterization of GAS clones [4].  
 While some scarlet fever outbreaks were reported as being caused by isolates of a 
particular emm type [5, 14], others were found to be multiclonal outbreaks, with scarlet 
fever isolates of the same emm type occurring across multiple genetic lineages [27]. In 
other studies, temporal changes in the prevalence of the emm types associated with scarlet 
fever were reported [6–8, 29]. In some cases, this was related to the natural fluctuations of 
emm types [8], while in others a relationship with decreases in antimicrobial resistance and 
changes of the clonal composition of the population were detected [6]. 
 The aims of this study were to characterize a collection of S. pyogenes isolates 
responsible for scarlet fever and to compare it with non scarlet fever pharyngeal isolates, in 
order to gain insights into the possible bacterial characteristics associated with this 
syndrome. With this in mind, we undertook the phenotypic and molecular characterization 
of 101 scarlet fever isolates and 202 non-scarlet fever isolates. All the isolates were 
characterized by antimicrobial susceptibility testing, T and emm typing , PFGE and a 
recently developed method to screen GAS isolates for the presence of 11 SAg genes, that 
allowed the detection of all the known allelic variants of these genes [16]. No emm type or 
SAg profile were associated with the ability to cause this disease. In contrast, one PFGE 
cluster and specific superantigen combinations were associated with scarlet fever. 
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 MATERIALS AND METHODS 
 
 Bacterial isolates and identification 
 A total of 101 S. pyogenes isolates recovered from throat swabs and associated with 
a diagnosis of scarlet fever were collected in the microbiology laboratory of a large 
teaching hospital in Lisbon, between January 2002 and December 2008. For each scarlet 
fever isolate, two non-scarlet fever isolates (isolates recovered from pharyngeal exudates, 
associated with tonsillo-pharyngitis which will be referred as pharyngitis isolates) were 
randomly chosen from among the isolates recovered in that year in the same laboratory. A 
single isolate from each patient was included in the study. The total number of isolates 
analyzed was n=303 and the median age of patients with scarlet fever was 5 yrs and of 
those with pharyngitis was 4 yrs. Isolates were identified to the species level by colony 
morphology, β-hemolysis on sheep blood agar, and a commercial latex-agglutination 
technique (Slidex Strepto A, BioMérieux, Marcy l’Etoile, France).  
 
 Antimicrobial susceptibility testing and macrolide resistance phenotype  
 Susceptibility to penicillin, erythromycin and clindamycin (Oxoid, Basingstoke, 
UK) was tested using disk diffusion according to CLSI recommendations [9]. The 
macrolide resistance phenotype was determined according to a double disk test previously 
described [20]. Bacitracin susceptibility was determined for all isolates by disk diffusion 
using disks containing 0.05 U of bacitracin (Oxoid, Basingstoke, UK) as previously 
described [26].  
 
 PCR determination of the macrolide resistance genotype 
 Total bacterial DNA was isolated according to the methodology described by the 
CDC (http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). PCR reactions to 
determine which of the macrolide resistance determinants (erm(B), erm(A) or mef) was 
present and to discriminate between mef(A) and mef(E) were performed as previously 
described [15, 25]. 
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 T and emm typing 
 T typing was performed by slide agglutination using sera for types 1, 2, 3, 4, 6, 8, 9, 
11, 12, 13, 18, 22, 23, 25, 28, 5/27/44, 14/19 and Imp.19 (Hemolytic streptococcus Typing 
Antisera for Group A (T-typing) SEIKEN, Denka Seiken, Tokyo, Japan), according to the 
manufacturer’s instructions and previously published procedures [17].  
 emm typing was performed as described by the CDC 
(http://www.cdc.gov/ncidod/biotech/strep/protocols.htm). Amplification products were 
purified using the High Pure PCR Purification Kit (Roche, Mannheim, Germany) 
according to the manufacturer’s instructions, sequenced using primer emmseq2[1] and the 
DNA sequences were searched against the emm sequences deposited in the CDC database 
(http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm).  
 
 SAg genes profiling 
 The presence of 11 SAg genes was tested in two multiplex PCR, as previously 
described, using speB and speF as internal controls [16]. One PCR reaction was used to 
detect the presence of speF, speG, speH, speJ, speK, ssa and smeZ and the genes speA, 
speB, speC, speI, speL and speM were screened in another reaction [16].  
 
 Pulsed-field gel electrophoresis (PFGE) 
 PFGE was performed as previously described [26]. Bionumerics software (Applied-
Maths, Sint-Martens-Latem, Belgium) was used to create UPGMA (unweighted pairgroup 
method with arithmetic mean) dendrograms of the SmaI or Cfr9I fragment patterns. The 
Dice similarity coefficient was used, with optimisation and position tolerance settings of 
1.0 and 1.5, respectively. PFGE clusters were defined as isolates with ≥ 80% similarity [4]. 
A PFGE-based cluster was considered to be a major lineage if it included more than five 
isolates.  
 
 Statistical analysis 
 In order to compare the probability of a given emm type, PFGE clone or SAg 
profiles to be associated with scarlet fever, the odds ratios (OR) and the corresponding p-
values, corrected for multiple testing through the False Discovery Rate (FDR) linear 
procedure [3] were calculated by reference to all other emm types, PFGE clones and SAg 
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profiles, as appropriate. Multivariate logistic regression was used in exploratory analysis to 
detect associations with scarlet fever, using each of the SAg genes as predictor variables. 
After considering all SAg genes, only SAg genes with p<0.05 were retained in the final set 
of variables that were tested for interaction terms. Since the speL and speM genes always 
co-occurred in our collection, they were considered as a single variable in our analyses.  
The R (version 2.12.0) software and the Epiools package (http://medepi.com/epitools/) 
were used for the statistical analysis.  
 The Simpson’s index of diversity (SID) and the corresponding 95% confidence 
intervals were used to evaluate diversity [4].  
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 RESULTS 
 
 Antimicrobial susceptibility testing and macrolide resistance phenotype 
 All isolates included in this study were susceptible to penicillin. Macrolide 
resistance was detected in 35 isolates (12%). The majority of macrolide resistant isolates 
presented the M phenotype (n=19); 15 isolates presented the cMLSB phenotype and only 
one the iMLSB phenotype. All the M isolates carried the mef(A) gene and the erm(B) 
resistant determinant was present in all the MLSB isolates. One cMLSB isolate carried both 
the mef(A) and erm(B) genes. All macrolide resistance isolates included in the scarlet fever 
group (n=10) presented the M phenotype. The MLSB isolates were all included in the 
pharyngitis subset. 
 Bacitracin resistance was detected in nine isolates, all emm28. The majority (n=7) 
also presented the cMLSB phenotype. No bacitracin resistance was detected among the 
scarlet fever group. 
 
 Clonal characterization 
 The characteristics of the 303 isolates included in this study are summarized in 
Table 5.1. A total of 22 emm types and 17 T types were found. Approximately 8% of the 
isolates were T non-typeable (Table 5.1). 
 All 303 isolates were typable by PFGE using either SmaI or Cfr9I and 33 PFGE 
clusters and 16 major lineages were identified, containing 272 isolates (89%). In most 
cases, each PFGE cluster was associated with a particular T type, emm type, and SAg 
profile (Table 5.1).  
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TABLE 5.1 – Properties of the 303 GAS isolates collected from tonsillo-pharyngitis in Portugal   
emm type 
(no. of 
isolates) 
 
 
 
PFGE cluster 
(SF/NSF)a T types
b 
(no. of isolates) SAg profiles (no. of isolates) 
4 (58) A49(22/26) 4(46), 3(1), NT(1) 23(44), 22(2), 47(1), 91(1) 
I10(6/4) 4(8), 1(1), 2/4(1) 23(5), 30(3), 27(2) 
1(37) B33(8/24) 1(32) 10 (23), 3(9) 
Other (5) 1(5) 10(3), 3(1), 8(1) 
3(36) C30(13/13) 3(17), 3/13(4), NT(5) 8(20), 88(3), 89(1), 92(1), 37(1) 
L8(6/2) 3(6), 3/13(1), 5/27/44(1) 8(5), 88(2), 52(1) 
Other (0/2) NT(2) 8(1), 33(1) 
87(26) D28(15/11) 28(20), 2(1), NT(5) 20(21), 44(1), 21(1), 27(1), 18(1), 12(1) 
12(24) E20(3/14) 12(13), NT(4) 16(6), 33(4), 17(2), 73(1), 35(1), 77(1), 
85(1), 34(1) 
Other (0/7) 12(7) 16(2), 35(2), 17(1), 76(1), 14(1) 
28(18) J10(1/7) 28(8) 27(7), 21(1) 
M7(1/6) 28(6), NT(1) 24(5), 27(2) 
Other (0/3) 28(3) 24(2), 3(1) 
89(17) G17(2/15) B3264(17) 29(12), 27(3), 43(1), 46(1) 
44(15) F18(4/7) 5/27/44(7), 12(2), 25(1), NT(1) 67(5), 32(5), 76(1) 
Other (3/1) 5/27/44(3), NT(1) 67(1), 8(1), 16(1), 87(1) 
6(14) H14(3/9) 6(12) 2(8), 26(2), 43(1), 46(1) 
Other (1/1) 6(2) 2(2) 
75(14) F18(1/5) 25(6) 42(3), 25(1), 45(1), 83(1) 
Other (0/8) 25(8) 39(4), 25(1), 81(1), 82(1), 84(1) 
2(8) 
 
K9(0/4) 2(4) 31(3), 79(1) 
Other (2/2) 2(3), 4(1) 31(2), 78(1), 20(1) 
11(7) O7(1/6) 11(6), 12(1) 5(4), 16(1), 17(1), 86(1) 
9(7) N7(1/6) 9(6), 3(1) 40(5), 74(1), 38(1) 
78(6) P5(1/3) 11(2), 28(1), B3264(1) 29(3), 80(1) 
Other (0/2) 11(1), 28(1) 29(2) 
22(5) K9(0/2) 12(2) 19(1), 21(1) 
 Other(1/2) 11(1), 12(1), 5/27/44(1) 16(1), 38(1), 75(1) 
 
 
 
Otherc Otherd Multiplee Multiplef 
 
a PFGE clusters defined as major lineages are designated by uppercase letters, followed by the number of isolates 
included in that PFGE cluster, in subscript. Whenever a PFGE cluster included fewer than 5 isolates of that particular 
emm type, it was not discriminated and all such isolates were grouped under “other”. The number of scarlet fever (SF) 
and non-scarlet fever (NSF) isolates are indicated in parenthesis. 
b  NT, nontypeable 
c 7 emm types (n=11): 77 (n=3), 48(n=2), 94(n=2), 71(n=1), 58(n=1), 18(n=1), 102(n=1) 
d Seven PFGE clones (n=3 SF/ n=8 NSF) 
e Six T types: NT(n=4), B3263(n=2), 13(n=2), 28(n=1), 3(n=1), 8(n=1) 
f Eight SAg profiles: 27(n=3), 45(n=2), 46(n=1), 30(n=1), 29(n=1), 17(n=1), 60(n=1), 4(n=1) 
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 SAg profiling revealed that all 303 isolates carried the speB and speF genes.  As 
expected, the chromosomally located exotoxins were much more frequent than those 
carried in bacteriophages (Table 5.2).  
 
TABLE 5.2. Odds ratios (OR), 95% Confidence intervals (CI95%) and corresponding p- values of 
associations between SAg genes and scarlet fever. 
Gene 
Scarlet 
fever 
(no. of 
isolates) 
Pharyngitis 
(no. of 
isolates) 
Univariate analysis Multivariate analysis 
OR (95% CI) p OR (95% CI) p 
speH 12 34 0.667 [0.299-1.401] 0.310 0.995 [0.323-2.955] 0.992 
ssa 73 75 4.392 [2.548-7.726] <0.001
b
 6.041 [3.084-12.458] <0.001
d
 
speI 10 23 0.856 [0.348-1.966] 0.845 2.542 [0.824-8.026] 0.105 
speK 26 43 1.281 [0.7-2.316] 0.387 0.961 [0.402-2.198] 0.926 
speJ 39 75 1.065 [0.63-1.79] 0.803 1.777 [0.907-3.567] 0.098 
smeZ 100 196 3.052 [0.363-142.11] 0.431 0.578 [0.052-13.877] 0.675 
speG 72 174 0.401 [0.213-0.752] 0.003
c
 0.47 [0.181-1.189] 0.114 
speL/M
a
 4 21 0.356 [0.086-1.098] 0.075 0.886 [0.177-3.519] 0.870 
speA 37 54 1.582 [0.917-2.719] 0.085 4.418 [1.936-10.652] 0.001
d
 
speC 65 127 
1.066 [0.631-1.815] 
0.899 
2.125 [1.036-4.511] 
0.044
d
 
a speL and speM were always detected together 
b Significant association with scarlet fever in univariate analysis 
c Significant association with pharyngitis in univariate analysis 
d Significant association with scarlet fever in multivariate analysis 
  
 
SAg gene profiling analysis revealed the presence of 60 different profiles, of which 29 
were unique profiles and 20 were new profiles relative to our previous SAg survey [16] 
(see Table, Supplemental Digital Content 1, which details all the superantigen gene 
profiles identified in our collection).  
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 Differences between emm types, exotoxins and PFGE clusters between scarlet 
fever and pharyngitis isolates 
 With the exception of T typing, in all the other typing methods used to characterize 
the isolates, the diversity of the scarlet fever group was lower than the diversity of the 
pharyngitis isolates (Table 5.3). 
 
TABLE 5.3 - Simpson’s index of diversity and 95% Confidence intervals (CI95%) of the typing 
methods used in the analysis of the 101scarlet fever isolates and 202 pharyngitis GAS isolates. 
 
 
 
 In the scarlet fever group, emm4, emm3, emm87 and emm1 were the most prevalent 
and together accounted for 72% of the isolates. In the pharyngitis group emm4 was also the 
most frequently found, followed by emm1, emm12, emm3 and emm28 with 54% of the 
isolates included in these emm types. The calculation of OR identified emm87, emm4 and 
emm3 (p=0.009 for emm87 and emm4 and p=0.013 for emm3) as associated with scarlet 
fever, although FDR correction did not support any of these associations. 
 Among the 16 major PFGE clusters, only one (K9) contained solely pharyngitis 
isolates and no major lineage included exclusively scarlet fever isolates. Four PFGE 
clusters were associated with scarlet fever including clusters A49, grouping emm4 isolates, 
C30 and L8, both including emm3 isolates (p=0.007 for C30, p=0.032 for A49 and p=0.018 
for L8). However, PFGE clone D28, grouping all emm87 isolates and two isolates 
representing emm2 and emm18, was the only PFGE cluster whose association was robust 
to FDR correction (p=0.002). 
 The analysis of the SAg profiles revealed that in the scarlet fever isolates, 33 
different profiles were found and 10 included 2 or more isolates. Among the pharyngitis 
isolates, 48 different profiles were detected. There were differences in the prevalence of 
SAg profiles between the two collections, with the calculation of OR identifying profiles 
Typing method 
SID (CI95%) [no. of partitions] 
Scarlet fever isolates (n=101)  Pharyngitis isolates (n=202) 
PFGE 0.880 (0.849-0.911) [19]  0.938 (0.926-0.949) [32] 
emm typing 0.853 (0.816-0.890) [18]  0.921 (0.909-0.933) [20] 
SAg profile 0.900 (0.865-0.935) [33]  0.951 (0.940-0.962) [48] 
T typing 0.870 (0.835-0.904) [15]  0.910 (0.898-0.922) [15] 
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20, 23 and 32 as associated with scarlet fever (p=0.004 for SAg profile 20, p=0.013 for 
SAg profile 23 and and p=0.044 for SAg profile 32), but none of these associations was 
supported by FDR. In a univariate analysis, ssa was associated with cases of scarlet fever, 
while speG was underrepresented in this group. In contrast, in a multivariate analysis, not 
only ssa but also speA and speC were significantly associated with scarlet fever (Table 
5.2). The logistic regression model using the presence of these three genes as explanatory 
variables presented a good fit to the data (Hosmer-Lemeshow goodness of fit test, 
p=0.263). The inclusion of interaction terms between these three variables was not 
supported since the interaction terms were not significant and therefore no interaction 
terms were considered.  
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 DISCUSSION 
 
 The macrolide resistance rate detected among scarlet fever isolates was similar to 
the overall macrolide resistance reported in Portugal [24], indicating that macrolide 
resistant clones were not particularly excluded from this population. Interestingly, the 
MLSB phenotype was never detected in the scarlet fever group of isolates but the numbers 
were too low to draw any conclusions. 
 The SID values for all typing methods used in this study showed that the diversity 
of scarlet fever isolates was lower than the diversity of the pharyngitis isolates (Table 5.3). 
This supports the hypothesis that particular genetic lineages are more prone to cause this 
syndrome than others. 
 For most cases, isolates of the same emm type were divided into more than one 
PFGE cluster, although this distinction was not supported by SAg profling. In general, 
isolates with the same emm type, grouped in different PFGE clusters, share the same SAg 
profile. The exceptions to this were emm28 isolates, where the prevalent SAg profile was 
different in the two lineages representing these isolates (Table 5.1). These results are in 
agreement with other studies, that reported an association of emm with exotoxin profile 
[10, 16]. 
 The calculation of OR and the correction for multiple testing through FDR only 
supported the association of the major lineage K9, grouping mostly emm87 isolates, with 
scarlet fever. However, before the correction for multiple testing, other associations with 
scarlet fever were significant, such as the association of emm87, emm4 and emm3 and 
exotoxin profiles 20, 23 and 32. Although emm4 is among the most prevalent emm types 
described in scarlet fever [6–8, 29], the association of emm3 and emm87 with scarlet fever 
was rarely described.  The recent scarlet fever outbreaks were caused by emm12 isolates 
[5, 27] and a food-borne outbreak of scarlet fever in adults, in China, was linked to emm75 
[12]. In a day care center in Mexico, emm22, macrolide resistant S. pyogenes were 
responsible for a scarlet fever outbreak [14]. In our collection, these emm types are rare 
among scarlet fever isolates (Table 5.1). In some epidemiological studies, the emm types 
more frequently associated with scarlet fever were also frequently found in the general 
GAS population [5, 23]. In agreement with this, a study conducted in Portugal found 
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emm3, emm87 and emm4 among the most frequent emm types in pharyngitis, with emm3 
and emm87 associated with macrolide susceptibility [24].  
 The outbreaks reported in Hong Kong and Shangai were caused by emm12 isolates 
carrying speC, speJ, ssa and smeZ and in one of the outbreaks speA was conspicuously 
absent from outbreak isolates [5, 27]. speC and ssa were found to be in the same prophage, 
designated by ΦHKU.vir, different from the usual prophage carrying these two genes 
(Φ9429.1). In the scarlet fever group of isolates analyzed here, three isolates presented 
emm12 and only one carried both exotoxins simultaneously, indicating that the lineage 
found in Hong Kong and Shangai was largely absent from Portugal. Isolates carrying 
simultaneously speC and ssa were frequent (n=86) and were overrepresented in isolates 
recovered from cases of scarlet fever (p<0.001), suggesting that bacteriophages related to 
the ones found in these recent outbreaks could be circulating in Portugal. In agreement 
with these observations, a multivariate analysis identified speC and ssa, together with the 
historically recognized speA gene, as being associated with scarlet fever. These toxins are 
present, individually or together, in the majority of the isolates representing the emm types 
and major PFGE lineages that were found associated with scarlet fever. 
 Our study has the limitation of having been conducted in a single hospital. This 
could have made it prone to biases due to the circulation of a limited number of lineages 
and the occurrence of outbreaks, in spite of all patients included being outpatients. 
However, we do not believe this to be the case, since the diversity of the isolates causing 
pharyngitis is similar to the one found in a nationwide study (Table 5.3) [24], indicating 
that the GAS clones isolated in this hospital reflect the clones found in the whole country. 
We have also not noted any significant temporal clustering of cases, beyond those 
seasonally expected (data not shown). We characterized a relatively small number of 
isolates but scarlet fever in Portugal, similarly to pharyngitis, is mostly managed without a 
microbial investigation, with this being performed mostly for epidemiological purposes. 
On the other hand, the availability of rapid antigen tests means that an isolate will not 
always be recovered, even when an ethiological diagnosis is sought. However, we do not 
know of any bias when seeking culture and the isolates in our collection are expected to 
reflect the characteristics of the overall GAS population causing scarlet fever.  
 Our study indicates that in a non-outbreak context, a large number of distinct 
genetic lineages have the ability to cause scarlet fever cases, although the diversity of these 
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isolates is lower than those causing pharyngitis, indicating that the first are not a simple 
reflection of the latter. We have confirmed that the presence of the historically recognized 
exotoxin encoding gene speA is associated with isolates recovered from scarlet fever. We 
have also shown that the genes speC and ssa, whose importance was documented in the 
context of recent outbreaks of scarlet fever, were also associated with scarlet fever in non-
outbreak conditions in Portugal. Although scarlet fever undoubtedly results from an 
interplay between the infecting bacteria and the host, the presence of these bacterial genes 
can be used to monitor the strains with potential to cause the cyclical resurgences of this 
disease that are known to occur. 
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Supplemental Digital Content 1 – Superantigen genes (SAg) profiles identified in 303 GAS isolates  
SAg 
profile 
(no. of 
isolates) 
speA speC speG speH speI speJ speK speM speL ssa smeZ emm type (no. of isolates) 
2 (10) + + + - - - + - - - + 6(10) 
3 (11) + + + - - + - - - - + 1(10), 28(1) 
4 (1) + + + - - - - + + - + 18(1) 
5 (4) + + + - - - - - - - + 11(4) 
8 (28) + - + - - - + - - + + 3(26), 1(1), 44(1) 
10 (26) + - + - - + - - - - + 1(26) 
12 (1) - + + + + + - - - + + 87(1) 
14 (1) - + + + - - - - - + + 12(1) 
16 (11) - + + + + - - - - - + 12(8), 1(1), 22(1), 44(1) 
17 (5) - + + + - - - - - - + 12(3), 58(1), 11(1) 
18 (1) - + + - - + + - - + + 87(1) 
19 (1) - + + - - - + - - + + 22(1) 
20 (22) - + + - - + - - - + + 87(21), 2(1) 
21 (3) - + + - - - - - - + + 87(1), 22(1), 28(1) 
22 (2) - + - - - - - + + + + 4(2) 
23 (49) - + - - - - - - - + + 4(49) 
24 (7) - + + - - + + - - - + 28(7) 
25 (2) - + + - - - + + + - + 75(2) 
26 (2) - + + - - - + - - - + 6(2) 
27 (18) - + + - - + - - - - + 28(9), 89(3), 4(2), 87(1), 
77(1), 48(1), 102(1) 29 (18) 
- + + - - - - - - - + 89(12), 78(5), 48(1) 
30 (4) - + - - - - - - - - + 4(3), 77(1) 
31 (5) - + + - - - - + + - - 2(5) 
32 (5) - - + + + + - - - + + 44(5) 
33 (5) - - + + + - - - - - + 12(4), 3(1) 
34 (1) - - + + - + - - - - + 12(1) 
35 (3) - - + + - - - - - - + 12(3) 
37 (1) - - + - - - + - - + + 3(1) 
38 (2) - - + - - + - - - + + 22(1), 9(1) 
39 (4) - - + - - - - + + + + 75(4) 
40 (5) - - + - - - - - - + + 9(5) 
42 (3) - - + - - - + + + - + 75(3) 
43 (2) - - + - - - + - - - + 6(1), 89(1) 
44 (1) - - + - - + - - - - + 87(1) 
45 (3) - - + - - - - + + - + 94(2), 75(1) 
46 (2) - - + - - - - - - - + 77(1), 89(1) 
47 (1) - - - - - - - - - - + 4(1) 
52 (1) + + + - - - + - - + + 3(1) 
60 (1) + - + + + + - - - - + 71(1) 
67 (6) - - + + - + - - - + + 44(6) 
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SAg 
profile 
(no. of 
isolates) 
speA speC speG speH speI speJ speK speM speL ssa smeZ emm type (no. of isolates) 
73 (1) - - + - + - - - - - + 12(1) 
74 (1) - - + - - + + - - + + 9(1) 
75 (1) - - - - + + + - - + + 22(1) 
76 (2) - - + + - - - - - + + 12(1), 44(1) 
77 (1) - - + + + - - - - + + 12(1) 
78 (1) - + + - - - + + + - - 2(1) 
79 (1) - + + - + - - + + - - 2(1) 
80 (1) - + + - + - - - - - + 78(1) 
81 (1) - + + - + - - + + - + 75(1) 
82 (1) - + + - + - + + + - + 75(1) 
83 (1) - + + - + + + + + - + 75(1) 
84 (1) - + + - + - - - - + + 75(1) 
85 (1) - + + - + + - - - + + 12(1) 
86 (1) - + + + - + - - - - + 11(1) 
87 (1) - + + + - + - - - + + 44(1) 
88 (5) + - + - - + + - - + + 3(5) 
89 (1) + - + + - - - - - + + 3(1) 
90 (1) + + + - - + + - - - + 6(1) 
91 (1) + + + - - - - - - + + 4(1) 
92 (1) + + + + - - - - - + + 3(1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scarlet fever GAS 
 
197 
 
 REFERENCES 
 
1.  Beall, B., R. R. Facklam, J. A. Elliott, A. R. Franklin, T. Hoenes, D. Jackson, L. Laclaire, 
T. Thompson, and R. Viswanathan. 1998. Streptococcal emm types associated with T-
agglutination types and the use of conserved emm gene restriction fragment patterns for 
subtyping group A streptococci. J. Med. Microbiol. 47:893–898. 
2.  Beall, B., R. Facklam, and T. Thompson. 1996. Sequencing emm-specific PCR products for 
routine and accurate typing of group A streptococci. J. Clin. Microbiol. 34:953–958. 
3.  Benjamini, Y., and Y. Hochberg. 1995. Controlling the False Discovery Rate: a Pratical and 
Powerful Aproach to Multiple Testing. J. Roy. Stat. Soc. B Met. 57:289–300. 
4.  Carriço, J. A., C. Silva-Costa, J. Melo-Cristino, F. R. Pinto, H. de Lencastre, J. S. 
Almeida, and M. Ramirez. 2006. Illustration of a common framework for relating multiple 
typing methods by application to macrolide-resistant Streptococcus pyogenes. J. Clin. 
Microbiol. 44:2524–2532. 
5.  Chen, M., W. Yao, X. Wang, Y. Li, M. Chen, G. Wang, X. Zhang, H. Pan, J. Hu, and M. 
Zeng. 2012. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 
2011 in Shanghai, China. Pediatr. Infect. Dis. J. 31:e158–162. 
6.  Chen, Y.-Y., C.-T. Huang, S.-M. Yao, Y.-C. Chang, P.-W. Shen, C.-Y. Chou, and S.-Y. 
Li. 2007. Molecular epidemiology of group A streptococcus causing scarlet fever in northern 
Taiwan, 2001–2002. Diagn. Microbiol. Infect. Dis. 58:289–295. 
7.  Chiou, C.-S., T.-L. Liao, T.-H. Wang, H.-L. Chang, J.-C. Liao, and C.-C. Li. 2004. 
Epidemiology and molecular characterization of Streptococcus pyogenes recovered from 
scarlet fever patients in central Taiwan from 1996 to 1999. J. Clin. Microbiol. 42:3998–4006. 
8.  Chiou, C.-S., Y.-W. Wang, P.-L. Chen, W.-L. Wang, P.-F. Wu, and H.-L. Wei. 2009. 
Association of the shuffling of Streptococcus pyogenes clones and the fluctuation of scarlet 
fever cases between 2000 and 2006 in central Taiwan. BMC Microbiol. 9:115. 
9.  Clinical and Laboratory Standards Institute. 2012. Performance Standards for 
Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Clinical and 
Laboratory Standards Institute, Pennsylvania, USA. 
10.  Commons, R., S. Rogers, T. Gooding, M. Danchin, J. Carapetis, R. Robins-Browne, and 
N. Curtis. 2008. Superantigen genes in group A streptococcal isolates and their relationship 
with emm types. J. Med. Microbiol. 57:1238–1246. 
11.  Cunningham, M. W. 2000. Pathogenesis of Group A Streptococcal Infections. Clin 
Microbiol Rev 13:470–511. 
Chapter 5 
 
198 
 
12.  Dong, H., G. Xu, S. Li, Q. Song, S. Liu, H. Lin, Y. Chai, A. Zhou, T. Fang, H. Zhang, C. 
Jin, W. Lu, and G. Cao. 2008. Beta-haemolytic group A streptococci emm75 carrying altered 
pyrogenic exotoxin A linked to scarlet fever in adults. J. Infect. 56:261–267. 
13.  Duncan, C. J., S. R. Duncan, and S. Scott. 1996. The dynamics of scarlet fever epidemics in 
England and Wales in the 19th century. Epidemiol. Infect. 117:493–499. 
14.  Espinosa de los Monteros, L. E., I. M. Bustos, L. V. Flores, and C. Avila-Figueroa. 2001. 
Outbreak of scarlet fever caused by an erythromycin-resistant Streptococcus pyogenes emm22 
genotype strain in a day-care center. Pediatr. Infect. Dis. J. 20:807–809. 
15.  Figueira-Coelho, J., M. Ramirez, M. J. Salgado, and J. Melo-Cristino. 2004. 
Streptococcus agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, 
serotype distribution, and clonal analysis of macrolide-resistant isolates. Microb. Drug Resist. 
10:31–36. 
16.  Friães, A., F. R. Pinto, C. Silva-Costa, M. Ramirez, and J. Melo-Cristino. 2012. 
Superantigen gene complement of Streptococcus pyogenes-relationship with other typing 
methods and short-term stability. Eur. J. Clin. Microbiol. Infect. Dis. 32:115–125. 
17.  Johnson, D. R., E. L. Kaplan, J. Sramek, R. Bicova, J. Avlicek, H. Havlickova, J. 
Motlova, and P. Kriz. 1996. Laboratory diagnosis of group A streptococcal infections. World 
Health Oganization. 
18.  Lamden, K. H. 2011. An outbreak of scarlet fever in a primary school. Arch. Dis. Child. 
96:394–397. 
19.  Luk, E. Y. Y., J. Y. C. Lo, A. Z. L. Li, M. C. K. Lau, T. K. M. Cheung, A. Y. M. Wong, 
M. M. H. Wong, C. W. Wong, S.-K. Chuang, and T. Tsang. 2012. Scarlet Fever epidemic, 
Hong Kong, 2011. Emerg. Infect. Dis. 18:1658–1661. 
20.  Melo-Cristino, J., M. L. Fernandes, and Portuguese Surveillance Group for the Study of 
Respiratory Pathogens. 1999. Streptococcus pyogenes isolated in Portugal: macrolide 
resistance phenotypes and correlation with T types. Microb. Drug Resist. 5:219–225. 
21.  Morens, D. M., G. K. Folkers, and A. S. Fauci. 2004. The challenge of emerging and re-
emerging infectious diseases. Nature 430:242–249. 
22.  Ohga, S., K. Okada, K. Mitsui, T. Aoki, and K. Ueda. 1992. Outbreaks of group A beta-
hemolytic streptococcal pharyngitis in children: correlation of serotype T4 with scarlet fever. 
Scand. J. Infect. Dis. 24:599–605. 
23.  Perea-Mejía, L. M., A. E. Inzunza-Montiel, and A. Cravioto. 2002. Molecular 
characterization of group A Streptococcus strains isolated during a scarlet fever outbreak. J. 
Clin. Microbiol. 40:278–280. 
Scarlet fever GAS 
 
199 
 
24.  Silva-Costa, C., A. Friães, M. Ramirez, and J. Melo-Cristino. 2012. Differences between 
macrolide resistant and susceptible Streptococcus pyogenes: the importance of clonal 
properties in addition to antibiotic consumption. Antimicrob. Agents Chemother. 56:5661–6. 
25.  Silva-Costa, C., F. R. Pinto, M. Ramirez, and J. Melo-Cristino. 2008. Decrease in 
macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal. Clin. 
Microbiol. Infect. 14:1152–1159. 
26.  Silva-Costa, C., M. Ramirez, and J. Melo-Cristino. 2006. Identification of macrolide-
resistant clones of Streptococcus pyogenes in Portugal. Clin. Microbiol. Infect. 12:513–518. 
27.  Tse, H., J. Y. J. Bao, M. R. Davies, P. Maamary, H.-W. Tsoi, A. H. Y. Tong, T. C. C. Ho, 
C.-H. Lin, C. M. Gillen, T. C. Barnett, J. H. K. Chen, M. Lee, W.-C. Yam, C.-K. Wong, 
C.-L. Y. Ong, Y.-W. Chan, C.-W. Wu, T. Ng, W. W. L. Lim, T. H. F. Tsang, C. W. S. 
Tse, G. Dougan, M. J. Walker, S. Lok, and K.-Y. Yuen. 2012. Molecular characterization 
of the 2011 Hong Kong scarlet fever outbreak. J. Infect. Dis. 206:341–351. 
28.  Tyler, S. D., W. M. Johnson, J. C. Huang, F. E. Ashton, G. Wang, D. E. Low, and K. R. 
Rozee. 1992. Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction 
and association with disease in strains isolated in Canada from 1940 to 1991. J. Clin. 
Microbiol. 30:3127–3131. 
29.  Yan, J.-J., C.-C. Liu, W.-C. Ko, S.-Y. Hsu, H.-M. Wu, Y.-S. Lin, M. T. Lin, W.-J. 
Chuang, and J.-J. Wu. 2003. Molecular Analysis of Group A Streptococcal Isolates 
Associated with Scarlet Fever in Southern Taiwan between 1993 and 2002. J. Clin. Microbiol. 
41:4858–4861. 
30.  Yu, C. E., and J. J. Ferretti. 1991. Frequency of the erythrogenic toxin B and C genes (speB 
and speC) among clinical isolates of group A streptococci. Infect. Immun. 59:211–215. 
31.  Yu, C. E., and J. J. Ferretti. 1989. Molecular epidemiologic analysis of the type A 
streptococcal exotoxin (erythrogenic toxin) gene (speA) in clinical Streptococcus pyogenes 
strains. Infect. Immun. 57:3715–3719. 
 
 
 
 
 
 
 
 
 
  
CHAPTER 6 
 
 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General discussion 
 
203 
 
 Streptococcus pyogenes is a pathogen with the ability to cause a wide variety of 
infections in its sole host, the human, ranging from uncomplicated infections in the upper 
respiratory tract or the skin, such as tonsillo-pharyngitis or impetigo, to severe, life 
threatening infections like necrotizing fasciitis or streptococcal shock toxic syndrome [12]. 
In spite of extensive use, penicillin remains the antibiotic of choice for the treatment of 
infections caused by GAS, but in cases of allergy, macrolides are a suitable alternative, 
with the additional advantage of having an oral route of administration. This is particularly 
important in children and in Portugal where there is no oral penicillin available. However, 
soon after its introduction in the clinical practice, macrolide resistance arose in clinical 
isolates of S. pyogenes. There are large geographical and temporal differences in the 
macrolide resistance rates and phenotypes, and the clonal composition of the population 
can also vary greatly. More importantly, the relationship between the antimicrobial 
consumption and macrolide resistance is not always so obvious, implying a role for the 
natural fluctuations of resistant clones in the prevalence of macrolide resistance rate and 
phenotypes.  
 Given this, the main goal of this Thesis was the characterization of S. pyogenes 
associated with tonsillo-pharyngitis, with a special emphasis on macrolide resistance. A 
large part of this study involved the determination of macrolide resistance rate in Portugal 
and the characterization of macrolide resistant isolates. The work presented here involved 
the determination of the macrolide resistance phenotypes and genotypes and its evolution 
throughout a large period of time, from 1998 to 2011. In order to identify the circulating 
clones in this period and to compare them with others in circulation in other European 
countries, we also performed the phenotypic and molecular characterization of the resistant 
isolates. In an attempt to find out if the macrolide resistant population was mirroring the 
general population, a study comparing both susceptible and resistant populations was 
performed, providing new insights about the dynamics of the resistant population.  
 
 
 Intrahost variation in infection 
 
 The incidence of genotipically or phenotipically different isolates of the same 
species in the same niche is well known for bacteria; a classic example is the co-
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colonization with S. pneumoniae, or the carriage of multiple (generally two) different 
pneumococcus isolates [6, 27, 33]. In S. pyogenes there are few studies and contradictory 
results and we raised the question of whether the usual procedure in the microbiology 
laboratory (the isolation and subculture of one single colony to perform antimicrobial 
susceptibility testing and molecular characterization) was the most suitable to identify the 
real antimicrobial resistance rate. The fact that macrolide and tetracycline resistance genes 
are carried in mobile genetic elements, with the ability to be transferred between 
streptococcal species [19, 20, 24, 32] could contribute to this heterogeneity even in the 
same host. However, the results presented in chapter 2 of this thesis demonstrated that 
lateral gene transfer events, leading to the emergence of a resistant subset of isolates within 
the infecting population are not occurring in pharyngitis, at least in our collection. These 
results are in agreement with one study that included both carriage and infection isolates 
[29] but are contrary to another in which mixed infections with different isolates of the 
same genetic background were reported [40]. The difference between the latter study and 
the results presented here could be related to the fact that in our collection only one isolate 
presented emm3, which was the emm type expressed for by all the isolates that showed 
antimicrobial resistance or molecular differences. However, this situation seems to be 
unlikely, because we have previously demonstrated that although emm3 isolates were 
highly prevalent among the macrolide susceptible GAS population causing pharyngitis, 
they are rarely found among the resistant population. Nevertheless, our results seem to 
prove the adequacy of the single colony strategy commonly used in the microbiology 
laboratory in routine and epidemiological studies. 
 
 Epidemiology of macrolide-resistant GAS in Portugal 
 
 In Portugal, high rates of macrolide resistance in S. pyogenes causing tonsillo-
pharyngitis were reported in the beginning of this study. In the first period analyzed here, 
between 1998 and 2003, macrolide resistance was one the highest in Europe (27%) and 
stable. However, this stability masked a complete inversion of the prevalence of the 
macrolide resistance phenotypes with the MLSB phenotype that accounted for 85% of the 
isolates recovered in 1998 being expressed by only 23% of the resistant isolates in 2003. 
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This situation was very unusual, especially because is occurred in a very short period of 
time.   
 The frequent association of the dominance of the M phenotype with high macrolide 
resistance rates, reported in Spain [2], in Taiwan, the US and Canada [21, 22, 25] 
suggested a role for the higher genetic mobility of the elements carrying the resistance 
determinants conferring the M phenotype in the rapid dissemination of some successful 
clones, with a concomitant increase in the macrolide resistance rate [24]. However the 
situation reported in Portugal, as well as in Italy and France, was in sharp contrast: high 
rates of macrolide resistance were reported in populations with a clear dominance of the 
MLSB isolates [3, 15]. Furthermore, in other European countries, a dominance of the 
MLSB phenotype was accompanied by lower macrolide resistance rates (average 12%) 
[28]. All these countries present differences in the clonal composition of the populations, 
implying an important role for the circulating clones in the prevalence of both macrolide 
resistance rates and phenotypes.   
 At this point, it was known that in order to achieve a better characterization of the 
genetic lineages of S. pyogenes, other typing methods, such as pulsed-field gel 
electrophoresis (PFGE) or multilocus sequence typing (MLST), had to be performed [7], 
but the fact that isolates presenting the M phenotype were resistant to SmaI digestion was 
hampering the comparison of the PFGE profiles. This resistance was proved to be due to 
the presence of a hybrid bacteriophage/transposon genetic element that encoded a 
methyltransferase that rendered DNA refractory to cleavage by the endonuclease SmaI 
[17]. Resistance to SmaI digestion was described frequentely, and to overcome this, a 
digestion with alternative enzymes such as SfiI was carried out [11, 14, 39]. However, this 
approach did not allow the direct comparison of M and MLSB isolates, which from our 
point of view was very important. Given this, Cfr9I (a SmaI isosquizomer) was used and 
an UPGMA dendrogram could be generated including all the isolates, independently of 
their phenotypes. Using PFGE, it was possible to identify 8 major lineages, mostly defined 
by the same emm type, T type and ST, grouping more that 90% of the isolates in a 
population with high genetic diversity. All the genetic lineages were found to be described 
in other European countries, although in some cases the macrolide resistance rates and the 
prevalence of the macrolide resistance phenotypes showed significant differences, 
implying a role for other properties of these genetic lineages or differences in antimicrobial 
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consumption. The unusual situation documented in Portugal motivated the pursuing of 
these studies and with the inclusion of isolates recovered in the following 3 years it was 
possible to detect a decreasing trend in macrolide resistance that started in 1999. The 
fluctuations in the prevalence of both macrolide resistance phenotypes were still evident, 
although in the period 2004-2006, this decrease in macrolide resistance could be attributed 
mainly to a decrease in the prevalence of the M phenotype. Some differences were noted in 
the clonal composition of the population, but overall, the main genetic lineages identified 
had already been found in Portugal. The decrease in macrolide resistance still accompanied 
by fluctuations in the prevalence of the phenotypes in a population with high genetic 
diversity led to continued surveillance studies, especially because macrolide consumption, 
known to be a major driver of erythromycin resistance was one of the highest in Europe 
[1]. In spite of this, we reported a continuing decline in macrolide resistance from 2007 to 
2011. Possible explanations for this unusual pattern can only be speculative.  Macrolide 
consumption should not be the cause, although the data we refer to is the total 
consumption, without a differentiation between children and adults. If pediatric 
consumption was much lower, then the decrease in macrolide resistance could be a 
consequence of this difference, because the great majority of isolates included in this study 
were isolated from children. However, we have currently no means to find out the real 
pediatric consumption.  
 Tetracycline resistance is often referred as possible factor contributing to alterations 
in macrolide resistance rates [30], since the genetic elements responsible for resistance to 
both antibiotics are often carried together. In the subset of isolates included in this study, 
tetracycline resistance is, with only one exception, carried in some lineages of MLSB 
isolates. Co-selection could have played a role in the decrease of macrolide resistance in 
1999 to 2011, because a decrease in tetracycline consumption, concomitant to a decrease in 
tetracycline resistance was reported between 2000 and 2009 [31]. However, in that period, 
tetracycline consumption was much lower than erythromycin consumption; it would be 
less likely that tetracycline consumption would affect macrolide resistance than the 
contrary, although this is only speculative. 
 One possible explanation for the decrease in macrolide resistance is possible 
immunity developed by the human population against some of the antigens and M proteins 
displayed by S. pyogenes. The analysis of the clonal composition of the population in the 
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whole period studied in this thesis (1998-2011) (Figure 3.4.3, chapter 3.4) revealed large 
fluctuations of the main emm types, with waves of clones that, with few exceptions, are 
present in the population throughout the study period. It is possible, although speculative, 
that the immunity developed against some emm types can also confer protection against 
other emm types, as already demonstrated in GAS vaccine studies [13, 23], leading to a 
decrease in macrolide resistance if the circulating clones present immunologically cross-
reacting M proteins.  
 Another possible explanation could be the existence of transmission differences 
between the different emm types, or genetic lineages, as already reported for S. 
pneumoniae [16, 37], where small but significant transmissibility differences were found 
between some serotypes. If emm11, more prevalent in the last years of the study would 
have had a smaller ability for host-to-host transmission, then its dominance among the 
macrolide resistance population would drive macrolide resistance down. On the contrary, if 
other emm types, like emm22, associated with high macrolide resistance in the early years 
of the study, would have an intrinsic feature conferring a higher transmissibility rate, than 
the successful spread of this clone would have the opposite effect on macrolide resistance. 
However, this is only speculative and could be unrelated to the main antigens, since the 
same genetic lineage (emm11-T11-ST403) was associated with an increase in macrolide 
resistance in Spain. However, other properties of this lineage can be different between the 
two countries, undetectable by the typing methods used in current GAS epidemiological 
studies. 
  Even considering all these possible explanations, it is still intriguing how in a 
context of high macrolide consumption, a high macrolide resistance rate was not sustained. 
It is particularly interesting how high intermediate-acting macrolides, known to select for 
the erm(B) gene, paralleled a decrease in the prevalence of MLSB isolates, contrary to a 
previous study, that found that clarithromycin, an intermediate-acting macrolide was more 
effective in eradicating the mef(A) isolates than long-acting macrolides, such as 
azithromycin, thereby allowing the expansion of erm(B) carrying isolates [26]. According 
to the same study, the consumption of azithromycin would favor the emergence of M 
isolates, which in Portugal was only evident until 2003 although the use of long-acting 
macrolides was reported to be high during the whole study period [1].  
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 All the genetic lineages identified among macrolide resistant GAS in Portugal had 
been previously described in other countries. Frequently, macrolide resistance genotypes 
associated to each major lineage are the same, which could suggest a geographic 
dissemination of a few resistant clones. However, independent acquisition of resistant 
genes by the prevalent genetic lineages, followed by local spread must also play a role, 
because it is also very common to find lineages with the same characteristics as the ones 
described here in susceptible isolates or in isolates presenting a different resistance 
conferring genotype, as is the case of emm12-ST36 isolates: in the period between 1998 
and 2003, this lineage was mostly associated with the M phenotype and the mef(A) gene, 
while in 2004-2006, these isolates carried the erm(B) gene and presented the cMLSB 
phenotype.  
 
 Erythromycin-resistant and -susceptible GAS 
 
 In an effort to explain the origin of the macrolide resistant GAS in Portugal, a 
subset of susceptible and resistant isolates recovered between 2000 and 2005 was 
compared. At this point, it remained unknown whether the macrolide resistant clones 
circulating in Portugal were simply the reflection of the general population, emphasizing 
the role of the local acquisition of the resistant determinants followed by dissemination or 
the introduction of other successful resistant clones the from different locations. 
 Given the differences found and presented in chapter 4 of this thesis, reflected in 
the emm types and PFGE clones associated to each of the macrolide susceptible and 
resistant subsets, as well as in the diversity of the populations, the macrolide resistant 
population seems to have its own dynamics, rather than mirroring the behavior of the 
general population. Given this, it was suggested that horizontal gene transfer resulting in 
the acquisition of macrolide resistant determinants by the most frequent GAS lineages 
circulating is not frequent and the macrolide resistant clones described in Portugal are 
probably the result of the geographic dissemination of a few resistant lineages. The reasons 
why some emm types, with high occurrence in the susceptible population like emm3, 
emm6, emm87 and emm89, are persistently rare or even absent among the resistant subset 
remains unknown. In agreement to our results, a recent study addressing the global emm 
type distribution identified emm1, emm12, emm28, emm3, emm4, emm89 and emm6 as the 
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major emm types found in GAS populations in high-income countries [36] and all except 
emm3, emm89 and emm6 were previously identified as one of the most widely dispersed 
clones of macrolide resistant S. pyogenes [41]. At least for these emm types, it is not a 
question of being in the right place at the right time, as stated by the authors, and this 
seems to be also the case of emm94, which is absent from our collection, is widely 
distributed in macrolide resistant clones, but relatively rare throughout the world [36, 41]. 
The dominance of these emm types among macrolide susceptible or resistant populations 
could be related to lower or higher transmission rates of susceptible and resistant isolates 
of the same emm type, respectively, as already demonstrated for S. pneumoniae where 
serotype susceptible and resistant strains showed a different ability to be transmitted [16].  
 
 Scarlet fever GAS 
  
 The large collection of S. pyogenes recovered from pharyngitis and scarlet fever 
patients and contradictory reports of association with specific GAS exotoxins motivated 
the study presented in chapter 5 of this thesis. In Portugal, a large number of different 
genetic lineages was found in association with scarlet fever, contrary to the recent outbreak 
reports [8, 38]. Although not significant, it was possible to establish an association between 
some emm types and scarlet fever. Among the 11 exotoxins screened in this collection, 
only ssa was associated with scarlet fever in a univariate analysis; using a multivariate 
analysis approach, it was possible to associate also speA and speC. However, all these 
associations can be simply reflecting the high prevalence of specific genetic lineages 
among the general GAS population [34]. These isolates could also have some intrinsic 
feature providing enhanced potential for causing scarlet fever that is unrelated to their 
exotoxins gene content, making it difficult to reach definite conclusions. A recent study 
found that ssa and emm4 was significantly associated with pharyngitis [18], and results 
presented in chapter 4 of this thesis showed that emm4, emm3 and emm87 were statistically 
associated with macrolide susceptibility in the general GAS pharyngeal population. All 
these lineages carried ssa; however, emm3 isolates carried speA, but not speC, contrary to 
emm4 and emm87 isolates, suggesting that the presence of both exotoxins is not necessary 
to the pathogenesis of scarlet fever.  
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Concluding remarks and future perspectives 
 
 The work presented in this thesis provides new insights into the dynamics of 
macrolide resistant S. pyogenes population.  The results presented here seem to point to a 
role for the natural fluctuations of macrolide resistance clones in the prevalence of 
macrolide resistance rates; even in the presence of a selective force such as high 
antimicrobial consumption, macrolide resistance rate reached the lowest level ever 
reported in Portugal. However, continued surveillance studies are needed; there are reports 
of increasing macrolide resistance rates even when antibiotic prescriptions showed a 
decreasing trend [9]. As macrolides represent a suitable alternative to penicillin in the 
treatment of GAS infections, the updated knowledge of resistance rates and phenotypes is 
useful in the empiric treatment of these infections. On the other hand, the molecular 
characterization of macrolide resistant isolates is important in the understanding of the 
dynamics of specific clones in close geographic areas and to evaluate the success of 
particular clones.  
 
 The comparison between macrolide resistant and susceptible populations presented 
in chapter 4 revealed that the most frequent genetic lineages found among macrolide 
resistant GAS isolates are not simply mirroring the general population, indicated by 
differences in the diversity of both populations, detected in all typing methods used. There 
are specific genetic lineages associated with each of the subsets of isolates, and in some 
cases, only the analysis by PFGE could differentiate macrolide resistant and susceptible 
isolates of the same emm types, like emm4 and emm1. Apart from being included in 
different PFGE clones and having different antimicrobial susceptibility, they share all the 
other molecular properties (T type, emm type and ST), which could suggest a common 
origin. However, other differences between the resistant and susceptible lineages, not 
detected by the methods used in the characterization of these isolates, could be present and 
responsible for this segregation. In this way, it would be interesting to perform whole 
genome sequencing of both macrolide susceptible and resistant isolates, to detect any 
additional differences between the two populations, other than the ones detected here.  
 The intriguing observation that some highly prevalent genetic lineages among the 
general population are rarely detected in resistant isolates, could be attributed to the 
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presence of a genetic barrier to the acquisition of macrolide resistance determinants, as 
already proposed for the M protein [10, 35]. It would be interesting to evaluate the 
transferability of the genetic elements carrying macrolide resistance genes, among different 
genetic backgrounds. If the macrolide susceptible genetic lineages are more resistant to the 
acquisition of those genetic elements, then this could be the explanation for their low 
prevalence among the macrolide resistant population. Moreover, these transferability 
experiments could be done in the presence of human pharyngeal epithelial cell lines, 
because a role for the host in the activation and transfer of some of these genetic elements 
was already suggested [4, 5].  
 
 Although the genetic elements found among the isolates causing scarlet fever in the 
recently described outbreaks were mostly absent from our collection, continuing 
surveillance is still needed, because the introduction of a highly successful clone could 
promote a rapid increase in GAS scarlet fever cases [8, 38]. In order achieve a better 
understanding of the differences between the scarlet fever and pharyngitis lineages, evident 
by a discrepancy in the diversity of both populations, the whole genome sequencing 
approach could also be useful in trying to identify molecular markers of this syndrome.  
 
 The observation that the single colony strategy remains suitable in the correct 
estimation of macrolide resistance rates, also potentially avoiding treatment failure, led us 
to believe that the results presented in this thesis did not provide an underestimate 
macrolide resistance. However, it would be interesting to see if there is some heterogeneity 
among the size and sequence of the M protein in the same host, and its implications for the 
interaction with the immune system.  
 
 The work presented in this thesis provided new insights into the dynamics of the 
GAS macrolide resistant population and in the identification of some potential markers for 
scarlet fever. However, some of the questions remained unanswered and others arose from 
the results presented here. Macrolide consumption does not seem to be the only driving 
force in determining macrolide resistance, but the reason for different dynamics in the 
resistant population are still unknown. Some genetic lineages were more frequently linked 
to resistance than others. Probably other molecular properties make these lineages more 
Chapter 6 
 
212 
 
prone to acquire and spread macrolide resistance, like a higher susceptibility to the 
acquisition of mobile genetic elements containing antimicrobial resistannce determining 
genes or others. Similarly, some genetic lineages were more prevalent in scarlet fever 
isolates than in pharyngitis isolates.  Both populations showed different diversities, 
suggesting that one is not mirroring the other. The potential molecular markers, other than 
exotoxins or specific emm types, remain to be identified.  
 
 Some of the questions raised from the work presented in this thesis can be used to 
guide the future directions of this work.  The use of other approaches, including next 
generation sequencing (NGS), will hopefully bring new insights into the dynamics of 
macrolide resistance in GAS, with an important contribution for the knowledge of such 
important human pathogen.   
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